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Summary 
Staphylococci are a leading cause of catheter-related infections (CRI). To reduce 
rates of these infections, catheter-locking solutions (CLSs) are frequently used. 
However, an effective CLS against these biofilm mediated infections has yet to be 
determined. The purpose of this study was to evaluate the efficacy, of currently 
available antiseptics, antibiotics as well as two novel antimicrobials, ML:8 and 
Citrox, as CLSs against staphylococcal biofilm.  
Two distinct assays were used for analysing each agent; one widely used assay 
using enriched growth media and one newly developed assay using minimal media 
and a preconditioning coating of human plasma. Static and flow models of 
staphylococcal biofilm formation were used to examine the effect of the test 
agents. Ethanol (30%) and TaurolockTM proved to be the most effective antiseptic 
agents, against established biofilms. In contrast, antibiotics were shown to have 
little effect on established biofilm in the enriched media assay. However, 
daptomycin, rifampicin and tigecycline all showed increased efficacy against 
biofilm viability when the minimal media assay was used. These findings were 
confirmed by confocal microscopy and live/dead staining. 
The novel agents ML:8 (1%), containing caprylic acid, and Citrox (1%), comprising 
of flavonoids, proved to be also effective against established biofilms. Cytotoxicity 
testing using THP-1 and HaCat cells indicated that both agents had minimal 
toxicity. No resistance to either agent, developed in S. aureus after 90 days 
exposure to both of these novel agents. Finally, ML:8 was shown to be effective 
against early stage S. aureus biofilm, while Citrox was shown to eradicate mature 
biofilm in a rat CRI model. Analysis of the bacterial transcriptional response to both 
novel agents revealed a decrease in expression of genes associated with 
adherence and genes encoding bacterial exoenzymes, while expression of toxin 
genes was both up- and down-regulated. Taken together, these data reveal the 
optimum currently available antiseptic and antibiotic agents to treat staphylococcal 
biofilm within a CLS and the efficacy of the novel antimicrobials ML:8 and Citrox 
within this model of infection.  
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Chapter One: Introduction 
Extracts from this chapter have been published incurrent pharmaceutical design in 
a review entitled “Current and future approaches to the prevention and treatment of 
staphylococcal medical device-related infections” 
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1.1  The Staphylococci 
Belonging to the family Staphylococcaceae, the genus Staphylococcus comprises 
over 47 recognised species (1). Staphylococci are catalase-positive, oxidase-
negative Gram-positive cocci that appear in microscopic clusters upon staining. 
Members of this genus are also commonly described as being non spore forming, 
non motile, facultative anaerobes that range in size from 0.8-1µm (2). 
Staphylococci can be sub-categorised into two distinct groups based on the 
organisms’ ability to produce the enzyme coagulase, which converts fibrinogen to 
insoluble fibrin. The resulting groups are the coagulase-positive staphylococci, 
such as Staphylococcus aureus, and the coagulase-negative staphylococci 
(CoNS), which includes Staphylococcus epidermidis. In humans, these two 
species are most commonly associated with disease.  
Both species are commensals, with S. epidermidis colonising mostly mucous 
membranes and epithelial surfaces and S. aureus mainly inhabiting the mucosal 
surface of the anterior nares and the epithelium of the groin and axillae. 
Colonisation with either species does not usually cause any adverse effects. S. 
epidermidis is an opportunistic pathogen as it does not routinely cause infection in 
a healthy individual. If S. aureus gains access through a breach in the epithelial or 
mucosal layers serious infections can occur. Staphylococcal infections range from 
superficial skin infections to more serious invasive infections such as infective 
endocarditis, cellulitis or septic arthritis (3). Both organisms are remarkably 
versatile and adaptable pathogens with a large number of virulence factors. It is 
this wide array of virulence factors, including extracellular toxins and surface 
structures, which facilitate tissue colonisation, immune evasion and tissue 
destruction.  
1.2   Staphylococcal infections 
Staphylococci, in particular S. aureus and S. epidermidis possess a diverse and 
large repertoire of virulence factors that help both become effective pathogens, 
when needed (3). Both species share a core genome of 1,681 open reading 
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frames with genomic islands in non-synthetic regions being the main basis of 
variation in virulence between the two organisms (4).  The S. aureus genome 
contains genomic islands that encode a variety of virulence factors, many of which 
are absent in the closely related S. epidermidis. S. epidermidis biofilm formation is 
a key virulence factor on which S. epidermidis relies for establishing successful 
infections (5). S. epidermidis, which for a long time was regarded as commensal, 
produces exopolymers and proteins that aid in immune evasion and are cytolytic. 
Their most important contribution to the pathogenesis of S. epidermidis infection is 
through aiding biofilm formation (5). A strong correlation between the pathogenicity 
of S. epidermidis and biofilm formation has been reported (6). These factors result 
in S. epidermidis being one of the most common causes of device-related 
infections.  
S. aureus can cause a wide variety of infections. These can be broadly classified 
into skin and soft tissue infections and invasive systemic infections. Superficial skin 
infections range in severity from boils and folliculitis to more serious conditions, 
such as cellulitis and staphylococcal scalded skin syndrome, the latter of which is 
mediated by production of exfoliative toxins. Invasive systemic infections caused 
by staphylococci include infective endocarditis, septic arthritis, osteomyelitis and 
toxic shock syndrome. Some of the most severe infections caused by 
staphylococci are bloodstream infections (BSI). BSIs due to staphylococci are 
frequently related to implanted medical devices such as intravascular catheters 
(IVCs). Staphylococci are responsible for over 40% of hospital-acquired 
bacteraemia (7). In turn, S. aureus is associated with 61% of hospital-related 
staphylococcal infections (7). 
A survey carried out by the Health Protection Surveillance Centre (HPSC) for the 
European Antimicrobial Resistance Surveillance Network (EARS-Net) in Ireland 
from 2004 to 2014 reported a decrease in the number of S. aureus-related BSIs. 
This study was supported by 40-44 diagnostic microbiology laboratories in Ireland 
over ten years. The reported number of BSIs caused by S. aureus decreased from 
1,424 in 2005 to 1,094 in 2014 representing a reduction of 23.1%. Encouragingly, 
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the percentage of infections caused by methicillin resistant S. aureus (MRSA) also 
steadily decreased over the course of the study. In 2004, 41.8% (533/1,323) of S. 
aureus BSIs were reported to involve MRSA. This figure decreased to 19.5% 
(218/1,118) by 2014 (8). The HPSC had previously reported an increase in MRSA 
infection rates between 1999 and 2004 (9). These new data are encouraging; 
however, more work is needed to reduce rates of infection further. The risk of 
developing a BSI is increased with the use of implanted medical devices as they 
offer invading bacteria a surface on which to gain a foothold in the body and 
establish an infection (10).  
Figure 1.1 Trends for S. aureus bacteraemia in Ireland by year from 2004–2014. Graph 
illustrates the total numbers of MRSA and MSSA isolates from patients with bacteraemia. Data 
were collected and published by the Health Protection Surveillance Centre (11).  
1.3  Medical device-related infections 
1.3.1 Importance of medical devices in modern medicine 
Medical devices have been defined by the Food and Drug Administration (FDA), 
and other regulatory bodies such as the Irish Medicines Board (IMB), as all 
products, except medicines, used in healthcare for the diagnosis, prevention, 
treatment and monitoring of a disability or an illness (12). The use of implanted 
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medical devices has become common in modern healthcare systems. Among the 
most commonly used medical devices within modern medicine are IVCs, such as 
arterial lines and central venous and peripheral venous catheters. These devices 
aid or improve impaired physiological functions within the body by allowing 
administration of vital medication and fluids, dialysis and monitoring of 
intravascular pressure. Other commonly used medical devices include prosthetic 
joints, pacemakers and neurosurgical shunts (13); these greatly improve the 
quality of life for patients as well as reduce morbidity and mortality rates (14). 
Recovery times post surgery have been shortened in a number of cases and the 
surgical procedures required for device insertion has also become less invasive 
(14). The introduction of new materials, such as silicones and polyvinyl chloride, 
has also made many medical devices last longer and more stable when in situ. 
Despite these advances, the infection rates associated with implanted devices 
remain high (15-17) with 22% of MRSA BSIs and 32% of MSSA BSIs being 
device- or implant-associated in Ireland (18). These figures may be conservative 
as device association was unknown for a further 17 % for MRSA and 18% for 
MSSA BSIs (18).  
1.3.2 Catheter-related infections 
Although there are numerous examples of implanted medical devices associated 
with infections this project focuses on treatment of infection due to IVCs. IVCs 
were originally used as vascular access devices in patients on short-term dialysis. 
However, they have gradually become an acceptable form of permanent vascular 
access (19). Now these semi-permanent and permanent centrally placed venous 
access devices are used commonly to administer chemotherapy, antibiotics, 
parenteral nutrition, blood products and to obtain blood specimens for laboratory 
analysis (20). Catheter usage is increasing and will continue to do so with an 
ageing population. Catheter-related infections (CRIs) are a significant problem in 
medicine, especially in haemodialysis (HD) patients, patients in the intensive care 
unit (ICU) and in haematology and oncology patients. Consequently, catheter-
related BSIs have become alarmingly common in recent years (21), with treatment 
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costing up to $45,000/episode (22). It has been estimated that in the United States 
two thirds of all hospital-acquired primary BSIs are IVC-related. For example in the 
US, infection is the leading cause of IVC removal and patient morbidity in dialysis 
patients (23). In the UK and Ireland, this statistic is also worryingly high with, as 
mentioned above, at least half of hospital-acquired bacteraemia being IVC-related 
(7). Ageing populations, increased reliance on a broad range of catheter types and 
the emergence of antibiotic resistant pathogens are all combining to pose a set of 
rapidly growing economic and logistical problems for healthcare systems around 
the world (24).  
A CRI can occur when microorganisms enter the lumen of the catheter. Nutrient 
rich blood products, having been passed through the catheter, can provide 
optimum growth conditions for bacteria as they provide a coating with host-derived 
matrix proteins to which bacteria can adhere (25). These matrix proteins include 
fibrinogen, fibronectin and collagen all of which are known to facilitate bacterial 
attachment. Microorganisms on catheter surfaces are present in one of two forms: 
the planktonic free-floating form in which organisms disseminate over the catheter 
surface and the sessile form whereby organisms are embedded in an attached 
biofilm (26). Gram-positive organisms, mainly staphylococci, are responsible for 
most incidences of CRIs (27) as staphylococci have  teichoic acids, clumping 
factors and fibrinonectin binding proteins that aid attachment to IVCs. However, 
there are also other bacteria associated with device-related infections (DRIs) 
including Enterococcus species, Gram-negative bacilli and Candida species. 
These complex infections involve microbial, device and host factors (28). It is the 
ability of these bacteria and yeasts to form biofilm that allow them to persist on the 
device surface. Biofilms are communities of sessile bacteria that are encased in a 
self-produced extracellular polymeric substance in which sophisticated quorum-
sensing between bacteria regulates growth and development of the biofilm 
community (29). They are a significant cause of morbidity and mortality and as a 
result are a threat to patients’ health. 
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1.4 Pathogenesis of staphylococcal infection  
1.4.1 Host response to staphylococcal infection 
A human host responds to bacterial infection via the immune system. The host 
immune response can be divided into innate and adaptive responses. Innate 
immunity is the body’s immediate response to infection; it is a non specific 
response and it is the body’s first line of defence against invading pathogens. In 
contrast, adaptive immunity is highly specific for stimulating antigens and may take 
a number of days to become fully activated (30). Adaptive immunity is dependent 
on B- and T-lymphocytes recognising specific antigens. B-lymphocytes produce 
highly specific antibodies upon stimulation by a specific antigen (31). Upon 
activation of B-lymphocytes, they develop into plasma cells that produce large 
quantities of this specific antibody. T-lymphocytes can be categorised as being 
either helper, regulatory, cytotoxic or memory T-cells. Helper T-cells upon 
stimulation by an antigen assist with the differentiation of B-lymphocytes into 
plasma cells. Regulatory T-cells, as their name suggests, play a role in controlling 
immune reactions. Cytotoxic T-cells bind and kill invading pathogens. They have 
also been shown to infiltrate bacterial biofilms at sites of bone infection (32). The 
enterotoxins produced by some strains of S. aureus can activate T-lymphocytes, 
leading to increased levels of cytotoxic T-cells (33).  
The innate immune response, although unspecific, has the ability to recognise 
conserved microbial motifs on the surface of invading bacterial cells that 
differentiates them from host cells (34). These microbial motifs, also called 
pathogen-associated molecular patterns (PAMPs), include cell wall components 
such as lipopolysaccharide (LPS) and importantly for staphylococcal infections 
lipoteichoic acid (LTA) and peptidoglycan (PGN) (35). These PAMPs are detected 
by pattern-recognition receptors (PRRs) on a number of host cells including, 
macrophages and neutrophils. A number of PRRs have been described and these 
include the IL-1 receptor/Toll-like receptor (TLR) family of receptors, the 
nucleotide-binding oligomerisation domain (Nod)-like receptors (NLRs) and a 
number of secreted PRRs, such as collectins (36). In the host defence against 
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staphylococci, TLRs, which are transmembrane receptors, are known to be 
important PRRs (37). There are over ten TLRs currently known, of these TLR 2 is 
implicated most often in the host response to staphylococci (38). The PRRs 
involved in recognising components of staphylococci and cellular localisation of 
these PRRs are shown in figure 1.2.  
TLR 2 forms hetrodimers with TLR 1 and TLR 6 to recognise lipopeptides on the 
surface of invading staphylococci (39, 40). TLR 2 has been shown to also 
recognise peptidoglycan (41, 42) as well as the staphylococcal biofilm component 
polysaccharide intercellular adhesin (PIA) (43). NOD domain proteins are PRRs 
that are found in the cytoplasm. NOD 2 is important in the recognition of muramyl 
dipeptide, a breakdown product of Gram-positive peptidoglycan (44). 
Peptidoglycan receptor proteins (PGRPs or PGLYRPs) are secreted proteins that 
bind peptidoglycan and exert a bactericidal effect (45). Tumour necrosis factor-α 
(TNF-α) receptor 1, as the name suggests, binds TNF-α however, this receptor 
also binds S. aureus protein A. Previous studies have shown protein A also 
initiates nuclear factor kappa B (NF-κB) activation (46). Ultimately, the recognition 
of these PAMPs and the activation of the signalling cascades via these receptors 
lead to NF-κB translocation to the nucleus and the up-regulation of genes encoding 
proinflammatory cytokines, chemokines, adhesion molecules, and antimicrobial 
peptides (47).  
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Figure 1.2 Pattern recognition receptors (PRRs) that recognise staphylococci. Toll-like 
receptor 2 (TLR2) heterodimerises with TLR1 and TLR6 to recognise lipopeptides (including 
lipoteichoic acid (LTA)). TLR2 also recognises peptidoglycan (PGN) and CD14 and CD36 act as 
TLR2 co-receptors, they signal via adaptor proteins Mal and Myd88. Nucleotide-binding 
oligomerisation domain containing 2 (NOD2) is an intracellular cytoplasmic receptor that recognises 
peptidoglycan breakdown product muramyl dipeptide. Peptidoglycan receptor proteins (PGRPs or 
PGLYRPs) are secreted proteins that recognise PGN. TNFR1 is a cell surface receptor that is 
activated by TNF-α but has also been shown to recognise S. aureus protein A. Signalling from 
these PRRs promotes activation of NF-κB and other transcription factors that induce transcription of 
proinflammatory cytokines, chemokines, adhesion molecules, and antimicrobial peptides that are 
involved in the host defence against staphylococci. Adapted from Krishna et al., (2012) (47). 
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Cytokines are inducible proteins that are mainly produced following the stimulation 
of white blood cells as they play a key role in the innate response (48). However, 
other cell types can also produce them when stimulated.  Several cytokines have 
been identified and these include the interleukins (ILs), interferons (IFNs) and 
growth factors. Cytokines use complex feedback loops, both positive and negative, 
which allow for self regulation and the regulation of other cytokines. Cytokines may 
also be either pro-inflammatory or anti-inflammatory. The induction of cytokines 
and chemokines due to infection, particularly in the case of S. aureus, can be both 
beneficial and detrimental to the host. Staphylococcal molecules, such as LTA,  
peptidoglycan and a component of staphylococcal biofilm (PIA), can induce TNF-α, 
IL-1β, IL-4, IL-6, IL-8, IL-12 and IFN-γ (43, 49). Many of these are pro-
inflammatory, IL-8 acts as a strong chemoattractant for neutrophils. 
Macrophage/monocyte chemoattractant protein-1 (MCP-1) and macrophage-
inflammatory protein-1 (MIP-1) are chemoattractive proteins for monocytes. These 
elicit recruitment of phagocytes to the infectious site (49). 
1.4.2 Immune evasion by staphylococci 
The body’s primary defence against invasion by pathogens such as staphylococci 
are the outer physical barriers that include the skin and mucosal layers. When 
bacteria breach these barriers the host immune system becomes activated. Many 
cell wall components of S. aureus are pro-inflammatory and these stimulate a 
strong inflammatory response (50). Leukocytes are the hosts’ primary immune 
defence against invading bacteria (3). Leukocytes are white blood cells that can be 
divided into five classes based on morphological characteristics. Neutrophils are 
one such class. Their principal role is to phagocytose and kill invading bacteria 
(51). Neutrophils are activated by the release of chemoattractants that are induced 
from host cells when bacteria gain access and are recognised by the hosts innate 
immune response (35). S. aureus has been shown to secrete the chemotaxis 
inhibitory protein of staphylococci (CHIPS). This is an immune evasion strategy 
that prevents the further recruitment of neutrophils to the infection site (52). S. 
aureus also targets leukocytes by secreting toxins such as Panton-valentin 
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leukocidin (PVL). These toxins have been shown to form pores in the membranes 
of target cells (53). The capsule that surrounds most, if not all S. aureus strains, 
has previously been shown to have protective properties for the bacteria when 
exposed to neutrophils (54). Another method of resisting phagocytosis involves the 
staphylococcal protein A (SpA). This method of immune evasion in S. aureus 
involves SpA present on both the cell surface and freely secreted. SpA inhibits 
opsonphagocytosis mediated by the host antibodies, it also inhibits a B-cell 
response (55). S. aureus has several other mechanisms that it utilises to avoid the 
immune response, such as platelet activation, toxin secretion and resistance to 
antimicrobial peptides (35). However, S. epidermidis immune evasion strategies 
are not as well understood (5, 35). S. epidermidis strains express a surface-located 
macromolecule poly-γ-DL-glutamic acid (PGA). Its primary role is osmoprotection 
but it has also been shown to play a role in resistance to antimicrobial peptides and 
the prevention of opsonphagocytosis by neutrophils (56, 57). S. epidermidis has 
recently been shown to secrete a number of toxins, although less than S. aureus. 
Among these toxins are phenol soluble modulins (PSMs) (5). These are small 
amphipathic peptides with pro-inflammatory properties (35). PSMs have a number 
of functions however, one of the most important in relation to immune evasion is 
the ability of one PSM, PSMδ, to lyse erythrocytes and leukocytes (58). 
It is thought that the ability of S. aureus and S. epidermidis to form biofilm is an 
important immune evasion strategy (35). The biofilm component polymeric N-
acetyl-glucosamine (PNAG) / polysaccharide intercellular adhesion (PIA), has 
been shown to have protective properties against phagocytes (59). The ability of 
neutrophils to kill bacteria has been shown in S. epidermidis to be inhibited by the 
presence of a biofilm (60). The presence of this polysaccharide within and 
surrounding the biofilm protects bacterial cells within from destruction by 
antimicrobial peptides (AMPs). This is thought to be achieved by preventing the 
AMPs from reaching the cell membrane (61). Despite staphylococcal infections 
resulting in an increased level of anti-staphylococcal antibodies, protective 
immunity is not observed. Patients presenting with a staphylococcal infection often 
suffer from recurring infections (3, 62).  
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1.4.3 Treatment evasion by staphylococci 
Treatment of infection due to S. epidermidis and S. aureus in planktonic form is 
possible with the appropriate antibiotics. However, once these bacteria form a 
biofilm treatment becomes significantly more problematic. Bacteria in biofilms are 
inherently more resistant to treatments; this is due to a number of factors. One 
relates to the sheer number of bacterial cells within a biofilm, which are either 
encased in a polysaccharide layer or are tightly knit together by protein-protein 
interactions that effectively protect the cells from host response and antimicrobial 
treatment. When cells become embedded in a biofilm, their metabolic activity drops 
dramatically, they begin to grow slower and it is thought some may become 
dormant. The mode of action of many antibiotics requires bacteria to be actively 
growing and as a result they become much less effective against slow growing 
biofilm cells. A study by Olson et al., (2002), demonstrated a one thousand times 
increase in the minimum inhibitory concentration (MIC) of bacteria to antibiotics 
when embedded in a biofilm (63). This is due to the requirement for antibiotics to 
penetrate through the biofilm and have activity against biofilms cells with an altered 
growth rate and metabolism. 
1.5 Transcriptional response to treatment 
Transcriptomics is the study of all the transcripts found within a collection of cells. 
In its simplest form, transcriptomics is used to determine what genes are being 
transcribed under different environmental conditions. This can provide useful 
insights into how the cells react to a given stimulus. It has previously been shown 
to be a valuable tool in determining the mode of action for new antimicrobials, as 
well as determining bacterial processes affected by stress response (64). A 
primary mechanism indicating adaptive processes in a cell is the changing levels of 
transcription. Coupled with translation it can lead to changes in membrane 
composition and production of new proteins (65). The complete set of transcripts in 
a cell for a specific developmental stage or physiological condition is called the 
transcriptome. By understanding the transcriptome it is possible to interrupt the 
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functional elements of the genome (66). Various techniques have been developed 
to explore and quantify the bacterial transcriptome.  
Until recently, transcriptomic analysis was predominantly undertaken using 
microarray based methods. Microarray technologies use chips, which have an 
ordered grid structure with clusters of small fragments of DNA; each cluster of 
fragments on the grid represent transcripts, of a known gene function, from the 
organism of interest. Microarray chips are incubated with fluorescently labelled 
cDNA, synthesised from RNA, which hybridise to any corresponding DNA 
fragments on the microarray chip. Following hybridisation, the fluorescence 
intensity for each arrayed fragment on the microarray chip gives a relative 
abundance of each transcript in the sample. 
Microarray experiments are high throughput and relatively inexpensive (67). While 
microarrays have been instrumental in the progression of genome transcription 
analysis, the technology has relatively limited range for gene transcript levels. This 
is due to the background saturation spot density and quality. Sequences from 
multiple strains can significantly affect hybridisation efficacy as oligonucleotide 
probes designed for one strain may not work for others. Therefore, this method is 
only suited to organisms with known and, ideally, well annotated genomes (66).  
Transcripts may cross-hybridise to other DNA fragments on the microarray chip 
and therefore results can be unreliable (67). Cross-hybridisation creates a lot of 
background noise, therefore low-level transcripts are often lost within this noise 
(66). Saturation of signals and hybridisation points means that the exact 
abundance of high-level transcripts cannot be determined. Together, background 
noise and saturation issues mean that microarrays have a very limited dynamic 
range, making it difficult to draw a comparison between experiments (66). 
Advances in sequencing have led to high-throughput technologies, this in turn has 
led to several advances in transcriptomics. In 2008, a number of studies used 
RNA-Seq to provide transcriptomics data in place of microarrays (68-71). In RNA-
Seq, cDNA is sequenced using high-throughput sequencers; the quantity of each 
transcript should be proportional to the number of sequence reads for that 
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transcript. There are several advantages for this method. Firstly, RNA-Seq does 
not require the genome to be sequenced or annotated (66), though this will enable 
easier data analysis. Secondly, the low background noise and inability to be 
saturated mean RNA-Seq has a very large dynamic range; comparative data 
indicates that RNA-Seq can detect 25% more transcripts than microarrays (66, 67, 
70). RNA-Seq can also be used for several applications beyond quantification of 
transcripts, including determining transcriptional start sites, identifying splice 
variants in eukaryotes and investigation of non-coding RNA (67, 68, 72). RNA-Seq 
has also been shown to be highly reproducible and accurate (66). 
Despite the benefits that RNA-Seq provides over microarray, there are still some 
unresolved issues with RNA-Seq. Firstly, amplification steps used in cDNA 
production and library construction may create bias or PCR artefacts within results 
(66, 73). Secondly, fragmentation techniques used in library construction can 
create sequencing bias (66, 73). It is also believed there is a bias during 
sequencing towards genes with higher GC-contents (73). Bioinformatics analysis 
tools often aim to correct these bias’, however bioinformatics tools used to identify 
differentially expressed transcripts between samples can introduce their own bias. 
Different bioinformatics analysis pipelines run on the same datasets have been 
shown to dramatically alter results (73-75).  
1.6  Bacterial biofilm 
Bacteria were first described by Antonie van Leeuwenhoek in 1684, with the 
discovery of bacterial cells embedded in oral plaques, although it was not realised 
at the time this was the first observation of bacterial biofilm (76). It was not until the 
1930s that the clustered growth of these sessile communities on submerged 
surfaces was described (77, 78). However, it is only in recent decades that the 
medical importance and elaborate organisational structure of biofilms have been 
appreciated (79-81). Microorganisms in nature are present in one of two forms: the 
planktonic free-floating form, where organisms are disseminated over a surface, 
and the sessile form where organisms have become embedded in an attached 
biofilm (26). It is in the latter where the majority of microbes reside. Biofilms can be 
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defined as a community of bacterial cells encased in a self-produced polymeric 
matrix that is adherent to an inert or living surface (82). Biofilms are structures 
interspersed with aqueous channels that facilitate transport of nutrients into and 
waste products away from the structure (83). In biofilm communities, extracellular 
polymeric materials, or surface associated adhesins, anchor the cells to a surface 
and “glue” the bacteria together (84). The biofilm shields the bacterial cells from 
physical and chemical attack. The biofilm also traps nutrients and water that allow 
the microorganisms to survive in otherwise inhospitable environments (82). 
Characterisation of biofilm adhesins and extracellular matrices has been the focus 
of extensive research in order to develop effective agents for the treatment of 
biofilms (29, 85-87). The adaptive and genetic changes of the cells within the 
biofilm make them highly resistant to conventional therapeutic doses of 
antimicrobial agents and clearance by the host response. As a result, effective 
treatment often requires device removal, which can represent a significant clinical 
problem to the patient as it may impact treatment and expose them to the risks 
associated with anaesthetics  (88). 
1.7   Staphylococcal biofilm infections 
Staphylococci are recognised as the most frequent cause of biofilm-associated 
infections. Staphylococcal biofilms develop on implanted medical devices, such as 
IVCs. Amongst the staphylococci, S. aureus is regarded as the most virulent 
species due to the wide array of secreted and cell surface associated virulence 
factors, mechanisms of immune evasion and toxin production it possesses (89). 
Over recent decades the CoNS, most notably S. epidermidis, have become a well 
recognised opportunistic pathogen in patients with medical devices in situ (90).   
In order to assess future treatment strategies, a clear understanding of the 
pathogenesis of the staphylococcal biofilm needs to be elucidated. There has been 
significant progress in this area in recent years resulting in a clearer understanding 
of the stages involved in staphylococcal biofilm development. Biofilm formation by 
staphylococci has been proposed to occur in two stages, the first being the initial 
attachment to a surface and the second involving cellular proliferation and 
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accumulation of a multi-layered biofilm (see figure 1.3). Cells within the biofilm are 
then released and these may revert to planktonic state or they may seed and form 
biofilms in other body sites (15, 29).   
 
Figure 1.3 Biofilm formation. This  occurs in two stages (i) primary attachment to the surface of 
the implant and (ii) cellular proliferation and accumulation of a multi-layered biofilm composed of 
microcolonies separated by fluid filled channels (91). Dispersal of cells from the biofilm occurs after 
a critical mass of bacterial cells is reached. 
1.7.1 Factors contributing to initial biofilm attachment 
The initial attachment of bacteria to a surface is the first stage of biofilm formation. 
This may involve specific and non specific interactions of the bacterial cell with the 
surface being colonised. It is often the non-specific interactions such as cell 
surface hydrophobicity that influence adhesion to implanted medical devices (92).  
The staphylococcal major autolysin (Atl), a bi-functional protein, and teichoic acids 
are contributors to cell surface hydrophobicity and both have been implicated in 
primary attachment to surfaces (87). Other important factors in primary attachment 
are the surface characteristics of the implanted device, including hydrophobic 
properties (93). Following insertion into the patient, biomaterials are rapidly coated 
with a conditioning film comprising host-derived matrix proteins, such as 
fibronectin, fibrinogen and collagen (25). Some of these host proteins can act as 
receptors for bacterial attachment (91). Staphylococcal binding to extracellular 
matrix proteins is mediated by a group of exposed surface proteins referred to as 
Stage One 
Stage Two 
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microbial surface components recognising adhesive matrix molecules 
(MSCRAMMs) (94).  
1.7.1.1 The staphylococcal major autolysin (Atl / AtlE) 
Atl, along with teichoic acids, are believed to be significant contributors to cell 
surface hydrophobicity and have both been implicated in primary attachment to 
surfaces. Atl is a cell wall-anchored peptidoglycan hydrolase and it is the 
predominant peptidoglycan hydrolase in staphylococci (87, 95). Atl is a bifunctional 
protein with a N-terminal amidase domain, a central cell wall anchoring domain, 
which consists of three repeat regions of GW-dipeptide motifs, and a C-terminal 
glucosamidase domain (see figure 1.4) (96). The protein undergoes proteolytic 
processing via an uncharacterised mechanism to generate two extracellular lytic 
enzymes, amidase (AM) and acetylglucosaminidase (GL) that can be found in 
culture supernatants (97). These enzymes are found in both S. aureus and S. 
epidermidis. 
Houston et al., (2011) demonstrated that an atl deletion mutation reduces primary 
attachment rates and impairs biofilm formation on both hydrophilic and 
hydrophobic surfaces in MRSA isolates. However, the same mutation only 
impaired methicillin sensitive S. aureus (MSSA) biofilm formation on hydrophobic 
surfaces (87). Atl has a homologue in S. epidermidis called AtlE, which has also 
been shown to be important for primary attachment to abiotic surfaces (98). Atl is 
known to play an important role in cell division. Staphylococci with atl null 
mutations have been reported to grow in clusters as the cell wall is unable to fully 
separate (99). They have also been reported to have a rough cell surface and an 
impaired turnover of cell wall peptidoglycan (100). 
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Figure 1.4 Domain arrangement of the bifunctional Atl/AtlE protein. Diagram of the 137.8 kDa 
Atl / 148 kDa AtlE pro-protein.  Arrows indicate the post-translational cleavage sites. The signal 
peptide (SP), pro-peptide (PP), catalytic domains (cat), and R1 R2 R3 repeat domains are 
illustrated. Adapted from Zoll et. al., (2010) (101).  
1.7.1.2 Microbial surface components recognising adhesive matrix molecules 
It is well known that staphylococcal binding to extracellular matrix proteins is 
mediated by the surface proteins referred to as MSCRAMMs (94). These are cell 
surface ligand binding surface protein adhesins that allow staphylococci to readily 
bind to a variety of blood and extracellular matrix molecules (92). The binding of 
MSCRAMMs to their respective ligands is a vital process required for 
staphylococcal colonisation and invasion (102, 103). The S. aureus genome 
comprises of more than 20 genes encoding co-valently attached surface anchored 
adhesins. In comparison, there are just 12 genes encoding these covalently linked 
proteins in S. epidermidis RP62A (104). Many MSCRAMMs are implicated in the 
initial attachment stage of staphylococcal biofilm formation (105, 106), whereas 
others function in intercellular accumulation and the later stages of biofilm 
formation (107, 108). 
The term MSCRAMM was initially used to describe proteins based on functional 
similarities, namely the ability to bind to host extracellular matrix proteins (42). 
However, recent work has demonstrated that many MSCRAMMs have roles in 
staphylococcal virulence that go beyond binding to host ligands. Many 
MSCRAMMs are multifunctional proteins and also have roles in immune evasion, 
cell invasion, iron acquisition and asymptomatic colonisation (109). The term 
MSCRAMM is now used to describe a family of proteins based on structural rather 
than functional similarity. Thus, MSCRAMMs are now defined as proteins that have 
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a common mechanism for ligand binding mediated by at least two adjacent 
subdomains containing IgG-like folds in the N-terminal A region of the proteins 
(110, 111). 
1.7.1.2.1 Cell surface anchorage 
The anchoring of surface proteins to the cell wall in staphylococci requires both an 
N-terminal signal peptide and a C-terminal cell wall sorting signal (LPXTG motif) 
(112). A membrane bound transpeptidase, called sortase, cleaves the peptide 
bond between the theonine and glycine of the LPXTG motif and covalently links 
the carboxyl group of theonine with the amino group of the peptidoglycan cross 
bridges (113, 114). S. aureus has two genes encoding two separate sortase 
enzymes, srtA and srtB. SrtA is responsible for anchoring proteins bearing the 
LPXTG motif mentioned above. Strains lacking srtA are unable to anchor LPXTG 
proteins at the cell surface. As a result, SrtA mutants have been shown to be 
defective in a number of animal infection models of BSI and septic arthritis (115, 
116). SrtB is required to anchor the iron regulated surface protein, IsdC that has an 
NPQTN motif (115, 117). Staphylococci lacking SrtB show a slight defect in the 
ability to cause septic arthritis in a murine model (116). 
Some SrtA-anchored proteins are characterised as MSCRAMMs and interact with 
host extracellular matrix proteins to initiate primary attachment during biofilm 
formation, whereas others are implicated in the latter stages and mediate 
intercellular accumulation, such as the accumulation-associated protein (Aap) of S. 
epidermidis, and SasG of S. aureus. 
1.7.1.2.2 Collagen binding proteins 
Staphylococci can express proteins that facilitate binding of the bacterial cell to 
collagen.  In S. aureus, the collagen-binding protein (Cna) mediates attachment. 
Cna has been shown to facilitate the attachment of S. aureus to collagen and 
cartilage (118). In a septic arthritis murine model, a S. aureus cna mutant was 
significantly less virulent that the wild type cna-expressing parent strain (119). In S. 
epidermidis, the extracellular lipase, GehD, has been identified as a collagen 
36 
 
binding protein. The structure of GehD differs dramatically from Cna as it does not 
contain an LPXTG motif.  However, it does resemble the mammalian integrins 
previously shown to bind collagen (120). Recombinant mature GehD protein binds 
to collagens type I, II and IV and this attachment can be inhibited by anti-GehD 
antibodies. These results suggest GehD has a role as a cell surface-associated 
collagen adhesin as well as being a lipase (120). While collagen binding proteins 
have not been shown to be directly required for biofilm formation, it has been 
suggested that other important factors may be co-regulated with these proteins 
(121).  
1.7.1.2.3 Clumping factor proteins 
In S. aureus, the cell wall anchored proteins clumping factor A (ClfA) and B (ClfB), 
along with the fibronectin binding proteins A and B (FnBPA and FnBPB) recognise 
fibrinogen. Fibrinogen, a glycoprotein, is involved in blood clot formation. S. aureus 
has been shown to express several proteins that bind fibrinogen. ClfA is 
distinguished by the presence of a serine aspartate (SD) dipeptide-region located 
between a ligand-binding A region and C-terminal sequences associated with the 
attachment of the protein on the cell wall (122). The fibrinogen binding sites are 
located in the A domains (123, 124). In ClfA the A domain is divided into three 
subdomains, N1, N2, and N3 and the ligand binding site is contained within 
subdomains N2 and N3 (123, 124). ClfA is inhibited in its binding to fibrinogen by 
Ca2+ (125). ClfA mediates bacterial attachment to plasma clots formed in vitro and 
to plastic biomaterial. Thus, it is probably a significant factor in wound and foreign 
body infection involving biofilm. In a recent study on biofilm formation on plasma 
coated surfaces, ClfA was shown to be a critical factor in the ability of S. aureus to 
form biofilm under shear stress (126). In a rat infective endocarditis model, a clfA 
mutant was significantly less virulent than the wild-type parent strain (127). ClfB 
has also been shown to bind keratin (124). Both clfA and clfB are non allelic 
variants but are instead distinct genes. In contrast to ClfA, which is expressed 
during all stages of growth, ClfB is only expressed in cells grown aerobically to the 
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early exponential phase (124). It is absent from the surface of cells grown to 
stationary phase without aeration (124).  
1.7.1.2.4 Fibronectin binding proteins 
The ability to bind fibronectin is a common property of S. aureus isolates (128). In 
addition to its functions in cellular adhesion, differentiation and tissue repair after 
injury, fibronectin has adhesive sites for various molecules such as heparin, 
collagen, fibrin and specific integrins (129). The fnbA and fnbB genes (116, 128) 
encode two related fibronectin-binding proteins, FnBPA and FnBPB, both are 
expressed in most S. aureus strains (130). The expression of either FnBPA or 
FnBPB on the surface of S. aureus is sufficient to promote bacterial adhesion to 
immobilised fibronectin (128). They are known to be involved in the first phases of 
foreign body infection involving biofilm (128, 131). A role for the FnBPs in citrate-
induced S. aureus biofilm production has been reported (132). Mutations in the agr 
global regulatory locus, which represses expression of the FnBPs, was previously 
shown to promote biofilm production (133). Similarly mutation of LexA, a repressor 
of fnbB expression (134), also increased FnBP-mediated biofilm (133). Importantly, 
using a mouse foreign-body infection model, a fnbAB mutant was significantly less 
able to colonise a subcutaneous implanted catheter than the wild type or icaADBC 
mutant strains (133) suggesting that the FnBP-dependent biofilm phenotype may 
be an important virulence determinant (87). FnBPs are absent in S. epidermidis 
(135).  
1.7.1.2.5 Teichoic acids 
Teichoic acids (TAs) of S. aureus influence the net charge of the cell surface, play 
a role in primary attachment (136), influence cell shape (137) and interactions with 
epithelial cells (138) and control autolysis (136). Staphylococci contain two types of 
teichoic acid, peptidoglycan bound wall teichoic acids (WTA) and membrane 
anchored lipoteichoic acids (LTA) (138, 139). WTA comprise of octamers of ribitol 
phosphate whereas lipoteichoic acids contain glycerol phosphate groups (140). 
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There are several ways TAs contribute to the initial stages of S. aureus and S. 
epidermidis biofilm formation.  
Cell surface TAs are modified by the addition of positively charged D-alanine 
residues by the enzyme products of the dltABCD operon. The net charge of S. 
aureus TAs has been shown to be an important factor controlling attachment to 
and subsequent biofilm formation on inert surfaces. A dltA mutant was unable to 
form biofilm on glass or polystyrene due to defective primary attachment (136). 
This indicates that D-alanine modified teichoic acids are required for optimal 
staphylococcal attachment to hydrophilic and hydrophobic surfaces (136). In a 
more recent study, a LTA mutant demonstrated significant changes in cell surface 
hydrophobicity, which is essential for interactions with hydrophobic surfaces 
initiating primary attachment and biofilm formation by S. aureus. In addition to this, 
autolytic activity was reduced in a LTA mutant and, as discussed in an earlier 
section, the autolytic activity of Atl is another factor mediating primary attachment 
and biofilm formation (141). Deletion of tagO in S. epidermidis has been shown to 
induce changes consistent with the loss of WTA. These include increased 
sensitivity to osmotic stress and temperature. Through the use of this mutant, WTA 
was shown to be essential for S. epidermidis biofilm attachment and accumulation 
(142).  
1.7.1.2.6 Sdr proteins 
Sdr proteins are cell wall anchored proteins structurally related to the MSCRAMM 
proteins ClfA and ClfB.  Sdr proteins mostly consist of 4 main components: a 
ligand binding domain A, a collagen binding domain B, a serine aspartate (ser-asp) 
repeat region and a C-terminal region that anchors the protein to peptidoglycan 
(106, 143). In S. aureus, the sdr locus encodes three proteins SdrC, SdrD and 
SdrE. The SdrC, SdrD and SdrE proteins have an additional repeat region 
between the A region and the SD repeat. These collagen binding repeats can also 
bind Ca2+ and have a motif similar to that of ClfA. The binding of Ca2+ is necessary 
to maintain the structural integrity of the protein (143). In a study by Josefsson et 
al., (1998), sdrC was shown to be present in all S. aureus strains tested alongside 
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either sdrD or sdrE (143). The combined expression of sdrC and sdrD was 
previously linked to bone infections involving S. aureus (144). SdrE is able to 
induce aggregation of platelets (145). Plasma proteins are needed for this 
interaction suggesting that the binding is indirect (145). Functions for SdrC and D 
are still not known.   
S. epidermidis can also express three homologous cell surface associated proteins 
SdrF, SdrG and SdrH. SdrF has been shown to bind, with high affinity, to exposed 
hydrophilic as well as hydrophobic surfaces (146). It has also been demonstrated 
in a murine model of a ventricular assist device infection that the capacity of SdrF 
to adhere to the device was reduced with anti-SdrF antibodies (147). SdrG was 
first identified by Nilsson et al., (1998) where it was initially referred to as a 
fibrinogen binding protein (Fbe) (148). It has since been changed to SdrG after the 
discovery of a ser-asp repeating region (149). SdrG binds fibrinogen in a “dock, 
lock & latch” mechanism (150). Strong interactions such as this play an important 
role in DRIs. They allow the pathogen to adhere to the host protein-coated device 
and withstand constant shear forces (151). Deletion of sdrG leads to a decrease of 
adherence to fibrinogen-coated surfaces, and antibodies to SdrG lead to a 
decrease of S. epidermidis adherence to biomaterials in vivo (90, 152, 153). 
1.7.1.2.7 Iron regulated surface determinants 
Iron is an essential requirement for many bacterial processes, such as aerobic 
respiration and DNA replication (154). Bacteria, including staphylococci, have 
evolved strategies for the acquisition of iron from host cells. Haem is their preferred 
source of iron (155). The S. aureus haem absorption system involves a number of 
iron-regulated surface determinants (Isd). These comprise of surface proteins 
IsdA, IsdB, IsdC and IsdH, a membrane transporter (IsdD, IsdE and IsdF), a 
transpeptidase (S. aureus sortase B, SrtB) and the haem-degrading 
monooxygenases IsdG and IsdI (156, 157). The isd gene cluster is regulated by 
the ferric uptake repressor (Fur). In the presence of high iron concentrations, Fur 
binds to a DNA sequence on the isd transcriptional unit and inhibits transcription 
(158). IsdA has been previously shown to promote bacterial adhesion to the nasal 
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epithelial cells (159). Surface protein IsdC has been implicated in initial attachment 
of biofilm. One study revealed an isdC mutant resulted in a 36% reduction in initial 
attachment of S. lugdunensis biofilm. IsdC has also been indicated to be involved 
in the latter stages of biofilm formation but studies to expand on this have not been 
published (160). To date no Isd system has been observed in S. epidermidis.  
1.7.1.2.8 Non covalently attached cell wall proteins 
S. aureus also possesses a number of non-covalently attached cell wall associated 
proteins that bind to components of the host’s extracellular matrix. In S. aureus, 
elastin-binding protein (EbpS) mediates the binding of the cell to the elastin 
monomer, topoelastin and to soluble digested elastin fragments. Expression of 
ebpS has been correlated with the ability of cells to grow to a higher density in 
liquid culture, suggesting that EpbS may also have a role in regulating cell growth 
(161). The extracellular matrix protein (Emp) is expressed in the stationary growth 
phase and is closely associated with the cell surface. Emp can promote the 
adhesion to host proteins, such as fibronectin, fibrinogen and collagen and it is 
thought to contribute to S. aureus pathogenicity (162). S. epidermidis also possess 
a number of non-covalently linked cell wall proteins, such as Aap and the 
extracellular matrix binding protein (Embp). These proteins, however, are involved 
in the accumulation phase of biofilm formation and play a minimal role in early 
attachment (discussed below).  
1.7.1.2.9 Capsular polysaccharide 
Another factor that influences initial adherence in S. aureus is the capsular 
polysaccharide (CP). The majority of S. aureus strains express one of eleven CP 
types (163). Most strains associated with human colonisation or infection produce 
either CP type 5 or CP type 8 (164). A capsular polysaccharide has also been 
reported in S. epidermidis. Capsular polysaccharides have previously been 
reported to be involved in mediating attachment to biomaterials as well as forming 
a component of a biofilm layer (165, 166).  
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1.7.2 Factors contributing to the accumulation of staphylococcal biofilm 
After initial attachment of bacterial cells to a surface, intercellular accumulation and 
biofilm maturation occurs. Clinical isolates of S. aureus are capable of producing at 
least two distinct types of biofilm mediated by either the genes in the intercellular 
adhesin operon (ica) , which encode the enzymes involved in the synthesis and 
export of PNAG/PIA, or the fibronectin-binding proteins (FnBPs) (ica-independent 
biofilm) (167). For S. epidermidis biofilm formation, PIA has been reported to be 
essential (168), but there have been a number of S. epidermidis PIA-negative 
biofilm-related infections reported, with Rohde et al., (2005) reporting a small 
number of strains with the ability to form proteinaceous biofilm (169). In a study by 
Stevens et al., (2008) a similar observation was made in cerebral spinal fluid (CSF) 
isolates (170). 
1.7.2.1 Polysaccharide intercellular adhesion / polymeric N-acetyl-
glucosamine  
The production of PIA/PNAG by ica (intercellular adhesin) operon encoded 
enzymes (IcaADBC) (171, 172), is currently the best understood mechanism of 
biofilm formation in staphylococci. Production of this exopolysaccharide (see figure 
1.5) is an important virulence determinant in staphylococci causing biofilm 
infections. It has an amorphous structure that protects the bacterial cells residing 
within, from the host immune system, standard concentrations of antibiotics as well 
as several antiseptics. In addition, animal studies have shown that purified 
PNAG/PIA can elicit protective immunity against both S. epidermidis and S. 
aureus, leading authors to suggest its potential as an anti-staphylococcal vaccine 
(165, 173, 174). 
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Figure 1.5 Structure of polysaccharide intercellular adhesin (PIA/PNAG). The polysaccharide 
is a linear homoglycan composed of β-1,6-N-acetylglucosamine residues (GlcNAc). (175) 
 
1.7.2.2 icaADBC and biofilm formation 
PNAG/PIA produced by S. epidermidis and S. aureus is encoded by the ica operon 
(176, 177). The ica operon consist of four genes: icaA, icaB, icaC and icaD (figure 
1.6). The icaA gene product is a transmembrane protein that displays N-acetyl-
glucosaminyltransferases activity. It has been shown that co-expression with IcaD 
is needed for optimal activity. It was initially thought that the IcaA and IcaD 
polypeptide comprised a single protein, but western blot analysis revealed that 
IcaA and IcaD represent two distinct proteins (175). It was found that N-acetyl–
glucosamine oligomers produced by IcaAD reach a maximal length of only 20 
residues. It is only when icaAD is co-expressed with icaC that longer oligomer 
chains are synthesised. The exact function of the IcaC product, an integral 
membrane protein, is still unclear. However, it may assist translocation of the 
polysaccharide through the cytoplasmic membrane (175). IcaB is an extracellular 
protein and may act as a PIA/PNAG-specific deacetylase. The deaceylation of N-
acetylglucosamine residues introduces positive charges along the length of the 
molecule, and this appears to be important in PIA-mediated biofilm formation and 
immune evasion (177, 178). Deacetylatylated PIA has also been shown to be less 
immunogenic. Indeed, using a mouse model of device-related infection, Vuong et 
al., (2004) reported that a S. epidermidis ∆icaB mutant was significantly impaired in 
its ability to establish infection compared to a wild type strain (178).  
43 
 
 
Figure 1.6 PIA/PNAG production in S. epidermidis and S. aureus is encoded by the ica operon, 
which contains the structural genes required for biofilm formation. The Ica proteins are encoded by 
the ica gene locus containing the icaADBC operon and icaR , which encodes a negative regulatory 
protein. Expression of the icaADBC operon is regulated either directly at the icaA promoter or 
through expression of IcaR, both of which can be controlled by several of global regulatory proteins 
(SigB, SarA and LuxS). 
1.7.2.3 ica-independent biofilm 
Despite the important role of the icaADBC locus in PIA/PNAG production and 
staphylococcal biofilm development, several reports have highlighted the existence 
of ica-independent mechanisms of biofilm formation in clinical isolates of both S. 
aureus and S. epidermidis (169, 179-182). This perhaps is not surprising given the 
diverse array of cell surface adhesins employed by the staphylococci to bind to the 
extracellular matrix. Carriage of the ica locus is strongly associated with biofilm 
forming capacity in S. epidermidis and is more commonly found in isolates from 
DRIs than commensal strains (183, 184). In contrast, the relationship between ica 
and biofilm formation in S. aureus is more ambiguous even though this locus is 
maintained and expressed in almost all of S. aureus isolates (183, 185). In ica- but 
biofilm-positive strains of S. aureus and S. epidermidis, the ability to form biofilm 
remains but the mechanism is dependent on protein-mediated interactions (169).  
 
 
     icaR icaA ica
D 
icaB icaC 
 
PIA/PNAG 
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1.7.2.3.1 The biofilm associated proteins  
The biofilm associated proteins (Baps) are a family of LPXTG-surface proteins 
which share several structural and functional features that are involved in biofilm 
accumulation. The importance of the Bap protein was first described by Cucarella 
et al., (2001) (186). This was the first ica-independent biofilm mechanism reported. 
This group demonstrated that Bap was essential for both initial attachment and 
intercellular aggregation during biofilm development by bovine mastitis isolates 
(186). Despite the absence in human clinical S. aureus isolates, Bap has emerged 
as a member of over 100 surface proteins with conserved structural and functional 
characteristics, that play an important role in biofilm development (187). A Bap 
homologue was identified in S. epidermidis RP62A, designated Bhp (Bap 
Homologue Protein). It was found to be present in bovine as well as human strains 
of S. epidermidis. In 2005, a bhp mutation abolished biofilm formation in a strong 
biofilm forming bovine mastitis S. epidermidis isolate. Interestingly, it was observed 
that the strain lacked the ica operon. In addition, overexpression of bhp in an ica- 
strain of S. epidermidis induced biofilm forming capacity (188). In DRIs involving 
biofilms, Bhp is thought to be important in early stages of biofilm growth as well as 
intracellular attachment (189).  
1.7.2.3.2 Protein A 
Staphylococcal protein A (Spa) is a cell wall component of most S. aureus strains, 
it was the first of these proteins to be identified (190). Protein A is encoded by the 
spa gene (112). It is comprised of an N-terminal signal sequence, repeat domains 
and the cell wall attachment sequence (LPXTG). There are five N-terminally 
located repeats, these repeats bind to the Fc region of immunoglobulin (Ig) G (104, 
191). Protein A has been shown to bind to von Willebrand factor (192, 193), 
platelets (194) and the tumour-necrosis factor receptor one (TNFR1) (46). Spa has 
been shown to be important for S. aureus biofilm formation (195). Merino et al., 
(2009) demonstrated a significant contribution of protein A to the development of a 
foreign device infection involving biofilm in a murine model. It was also observed in 
this study that the attachment of protein A to the bacterial cell surface was not 
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required, indicating secreted protein A from S. aureus strains was sufficient to 
induce biofilm formation (195).  
1.7.2.3.3 Accumulation-associated protein 
A mutant lacking a 115-kDa protein in S. epidermidis RP62A was described by 
Schumacher-Perdreau et al., (1994). This protein was shown to be required for 
biofilm accumulation in ica- strains (196). Further work later confirmed this protein 
to be 140-kDa in size and it was named accumulation associated protein (Aap). 
Antiserum raised against the Aap protein inhibited the accumulation of S. 
epidermidis biofilm (197). Rodhe et al., (2005) showed  the accumulative function 
of the protein was only gained when the full length Aap (220 kDa) was 
proteolytically cleaved by either host or staphylococcal proteases. When this 
truncated form of Aap (140kDa) was expressed in an aap- strain, a biofilm-positive 
phenotype was induced. However, this was not the case with the full length, 
uncleaved protein (169). 
In S. aureus, the staphylococcal surface proteins G (SasG) and plasmin sensitive 
surface proteins (Pls) have been shown by sequence analysis to be Aap 
homologues (198-200). It is possible these surface adhesins could contribute to 
PIA/PNAG independent biofilm formation in S. aureus. Aap contains a LPXTG 
motif at its C-terminal that is recognised by sortase and anchored to the cell wall 
(189). Previous studies have suggested that Aap may anchor PIA/PNAG to the 
bacterial cell surface (197, 201). A recent study demonstrated that S. aureus SasG 
variants, with high numbers of B repeats, were capable of promoting biofilm (202). 
1.7.2.3.4 Extracellular DNA 
Extracellular DNA (eDNA) is an important component of the staphylococcal biofilm 
architecture that has only been recognised in recent years. In S. aureus and S. 
epidermidis biofilm formation, eDNA has both a structural and functional role (203). 
eDNA is released by autolysis of the bacterial cell in a process known as “altruistic 
suicide” (204). This occurs when one bacterial cell sacrifices itself for the common 
good of the biofilm community. In S. epidermidis, AtlE regulates this lysis. 
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However, in S. aureus it is mediated by two operons, lrgAB and cidABC (205-207). 
These operons encode the proteins LrgA and CidA respectively and both have 
previously been shown to be involved in the regulation of cell death (208). CidA is 
thought to be a holin that promotes murein hydrolase activity, while LrgA is an 
antiholin and represses this activity. Holins are a diverse group of small proteins 
that lead to hole formation and murein hydrolase activation (209). In staphylococci, 
increased amounts of eDNA lead to an enhanced biofilm formation, this has been 
demonstrated using an lrgAB mutant (210). 
1.7.2.3.6 Extracellular adherence protein 
The extracellular adherence protein Eap is a 60-70 kDa non-covalently linked 
surface protein that has a role in S. aureus biofilm formation. The Eap protein is 
found in various sizes in more than 96% of clinical S. aureus isolates screened 
(211). No homologues of this protein have been found in S. epidermidis (211). 
During the 1990s, a number of research groups isolated and characterised a 
number of proteins that shared similar binding properties to extracellular matrix 
glycoproteins and were of a similar size (212-214). The term Eap was first applied 
to the 60 kDa protein identified by M. K. Bodén and J. I. Flock (1992) and M. H. 
McGavin, et al., (1993) that had a high binding affinity to a variety of host ligands 
including bone sialoprotein, fibronectin and fibrinogen (212, 215, 216). A 
subsequent study in 2001 found that all of the proteins identified during the 1990’s 
exhibited extensive homology and were in fact the same protein, namely Eap 
(211). Secreted Eap mediates biofilm formation by binding with high affinity to 
epithelial, fibroblast and endothelial cells (217) and multiple host ligands including 
fibrinogen, fibronectin and serum proteins (216, 218, 219). Another mechanism by 
which Eap contributes to DRIs and biofilm formation is through direct interactions 
between secreted Eap proteins that can mediate intercellular aggregation and 
attachment to uncoated polystyrene (216, 220). Eap also contributes to biofilm 
formation under iron-limited conditions (221). 
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1.7.2.3.6 Other factors contributing to staphylococcal biofilm formation 
Extracellular matrix binding protein (Embp) has been shown to be essential for 
biofilm accumulation in ica- and aap- S. epidermidis strains (222). Embp is a cell 
surface protein that unusually lacks an LPXTG motif. This suggests a non-covalent 
bond mediating attachment to the cell surface (222). The embp gene has been 
shown to be expressed only in the presence of serum. The embp homologue in S. 
aureus is ebh. This gene is divided into two open reading frames, ebhA and ebhB, 
the transcription of which has been demonstrated to be under the control of the 
accessory gene regulator (agr) (223).  
The SesC protein is a sortase anchored LPXTG protein found in the S. epidermidis 
cell wall. It is encoded by the sesC gene (189). In a 2009 study, antibodies 
generated against SecS reduced biofilm forming capacity. It was also shown that 
sesC becomes upregulated during the accumulation phase of biofilm formation 
(224). In a more recent study, SesC was suggested as a promising vaccine 
candidate after S. epidermidis biofilm formation was inhibited in a rat model of 
subcutaneous foreign body infection by injecting animals with a recombinant 
truncated SesC. However, animals were not fully protected from infection (225). 
1.7.3 Regulation of biofilm  
1.7.3.1 icaR 
IcaR is the negative regulator transcribed divergently from the ica operon and the 
ica structural genes. IcaR belongs to the tetracycline repressor family of proteins, 
which are involved in gene regulation, acting as either transcriptional activators or 
repressors. The icaR gene is located upstream of the icaA gene (shown in figure 
1.6) and is a repressor of ica transcription in S. epidermidis (86, 226) and S. 
aureus (227). IcaR tightly regulates expression of the icaADBC locus in response 
to environmental stimuli. These stimuli include temperature changes and the 
addition of ethanol to growth medium, they have previously been shown to 
influence PIA-dependent biofilm formation (86, 226-228). Transcription of icaR was 
shown by Conlon et al., (2002) to be decreased in the presence of ethanol. 
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Exposure to salt is not thought to affect icaR expression but does result in an 
increase in biofilm formation through activation of the icaADBC locus (226). SarA 
and SigB have previously been shown to be positive regulators of icaR expression 
in S. aureus (229), this is in contrast to S. epidermidis where only SigB was shown 
to regulate IcaR. 
1.7.3.2 The accessory gene regulator (agr)   
Cells within a biofilm are an integrated community. This community uses quorum-
sensing (cell-to-cell signalling) to coordinate gene expression involved in 
attachment, maturation and detachment of the cells in the biofilm (230). These 
occur in response to environmental stimuli. The best characterised quorum-
sensing system in staphylococci is the agr system. The agr locus was first 
identified by Recsei et al., (1986) (231). About 150 genes have been shown to be 
regulated by a putative multi-component signal transduction system encoded by 
the agr locus (232), with at least 16 of these being associated with virulence genes 
(233). The agr locus facilitates communication between bacteria by producing and 
sensing a molecule called an autoinducing peptide (AIP).  The agr locus consists 
of two divergent promoters P2 and P3 that modulate transcription of two transcripts 
RNAII and RNAIII, respectively. The RNAII transcript contains four genes agrB, 
agrD, agrC and agrA. The RNAIII transcript acts as the effector molecule of the 
locus (230) (figure 1.7).  
Activation of the agr system has been shown to increase the production of 
extracellular proteases via the effector molecule RNAIII (234).  These proteases in 
turn can influence biofilm development and detachment. Recent studies have 
shown that upon dispersal from the biofilm, bacteria display high levels of agr 
activity whereas agr expression is repressed in cells that remain within the biofilm 
(29). Activation of the agr system and increased levels of protease activity degrade 
protein adhesins that cement the cells within the biofilm of ica- and polysaccharide-
independent biofilms. Thus, mutations in agr can promote ica-independent biofilm 
while having a neutral effect on ica-dependent types of biofilm (10, 29, 235, 236). It 
was recently reported  in S. aureus that high level expression of methicillin 
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resistance is accompanied by repression of both the agr and ica loci (237). This is 
consistent with the expression of protein adhesin mediated biofilm in clinical MRSA 
isolates. Glucose depletion has been previously shown to disperse S. aureus 
biofilms as agr becomes activated (29).  In S. epidermidis, biofilm forming capacity 
is increased in an agr mutant as agr negatively regulates atlE transcription (238). 
 
Figure 1.7 Agr quorum sensing. The P2 promoter transcribes the right operon consisting of 
agrABCD. The leftward operon is transcribed from the P3 promoter and this encodes RNAIII. AIP is 
derived from the gene product of agrD throughout the action of the AgrB protein, which is also 
responsible for the export of the peptide from the cell. This peptide interacts with AgrC causing it to 
auto-phosphorylate. The phosphate is then transferred to the response regulator AgrA which then 
activates P2 and P3. (Adapted from Cámara et al., 2002). 
1.7.3.3 The staphylococcal accessory regulator (SarA) 
The staphylococcal accessory regulator (SarA), is a central regulatory element that 
controls the expression of staphylococcal virulence factors (239). It was shown by 
Beenken et al., (2003) that sarA plays an important role in the expression of both 
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surface-associated and secreted virulence factors.  First identified in S. aureus, the 
SarA proteins share 84% homology with the protein found in S. epidermidis (240). 
SarA is a DNA binding protein that is preferentially transcribed during the early log 
phase of growth. The sarA locus encodes for the SarA protein and consists of 
three overlapping transcripts driven by three distinct promoters, P1, P2 and P3. 
SarA can control virulence gene regulation through agr-dependent and agr-
independent mechanisms (241). SarA can directly regulate expression of virulence 
genes by binding to target gene promoters or indirectly via the agr system. SarA is 
a positive regulator of the agr locus (242) but deletion of sarA is also known to 
increase extracellular protease production (85), suggesting that the role of sarA in 
biofilm regulation is complex. It can affect the expression of up to 120 additional 
genes, including upregulation of cell wall proteins and selected exoproteins as well 
as the down-regulation of protein A (85, 243).  
SarA regulates ica-dependent biofilm formation in a manner independent of the 
Agr system (85, 239) and the IcaR regulator (244). SarA binds to the icaA 
promoter with high affinity, upregulating transcription of the icaADBC locus and 
therefore promoting biofilm formation. SarA also promotes ica-independent biofilm 
formation by down-regulating extracellular protease production and promoting 
expression of surface adhesins to mediate primary attachment and intercellular 
accumulation (10, 179). Transcription of sarA was shown to be increased when 
exposed  to conditions of osmotic stress (10). Staphylococci with sarA mutations 
have been shown to have impaired ica-dependent and ica-independent biofilm 
formation in both S. aureus and S. epidermidis (85, 87, 108). 
1.7.3.4 Sigma factors  
Alternative sigma factors allow bacteria to adapt to metabolic and environmental 
stresses. SigB is an alternative sigma factor of S. aureus, and is homologous to 
SigB of Bacillus subtilis (245). The staphylococcal sigB operon consists of four 
genes encoding the RsbU, RsbV, RsbW and SigB proteins. RsbUVW are 
regulatory proteins that control the activity of SigB (246, 247). SigB controls over 
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250 genes involved in a diverse range of cellular processes. Many are adhesins 
upregulated by SigB while transcription of various exoproteins and toxins are 
repressed. This suggests that sigB is an important modulator of virulence in 
staphylococci (248).  SigB has a role in both S. aureus and S. epidermidis biofilm 
formation. SigB regulates biofilm formation in S. epidermidis in response to 
anaerobic conditions or conditions of osmotic stress (249, 250). S. aureus biofilm 
has also been shown to be effected by SigB. SigB is a positive regulator or icaR 
transcription (251). Mutation of sigB has been shown to impair ica-dependent 
biofilm in conditions of osmotic stress.  
1.7.3.5 The global regulator S. aureus exoprotein expression (Sae) 
SaeRS is a two component system (TCS) of regulation, that has been 
demonstrated to have an effect on expression of several virulence factors in S. 
aureus (252). The Sae TCS is involved in the regulation of not just biofilm 
formation under iron-limited conditions but also in the expression of toxins and 
immune evasion proteins, and is required during oxidative stress conditions (253). 
It has previously been shown to activate expression of hemolysin alpha and beta 
(Hla and Hlb) as well as Emp/ eap and FnbAB (254, 255).  
The sae operon is autoregulated and consists of four open reading frames, saeP, 
saeQ, saeR and saeS that encode for the response regulator (SaeR) and the 
receptor kinase (SaeS) of the two component system (256). The Sae TCS 
regulates biofilm-associated infections in a protease-dependent manner (257) and 
acts synergistically with SarA to regulate extracellular protease production (258). It 
has been suggested SaeRS regulates the transcription of proteins downstream of 
agr (256, 259). Sae-regulated protease activity and production of key virulence 
factors can reverse the attenuation of sarA mutants in a murine model of catheter-
associated infection (260). 
The role for the Sae TCS in S. epidermidis biofilm formation differs from that of S. 
aureus Sae-dependent biofilm formation. SaeRS deletion mutants have increased 
biofilm forming capabilities in S. epidermidis. This may be because the autolysis 
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genes atlE and aae become upregulated, which in turn results in increased 
amounts of eDNA (261). The Sae TCS was shown to have no impact on icaA 
expression, revealing that saeRS is regulating S. epidermidis biofilm formation in 
an ica-independent manner. 
1.7.3.6 Other factors, transcriptional regulators and two component systems 
Rbf, an araC-type transcriptional regulator, recently described in S. aureus has 
been shown to mediate glucose and NaCl-induced biofilm in an ica-independent 
fashion (262). This protein is thought to be required for cellular accumulation 
during biofilm formation and is widespread among S. aureus isolates. Transcription 
of the ica operon was not affected by an rbf mutation (262), suggesting that rbf 
controls biofilm development by a novel regulatory pathway.  
In S. aureus the Spx protein, which has been shown to interact directly with the α 
subunit of RNA polymerase and regulate transcription initiation, also contributes to 
stress resistance and biofilm regulation. It has been reported that spx mutants 
grow in planktonic culture in large clumps. ClpXP protease degrades Spx. Mutants 
of clpX and clpP have high Spx levels and bacterial cells are observed to grow as 
single cells with no clumping (263). From this finding it was deduced that Spx 
levels impact on cell-cell adhesion. The spx deletion mutants have been shown to 
have increased biofilm levels in ica+ strains. Transcription of icaADBC is increased 
in Δspx strains, leading to increased PIA production (263, 264).  
MgrA has recently been suggested to be a global regulator in S. aureus. MgrA is a 
small transcriptional regulator related to the SarA subfamily of regulators and 
contains a DNA-binding helix-turn-helix motif. Mutation of mgrA has been shown to 
affect a number of virulence factors including capsule production, protein A (Spa) 
expression and alpha-toxin production as well as antibiotic resistance and autolysis 
(265-267). Luong et al., (2006) (268) revealed that 13 cell wall-anchored proteins 
were found to be regulated by mgrA. These proteins include many LPXTG-domain 
proteins anchored to the cell wall by sortase such as protein A. More recently Tu 
Quoc et al.,(2007) (269) showed that mgrA has a role in biofilm formation in S. 
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aureus clinical isolates by creating insertion mutants defective in biofilm formation 
using bacteriophage Mu transposition. Jonsson et al., (2008) (270) also reported 
that mgrA is involved in the progression of septic arthritis and sepsis in medical-
device infections in mice. 
1.7.4 Biofilm formation under iron-limited conditions 
In humans and other higher vertebrates iron is assimilated from dietary 
components via duodenal enterocytes by the iron membrane transporter 
ferroportin. In the bloodstream iron is bound by ubiquitous transferrins that 
transport and donate iron to various types of cells for subsequent assimilation into 
proteins, such as the storage protein ferritin (271). The intracellular haem 
concentration within vertebrates is controlled by balancing the rates of haem 
biosynthesis and catabolism (272). The majority of haem is bound by haemoglobin, 
a complex oxygen transport protein found in erythrocytes. Therefore, more than 
90% of iron is sequestered intracellularly depriving infecting pathogens unless it 
can be liberated from the host cells. The serum concentration of iron is extremely 
low (ca. 10-24 M) (273). This limited availability of free iron and haem creates a 
defence mechanism called nutritional immunity that protects the host against 
infecting pathogens. In support of this idea, the virulence of many pathogens has 
been shown to be considerably enhanced in experimental infections by injecting 
iron compounds into the animal host (274-276). 
Factors important for staphylococcal biofilm have typically been examined in 
nutrient enriched media. This does not represent the iron limited conditions 
encountered by bacteria within the human host. Recent research in our laboratory 
has focused on the development of an in vitro model of infection that represents 
these conditions as well as other important factors in vivo (126). Factors important 
for biofilm formation in iron limited conditions on plasma coated surfaces were 
examined. Both the SaeRS system and coagulase were found to be required for S. 
aureus biofilm development in these conditions. Factors previously shown to be 
necessary for biofilm formation on abiotic surfaces in nutrient enriched conditions 
were redundant in this model. Further investigation also revealed a role for ClfA in 
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biofilm formation in the newly described conditions under conditions of shear; it 
was not found to effect biofilm formation in static conditions. A study by Vanassche 
et al., (2013) investigating S. aureus biofilm on plasma coated surfaces also 
showed a role for coagulase and for von Willebrand factor binding protein, both of 
which lead to a reduction in fibrin deposition and retention of S. aureus on 
catheters (277).  
1.7.5 Staphylococcal resistance to methicillin and biofilm formation 
The first methicillin resistant S. aureus strain was isolated in 1961, two years after 
the introduction of the antibiotic methicillin. Resistance is mediated by the 78 kDa 
penicillin-binding protein 2A (PBP2a) encoded by the mecA gene (278-280). The 
mecA gene is believed to have originated in CoNS species (281).  PBP2a is a 
high-molecular weight class B transpeptidase that has a lower affinity for β-lactam 
antibiotics. Hence, it can catalyse the formation of cross-bridges in peptidoglycan 
(282, 283) although the transglycosidase activity of the native PBP2, is also 
needed for cell wall synthesis. The mecA gene is located in the Staphylococcus 
cassette chromosomal mec, SCCmec, of which eleven different types have been 
characterised to date (284, 285).  
Previous investigations in our research group have focused on the relationship 
between antibiotic resistance and biofilm-forming capacity. These studies have 
revealed a link between biofilm composition and methicillin resistance. MSSA 
clinical isolates are more likely to produce a PIA/PNAG-dependent biofilm than 
MRSA isolates, which produce an Atl/FnBP-dependent biofilm in nutrient enriched 
conditions (10, 87, 286, 287), suggesting that methicillin susceptibility influences 
biofilm expression. The induction of high level methicillin resistance in an MSSA 
strain, 8325-4, was shown by Pozzi, Waters et al,.(2012), to cause a switch in 
biofilm phenotype. The wild type of this strain was shown to produce a PIA/PNAG-
mediated biofilm, however this phenotype changed to a protein-mediated biofilm 
when high level methicillin resistance was induced (237). This phenotypic switch 
was also shown by modifying MRSA strains to be susceptible to methicillin 
resistant (288). This work also revealed that increased PBP2a expression reduced 
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disease severity in vivo, using a mouse and caterpillar model (237, 288). Further 
work revealed increased methicillin resistance decreased agr activity, explaining 
the overall toxin decrease (289).  
Although S. epidermidis is capable of forming an ica-independent biofilm, 
PIA/PNAG production is considered the main biofilm mediator (290). The majority 
of S. epidermidis strains that carry the mecA gene exhibit heterogeneous 
resistance to methicillin (291). Mutations that altered PIA/PNAG production have 
also been shown to affect methicillin resistance in S. epidermidis (292, 293). 
1.8 Treatment and prevention of catheter-related infections caused by 
staphylococci 
1.8.1 Current guidelines 
Several approaches have been followed in an attempt to decrease the incidence of 
CRIs with multiple national and international guidelines published on the subject. 
For example, epic2: National evidence based guidelines for preventing healthcare 
associated infections (HCAI) in National Health Service hospitals in England, 
provide comprehensive recommendations on hand hygiene, the use of personal 
protective equipment and the prevention of infections resulting from the use of 
indwelling urethral catheters and central venous access devices (294). In recent 
times, the use of “care bundles”, which can be defined as “the bundling together of 
several scientifically grounded elements essential to improve clinical outcome” 
have been developed and are now used routinely in the prevention of CRIs (295). 
Care bundles provide a method for establishing evidence-based best clinical 
practice. However, a recent Cochrane review, on adherence to guidelines for the 
prevention of CRIs, found insufficient evidence to determine, with certainty, which 
interventions are most effective (296). Examples of other techniques used in the 
prevention of CRIs include the use of chlorhexidine impregnated sponges(297) and 
the application of prophylactic antibiotic ointment at a device exit site (21); all of 
which have been used with various success rates. 
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Treatment of staphylococcal CRIs remains a significant challenge. As described 
previously, in the human host, bacteria can form a biofilm on a biotic (e.g. an 
epithelial cell) or an abiotic (foreign body) surfaces pre-condition with host matrix 
proteins (25, 298). Mature biofilms are highly resistant to the action of the innate 
and adaptive immune defence systems, and to the action of antimicrobial agents. 
Numerous research groups have demonstrated the ineffectiveness of antibiotics 
against bacteria within a biofilm compared to than their planktonic counterparts. 
Antibiotics, such as vancomycin, daptomycin, gentamicin and rifampicin, are 
frequently used in the treatment of CRIs with variable success rates (299, 300). 
This has lead to the search for other means to treat CRIs with a view to improving 
outcomes. 
1.8.2 Evolving strategies for the treatment of CRI due to staphylococci 
1.8.2.1 Surface modification 
The focus of research in recent times has been the materials used to produce 
medical devices. As one of the requirements for staphylococcal biofilm infection is 
adherence to the polymer surface, strategies to prevent biofilm formation have 
been examined, including modification of the surface of biomaterials resulting in 
anti-adhesive surfaces. Incorporation of antimicrobial agents into medical device 
polymers has also been examined. 
Anti-adhesives prevent bacterial adhesion by forming a highly hydrated layer on 
the surface of the biomaterial. Anti-adhesive solutions bind the biomaterial and 
then take up free water molecules creating a hydrophilic surface that is negatively 
charged (301). Hydrophilic surfaces generally show less bacterial adhesion than 
hydrophobic ones (302). Carpobol 934, is a hydrophilic resin that is a cross-linked 
polyacrylate polymer, which prevents staphylococcal adhesion (303). Hyaluronan 
is a natural anti-adhesive hydrophilic polysaccharide that is found in the body fluids 
of all vertebrates. Hyaluronan is a particularly attractive option for prevention of 
CRIs as it has also been shown to have bacteriostatic properties against a range of 
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bacteria including S. aureus (304). Both carpobol 934 and hyaluronan have been 
shown to exhibit great potential to prevent biofilm formation (303). 
Catheters have also been coated or impregnated with various antibiotics, 
antiseptics and metals in an attempt to prevent colonisation of the device (305). It 
has been shown that polypropylene mesh sleeves coated with rifampicin and 
minocycline prevented S. aureus  biofilm on pacemakers in a rabbit infective 
endocarditis model (306). However, the success of these alternatives has varied, 
mainly due to the various environments into which the devices are placed, the 
diversity of ways in which organisms can colonise surfaces and the mounting 
concerns regarding the emergence of antimicrobial/antiseptic resistance (307). 
Nano-structured reservoirs, that can be integrated with metal ions for surface 
coating, or as a cement additive for bone implants, is also an emerging and 
promising area that has the potential to allow controlled drug release over a 
prolonged period of time (308, 309).  
1.8.2.2 Enzymatic disruption  
As discussed, when a mature staphylococcal biofilm has formed on a device, 
conventional treatment has a limited role in the eradication and treatment of CRIs. 
However, there are a wide variety of enzymatic agents that have the ability to 
depolymerise components of staphylococcal biofilm (310). These have been the 
subject of new research aimed towards investigating their effectiveness in 
removing a biofilm from a surface. Agents such as lysostaphin, dispersin B, DNase 
and proteases have all been shown to be effective in the reduction on biofilm on 
device surfaces (108, 310-313). 
However, it must be acknowledged that one of the main concerns with enzyme 
based biofilm therapy is the risk of dispersal and seeding of bacteria to other 
organs. Therefore, such therapies should be used in combination with systemic 
antimicrobial agents. Nevertheless, enzymatic degradation of the biofilm matrix 
represents a promising group of agents which may be used in the future. 
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1.8.2.3 Immunisation 
Although the majority of staphylococcal immunotherapy approaches target acute 
disease and bacteria in the planktonic stage the use of immunisation or vaccines to 
prevent staphylococcal CRIs is an evolving area of research. In the context of 
biofilm infections, two targets exist, namely the bacterial cells within the biofilm and 
the biofilm matrix itself (314). The staphylococcal biofilm matrix is composed of 
polysaccharide, protein or eDNA depending on the species and the strain.  As 
previously highlighted, PNAG/PIA, is the surface polymer produced by both S. 
aureus and S. epidermidis that promotes biofilm formation via an ica- dependant 
route. Active or passive immunisation with PNAG/PIA has been shown to be 
protective against S. aureus infection in a kidney infection model (174). However, 
research has indicated that only one component of PIA is immunogenic, and 
responses to this antigen are variable (315). Furthermore, not all S. aureus or S. 
epidermidis produce PNAG/PIA, and further research is required to determine the 
effectiveness of PNAG/PIA-based vaccines.  
Surface proteins of staphylococci, such as the previously described MSCRAMMS, 
represent a potential vaccine target because of their exposed location and role in 
virulence (316). Recombinant clumping factor A (rClfA) containing the fibrinogen 
binding domains, has been shown to be partially effective when used in an animal 
model of septic arthritis (317). Immunisation with recombinant clumping factor B 
(rClfB) has been shown to lead to less colonisation of the murine nares by S. 
aureus (318). Vaccination with iron-regulated surface determinant B led to 
increased survival rates of 20-40% in a murine sepsis model (319). Shahrooei et 
al.,(2012)  reported that active vaccination with the recombinant S. epidermidis 
surface exposed protein C (SesC) inhibited S. epidermidis biofilm formation in a rat 
model of subcutaneous foreign body infection (225). These may represent 
promising targets in the future for antibody mediated strategies against 
staphylococcal biofilm.     
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1.8.2.4 Photodynamic treatment 
An interesting and novel approach to the treatment of staphylococcal biofilm 
infections is the use of photodynamic therapy (PDT). This process involves treating 
microorganisms with a non toxic, light sensitive drug that becomes activated upon 
exposure to light at certain wavelengths (320). Cytotoxic reactive oxygen species 
and free radicals are generated as a result of exposure to light; these are able to 
exert a bactericidal effect. This can lead to inactivation of staphylococcal biofilms 
adhering to medical devices, without affecting eukaryotic cells. Sharma et al., 
(2008) described the significant dose dependent inactivation of a S. epidermidis 
and a MRSA strain exposed to toluidine blue O and laser treatment (321). PDT has 
been used in the eradication of biofilm in dental plaques and on oral implants (17). 
In the future, PDT may become a complementary therapy in clinical practice 
depending on various pharmacokinetics of the photosensitiser and on the 
accessibility to the device site (17). 
1.8.2.5 Quorum-sensing and biofilm dispersal 
In recent years, research has been undertaken in the area of targeting the quorum 
sensing mechanism of staphylococcal communication (29, 236, 322). As 
discussed, staphylococcal quorum-sensing systems play an important role in the 
pathogenesis of staphylococcal biofilm infections. Global gene expression can be 
controlled via the agr-system and the effector molecule RNAIII. The up-regulation 
of many secreted virulence agents, such as extracellular proteases (e.g. 
aureolysin, serine and cysteine proteases), through the agr-system can result in 
detachment of bacterial cells from within a biofilm. As described in an earlier 
section, this detachment allows for dissemination of the bacterial cells to potentially 
form biofilm in other areas (10, 29, 235, 236).  
In addition to proteases, other agr-regulated factors contributing to biofilm 
detachment include toxins such as δ-toxin (238). The activation of the agr quorum-
sensing system occurs in response to the extracellular concentration of an 
autoinducing peptide (AIP) signal that binds to the membrane-bound receptor 
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domain of the AgrC histidine kinase. Therefore, the use of AIP signal molecule 
analogues have been indicated as a potential antibiofilm strategy (29). To support 
this, Boles et al. (2008) reported that bacteria are dispersed from a staphylococcal 
biofilm when they display high levels of agr activity.  Conversely, agr expression is 
repressed in cells that remain within the biofilm. Furthermore, the addition of 
exogenous AIP was shown to activate the agr system throughout a mature S. 
aureus biofilm leading to complete disassembly and conversion of bacteria to a 
planktonic state (29). However, there are a number of challenges to overcome if 
this approach is ultimately to be used in the treatment of staphylococcal CRIs. The 
activation of agr may have an impact on the host innate and adaptive immune 
response as it may convert the staphylococcal strain into a more invasive 
pathogen (323, 324). Furthermore, across the staphylococcal species there are a 
variety of agr systems with each type recognising a unique AIP.  A universal agr 
activator has to be selected and produced before a therapeutic approach based on 
AIP analogues can be used on patients.  
Other influences on the agr-system in relation to staphylococcal biofilm 
pathogenesis include inducing the expression of phenol-soluble modulins (PSMs). 
PSMs are a family of amphipathic α-helical peptides (325, 326), which have been 
suggested to have surfactant properties (327). PSMs have recently been shown to 
be involved in biofilm detachment in a mouse model of S. epidermidis CRI and it 
has been suggested that exploiting this mechanism to target the bacteria could 
have therapeutic potential (328). Mannoprotein, a cell wall component of 
Saccharomyces cerevisiae, also has surfactant properties and has been used as 
an inhibitor of  S. aureus and S. epidermidis biofilm formation (329). 
1.8.2.6 Bacteriophage therapy 
Bacteriophages represent a novel approach to prevention or treatment of 
staphylococcal CRIs. Although used historically, their clinical use fell out of favour 
in many countries with the introduction of antibiotics. The ever increasing problem 
of antimicrobial resistance has re-focused interest on to these biological agents 
(330, 331). Conflicting studies have recently been published on the effect of phage 
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therapy in animal models. Yilmaz et al., (2013) reported dissolution of 
staphylococcal biofilm using species specific phage in conjunction with antibiotics 
in a rat model of implant-related MRSA osteomyelitis, with the effect on S. aureus 
more pronounced than that on Pseudomonas aeruginosa [60]. Seth et al., (2013) 
reported a benefit of topical bacteriophage treatment in a rat model of soft tissue 
infection but only if physical disruption (debridement) of the biofilm occurred before 
phage treatment. This perhaps indicates that access of the phage to the biofilm 
cells within may be important for effective treatment (330, 332). Furthermore, 
concerns remain regarding the optimum dose, route of administration, optimal 
duration of treatment, as well as the potential side effects on the normal bacterial 
flora with the use of higher doses of bacteriophages. A comprehensive study 
investigating the potential of bacteriophage therapy as prophylaxis and treatment 
of staphylococcal biofilm infections is required before their full role can be 
elucidated.  
1.8.2.7 Antimicrobial peptides 
Antimicrobial peptides (AMPs), commonly known as host defence peptides, are a 
group of peptides that are part of the host immune response and have properties 
that may make them promising candidates for use in the prevention or treatment of 
staphylococcal CRIs. The mechanism of action of this unique and diverse group of 
molecules is biophysical rather than biochemical, where the target is the 
cytoplasmic membrane structure itself (333). Fitzgerald-Hughes et al., (2012) 
highlighted the potential of natural cationic peptides as anti-staphylococcal agents 
(333). The potential of AMPs in bacterial infections, including biofilm-related 
infections, may be realised through their development as systemic agents. 
Although, most AMPs in clinical trials to date are for topical application, the 
targeted delivery of AMPs may further improve the therapeutic potential of these 
molecules.  
Two of the best studied AMPs, due to their antimicrobial activities, are the 
cathelicidin LL-37 and the human-beta defensins. These peptides have served as 
templates for the development of derivatives with improved potential for 
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therapeutic application and lower potential for toxicity than natural peptides. 
Cathelicidins have also been shown to inhibit staphylococcal biofilm. LL37, which 
is a 37 amino acid AMP found in humans, is of particular interest as it has been 
shown to inhibit initial attachment and biofilm formation in S. epidermidis (334, 
335). Other AMPs have recently been shown to inhibit S. aureus biofilms including 
the synthetic peptides indolicidin, KABT-AMP and nicin (336-339).  
Despite their broad spectrum rapid killing potential, there are a number of concerns 
with regard to the use of AMPs as systemic therapies. The main areas for concern 
include their potential toxicity or immunogenicity, their stability at various pH and 
osmotic conditions, the development of resistance and the unknown effect on 
innate responses to infection (340). Appropriate doses required to exert an effect 
on staphylococcal biofilms need to be determined as a recent study has 
highlighted that secreted proteases may play a role in resistance to these 
compounds (341). Nevertheless, these agents represent a novel, and possibly 
viable, option for preventing or treating staphylococcal CRIs and they should be 
explored further via appropriately designed studies. 
1.8.2.8 Small molecule and sortase inhibitors 
The potential role of small molecules such as fatty acids, amino acids, and sortase 
inhibitors in the treatment or prevention of staphylococcal biofilm has also been 
investigated recently. The fatty acid messenger cis-2-decenoic acid (C2DA) and 2-
aminoimidazole containing compounds have been of particular interest. C2DA is a 
medium-chain fatty acid chemical messenger produced by bacteria to signal 
prevention and dispersion of biofilms for multiple types of bacteria (342). Reports 
of several other studies have indicated that C2DA may also have growth inhibitory 
or bactericidal effects on planktonic cells as well as sessile bacteria (343, 344). 
Sortase enzymes play a key role in the anchoring of MSCRAMMS to the bacterial 
cell wall as well as survival within phagosomes (345), the effect of their inhibition 
on biofilm has been studied with numerous molecules identified as potential 
inhibitors of these enzymes (108). Oh et al., (2004) have reported on a novel class 
of S. aureus sortase inhibitors, the diarylacrylonitriles (346), with a derivative of this 
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molecule effective in treating bone and joint infections in a mouse model of S. 
aureus infection (347).  Frankel et al., (2004) reported the potential of small 
molecule vinyl sulfones for the treatment of S. aureus infections via inhibition of 
SrtA-mediated linkage of the FnBPs to the cell surface, highlighting the potential 
use of these agents to prevent adhesion to and colonization of host tissues during 
S. aureus infection (348).  
1.8.3 Catheter lock solutions 
Both the HPSC in Ireland (2014) and the infectious diseases society of America 
(IDSA) (2009) have published guidelines recommending catheter removal and 
systemic antimicrobial treatment on suspicion, or confirmation of a staphylococcal 
infection (349, 350). However, clinical circumstances, for example the lack of 
alternative venous access, bleeding disorders and co-morbid conditions often 
preclude device removal. An important and evolving strategy to prevent and treat 
CRIs due to staphylococci are catheter lock solutions (CLSs). A CLS is instilled 
into the lumen of the catheter and allowed to remain for a defined period of time 
before removal (351). This solution may be removed by withdrawing it from the 
catheter via a syringe or by simply pushing it through to the blood supply, the latter 
may only be carried out if the CLS is non toxic to the body. Use of a CLS has been 
shown to prevent bacteria from colonising the surface of the catheter and therefore 
prevent CRIs (352).  
Antimicrobial CLSs are relatively new to the market. They prevent intra-luminal 
colonisation and the development of biofilm. Heparin, or heparinised saline, is 
currently being used in many institutions as a CLS. This solution prevents 
thrombosis effectively, however, bacteria such as staphylococci can survive in 
heparin locked catheters because it has limited antimicrobial activity (352). In some 
studies, it has even been shown to stimulate staphylococcal growth (353). The use 
of CLSs to prevent infection has been widely researched; the main focus of this 
study is the use of a CLS as a treatment option in cases of confirmed 
staphylococcal infection. 
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In the cases of CRIs, the use of a CLS has been indicated when catheter salvage 
is a priority. However, when the infection is caused by S. aureus this approach is 
only recommended when no alternative insertion site is available (349, 354). This 
technique provides very high concentrations of antimicrobial agents at the site of 
infection, potentially giving the antimicrobial solution sufficient time to eradicate the 
attached bacterial cells. It has been suggested to have a promising therapeutic 
outcome in the case of S. epidermidis infection (355). No recommendations have 
been made on an appropriate agent for use as a CLS (355). As a result, the choice 
of antibiotic or antiseptic chosen is often based on in vitro susceptibilities. 
Conventional susceptibility testing may not necessarily indicate that the antibiotic is 
active against the same organisms embedded within the biofilm matrix (63). Also, 
concerns around selection of resistant organisms, toxicity and treatment failure 
have thus far limited their widespread application in the treatment of CRI.  
IDSA guidelines on the prevention of CRI issued in 2011 recommend the use of 
antimicrobial lock solutions in patients with long term catheters (356). The use of 
antibiotics as a CLS would help reduce the incidence of infection. However, there 
is a problem regarding the use of antibiotics a CLS due to the variable success 
rates reported and concerns regarding the development of antimicrobial resistance 
to these systemic antibiotics. 
1.8.3.1 Antibiotics 
Antibiotics such as oxazolidinones, tetracyclines, glycopeptides and lipopeptides 
have been used alone or in combination with variable success (357-359). Several 
antibiotics have been included in investigations of CRI (360, 361) with variable 
success rates for the treatment of established biofilm being seen.  A range of 
antibiotics were analysed as part of this project and are described in table 1.1. 
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Table 1.1 Antibiotic mechanism of action 
Antibiotic Class Mode of action Spectrum of activity 
Vancomycin Glycopeptide Inhibits second stage 
cell wall synthesis 
(362). 
Gram-positive bacteria. 
Shown to eradicate S. 
epidermidis and S. aureus 
biofilms (363). 
Tigecycline Glycyclines Protein synthesis 
inhibitor. 
Gram-positive and Gram-
negative bacteria. Effective 
against S. epidermidis and S. 
aureus biofilms (364, 365)  
Daptomycin Lipopeptide Inhibition of bacterial 
protein, RNA and 
DNA synthesis. 
Gram-positive infections. Has 
also been shown to be 
effective against biofilm (365). 
Fosfomycin Phosphonic Inhibits bacterial cell 
wall synthesis. 
Gram-positive and Gram-
negative infections (366) 
Gentamicin Aminoglycoside Inhibits bacterial 
protein synthesis. 
Gram-negative and Gram-
positive staphylococcal 
infections. Has been shown 
to have an effect on 
staphylococcal biofilm  (357). 
Linezolid Oxazolidinone Protein synthesis 
inhibitor. 
 
Gram-positive bacteria. 
Shown to eradicate S. 
epidermidis and S. aureus 
biofilms (363). 
Rifampicin Antimycobacterials Inhibits bacterial 
DNA-dependent RNA 
synthesis. 
Gram-positive and Gram-
negative. Effect shown 
against S. aureus and S. 
epidermidis biofilm (367). 
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1.8.3.3 Antiseptics 
Ethanol has long been reported to have antibacterial activity associated with 
surface protein denaturation and solubilisation of lipids (368), and has been shown 
to be an effective CLS, reducing infection rates in a number of studies (369, 370). 
Despite this, there are a number of potential drawbacks to the use of ethanol as it 
may not be compatible with all catheters. An incompatibility with polyurethane 
catheters has previously been reported (371); the use of ethanol as a CLS has 
also been associated with patient side-effects such as “inebriated like” symptoms 
and toxicity (372). Low concentrations of ethanol have previously been shown to 
induce biofilm formation in staphylococci (168). Further work is needed to examine 
the suitability of ethanol for use in sterilising an IVC.  
Chlorhexidine is a cationic antiseptic compound with two strong basic groups, both 
biguanides. At low concentrations it has little toxicity and it has been reported to be 
suitable for human use (373). Chlorhexidine acts by destabilising the bacterial cell 
wall, of both Gram-positive and Gram-negative bacteria, this makes the bacterial 
cytoplasmic membrane (inner membrane) vulnerable and results in leakage of cell 
components and cell death (374).  
1.8.3.4 Chelators 
Several chelators have been considered and examined for the use in CLSs. 
Ethylenediaminetetraacetic acid (EDTA) and citrated solutions are just two of 
these. EDTA is a chelator of divalent cations, and it has previously been approved 
for the treatment of mercury and lead poisoning (375). The effect of EDTA on 
bacterial cells has been shown to be bacteriostatic through the destabilisation of 
the divalent cations in bacterial cell membranes. This subsequently leads to cell 
lysis. It has also been demonstrated, on several occasions, to be effective on 
staphylococcal biofilms in vitro   (360, 376, 377). EDTA has the potential to be 
used in treatment of CRIs and has previously been used in combination with 
antibiotics in a CLS in the treatment of CRI (360). Traditionally, trisodium citrate 
was used as an anticoagulant as the citrate chelates calcium ions in the blood 
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disrupting the blood clotting process (378). In recent years, data has emerged 
highlighting the antimicrobial properties of this sodium citrate solution both by itself 
and in combination with other agents (379). It is the main component of two 
commercially available CLSs, namely Duralock-CTM and TauroLockTM. Duralock-
CTM is a 46.7% solution of sodium citrate, while TauroLockTM comprises of 4% 
sodium citrate and 1.35% taurolidine, a modified amino acid with antimicrobial 
properties. 
1.8.3.5 Novel agents used in this study 
1.8.3.5.1 ML:8 
ML:8 is a recently developed antimicrobial based on the naturally occurring free 
fatty acid caprylic acid and the natural emulsifying agent lecithin, which are 
processed together in a manner that achieves a sub-micron aqueous dispersal of 
the normally water insoluble free fatty acids. As a result of the process involved in 
synthesising ML:8, the free fatty acids in ML:8 are perfectly dispersible in water 
and compatible with most excipients. The antimicrobial properties of ML:8 have 
been recently published against bacteria associated with canine and feline 
peridontopathogens. It was shown at to have anti-biofilm properties as well as low 
cytotoxicity (380). A company focused on this area of research have shown the 
antimicrobial properties of ML:8 against S. aureus biofilm, however, the study was 
not peer reviewed (381). The effect of ML:8 was also examined in a model of 
staphylococcal CRI, ML:8 was shown to have an effect against staphylococcal 
biofilm in this study (382). However, it should be noted this publication contained 
limited strains as well as insufficient details on biofilm levels formed and the 
controls used.  
Caprylic acid is the main component in ML:8. This medium chain saturated fatty 
acid (C8H16O2), also called octanoic acid (structure shown in figure 1.8). It is 
naturally found in coconut oil, palm oil, butter fat as well as all mammalian milk. 
Caprylic acid is long known to have antimicrobial properties against a range of 
Gram-positive and Gram-negative bacteria (383-385). More recently, its efficacy 
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against biofilm has been noted (386). The precise mode of action of ML:8 is 
unknown, however a mode of action for monocaprylate has been suggested. 
Monocaprylate is the monoglyceride of caprylic acid. The antimicrobial mechanism 
of monocaprylate is thought to be confined to the cell membrane. It has been 
hypothesised that exposure increases membrane fluidity and the number of phase 
bound defects (387).  
 
Figure 1.8 Chemical structure of Caprylic Acid. An eight carbon straight-chain saturated fatty 
acid. With a terminal methyl group and terminal carboxyl group . 
1.8.3.5.2 Citrox 
Citrox is a commercially available formulation of soluble flavonoids derived from 
citrus fruits. Due to its antimicrobial properties it has become an attractive option 
for the treatment of infections. While the exact formulation of Citrox is not available, 
patent applications have indicated that the flavonoids included are neoeriocitrin, 
isonaringin, naringin, hesperidin, neohesperidin, neodiosmin, naringenin, poncirin 
and rhiofolin (388). The structures of these flavonoids are illustrated in figure 1.9. 
Its antimicrobial properties have been demonstrated against oral microorganisms 
(389). The antimicrobial effect of Citrox has also been examined as an aerosol on 
infected hospital surfaces. It was shown to be effective against S. aureus bacteria 
on a range of surfaces (390). Varying degrees of antimicrobial activity have been 
reported for flavonoids (391-393). The effects of a number of flavonoids including 
naringin and naringenin have been examined on S. aureus. Flavonoids were 
shown to be effective against staphylococci, however it should be noted this testing 
was carried out against planktonic cells only (394). The use of flavonoids in the 
treatment of biofilm has not been extensively explored. A small number of studies 
have showed a range of flavonoids to be effective against biofilm (395, 396), 
however, further work is needed to examine this. 
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A Naringin B         Neoeriocitrin
C            Isonaringin D         Hesperidin
E          Neohesperidin F        Neodiosmin
G            Poncirin H         Rhiofolin
I   Naringenin
 
Figure 1.9 Chemical structures of flavonoids in Citrox formulation. Formulation includes 
naringin (A), neoeriocitrin (B), isonaringin (C), hesperidin (D), neohesperidin (E), neodiosmin (F), 
poncirin (G), rhiofolin (H), and naringenin (I). 
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1.9 Summary and project aims 
With regard to the role of CLSs in the treatment of CRIs due to staphylococci there 
is as of yet no consensus on what is the best approach, partly because there is 
insufficient insight and knowledge about which agent, or combination of agents, is 
likely to be most efficacious in vivo against biofilm-forming staphylococci (324). 
The objectives of this study are to investigate the effectiveness of the various CLSs 
currently in use, as well as two novel agents, against a number of reference and 
clinical staphylococcal isolates of varying genetic backgrounds, methicillin 
susceptibility and biofilm forming capabilities.  It is hoped this research will lead to 
a novel approach to treating staphylococcal biofilms within a CLS.  
To address this objective the following specific aims were pursued: 
 To determine the effects of existing and novel therapeutic agents on 
planktonic and sessile S. aureus and S. epidermidis strains and isolates 
from patients with confirmed CRIs.  
 To develop an in vitro model of CRI to mimic the in vivo environment under 
static and flow conditions. 
 To evaluate the effectiveness of existing and novel therapeutics as CLSs, 
within the model of CRI, to eradicate staphylococcal biofilm formed under 
static and flow conditions. 
 To perform comparative microscopic analysis to determine the effect of 
existing and novel therapeutics on staphylococcal biofilms formed under 
conditions of flow. 
 To examine the possible mode of action of ML:8 and Citrox using 
transcriptome analysis and investigate their cytotoxicity and potential 
immunogenic properties. 
 To validate the efficacy of novel therapeutic agents in vivo using a rat-IVC 
model of infection.  
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2.1 Bacterial strains and growth conditions 
The bacterial strains and isolates used in this study are described in Table 2.1. S. 
aureus and S. epidermidis strains were grown with shaking at 37°C in Brain Heart 
Infusion medium (BHI; Oxoid) or RPMI-1640 (RMPI-1640; Thermo scientific) media 
as indicated. To reflect growth conditions in vivo, bacterial strains were grown in 
iron deficient medium - RPMI 1640 (397), which was originally designed to culture 
human leukocytes (397, 398)). BHI broth was supplemented with either 1% 
glucose (w/v) or 4% NaCl (w/v) as outlined below. S. epidermidis strain RP62A and 
MSSA strains SH1000 and BH48 form biofilm under osmotic stress conditions (4% 
NaCl (w/v)) (10, 108, 226). While MRSA strain BH1CC forms biofilm in conditions 
of acidic stress (1% Glucose (w/v)) (108). Strains used in this study include a 
combination of reference strains and clinical isolates collected from patients with 
staphylococcal infection. They represent strains from a variety of genetic 
backgrounds. Strains denoted with a BH have been isolated from Beaumont 
Hospital; this is an 820 bed tertiary care centre containing the national 
neurosurgical and renal transplantation units for the Republic of Ireland. 
Table 2.1 Reference strains and clinical staphylococcal isolates used 
Strain Characteristics  Reference or 
source 
S. aureus   
SH1000 Laboratory strain. Functional rsbU 
derivative of 8325-4 rsbU+. Clonal 
complex (CC) 8. 
(399) 
BH48 (04) MSSA clinical isolate, blood culture. CC 8. (10) 
 
BH49 (04) MSSA clinical isolate, central line blood 
culture. CC 8. 
(10) 
BH40 (04) MSSA clinical isolate, central line blood 
culture. CC 5. 
(10) 
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Strain Characteristics  Reference or 
source 
 
BH3 
 
MSSA clinical isolate, blood culture. CC 
121 
 
(400) 
BH4 MSSA clinical isolate, blood culture. CC15 (400) 
BH10 MSSA clinical isolate, blood culture.CC 
398 
(400) 
BH15 MSSA clinical isolate, blood culture. CC30 (400) 
BH18 MSSA clinical isolate, blood culture. CC 
45 
(400) 
BH21 MSSA clinical isolate, blood culture. CC 
22 
(400) 
BH1CC MRSA clinical isolate, blood culture. CC 8 (10) 
Dar 217 MRSA reference isolate.  CC5 (401) 
Dar 113 MRSA reference isolate. CC22 (401) 
Dar141 MRSA reference isolate. CC30 (401) 
Dar 70 MRSA reference isolate. CC45 (401) 
BH10 (03) MRSA clinical isolate, blood culture. CC 
22. 
(10) 
USA300 LAC 
Je2 
Parent strain, MRSA clinical isolate, skin 
and soft tissue infection. USA300 LAC 
cured of plasmids p01 & p03. CC 8 
(402) 
USA300 LAC 
Je2 ∆cap5E 
MRSA clinical isolate, cap5e deletion 
mutant. CC8 
(402) 
USA300 LAC 
lux  
MRSA strain USA300 LAC constitutively 
expressing luciferase (lux) from 
Photohabdus luminescens. CC8 
(403) 
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Strain Characteristics  Reference or 
source 
S. epidermidis   
RP62A Clinical isolate, central line blood culture.  (404) 
 
2.2 Sterilisation techniques and media preparations 
All agar media and broths were autoclaved at 121ºC for 15 min. NaCl and glucose 
solutions were prepared to a 20% (w/v) concentration and filter sterilised. After 
autoclaving, agar and broth media was tempered to 55ºC and room temperature, 
respectively, prior to the addition of NaCl or glucose. Antimicrobial agents for use 
as CLSs were prepared at a range of concentrations (as describes in Table 2.2) 
under strict aseptic technique, all diluents were autoclaved at 121ºC for 15 min 
before use. 
Table 2.2 Preparation of antimicrobial agents 
Agent Diluenta Concentration range 
Ethanol Water   3.75 – 80% (v/v) 
EDTA Water 0.93 mg/ml- 32 mg/ml 
Vancomycin Saline  1 µg/ml - 50 mg/ml 
Tigecycline Saline 1 µg/ml - 10 mg/ml 
Daptomycin Saline 1 µg/ml - 50 mg/ml 
Gentamicin Saline 1 µg/ml - 40 mg/ml 
Linezolid Saline 1 µg/ml - 4 mg/ml 
Rifampicin Saline 1 µg/ml - 10 mg/ml 
Fosfomycin Saline 1 µg/ml - 50 mg/ml 
ML:8 BHI / Saline 0.07 - 2% (v/v) 
Citrox BHI / Saline 0.015 - 10% (v/v) 
a
 diluent chosen based on manufactures guidelines or previously published investigations  
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2.3 Minimum inhibitory concentration testing 
Minimum inhibitory concentrations (MICs) were established using a modified 
method of the British Society for Antimicrobial Chemotherapy (BSAC) guidelines. 
To determine the MICs of each bacterium to vancomycin, gentamicin and linezolid, 
Etest® strips (Biomerieux) were used in accordance with manufacturer’s 
instructions. Briefly, an inoculum equivalent to a 0.5 McFarland standard 
(approximate cell density 1X108 CFU/ml) was spread using a sterile cotton bud in 
three different directions onto a BHI agar to ensure full coverage.  Etest® strips 
were placed into the middle of the inoculated plate using a sterile forceps. Plates 
were then incubated at 37ºC for 24 h and results recorded. MICs of the remaining 
agents (daptomycin, tigecycline, fosfomycin, rifampicin, EDTA, ethanol, sodium 
citrate, taurolodine, ML;8 and Citrox) were determined by serial broth dilution. A 
range of concentrations of each test agent was prepared (as described in table 
2.2) and to this 100 µl of a 0.5 McFarland suspension of each bacterial strain was 
added. Vials were incubated for 24 h at 37ºC before results were examined by 
visual inspection for the presence/absence of growth. 
2.4 Measurement of antimicrobial activity of treatment agents 
From an overnight culture, a 0.5 McFarland standard suspension of bacterial cells 
was prepared. From this, 100 µl was mixed with 0.9 ml of the test solution (e.g. 
ML:8) and incubated at room temperature for varying amount of times (30 s – 48 
h). After the allotted time, 100 µl of the solution was spread onto a BHI agar plate. 
These were then incubated at 37ºC for 24 h and colonies counted. Results were 
noted as the minimum treatment time and concentration taken to inhibit growth of 
bacteria on a plate. 
2.5 Static biofilm development 
2.5.1 Biofilm assay in nutrient enriched growth media  
Semi-quantitative measurements of biofilm formation, under static conditions were 
performed using 96-well polystyrene plates (Nunc, Denmark) according to the 
method originally described by Christensen et al., (1985) (405) and later adapted 
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by O’ Neill et al., (2007) (406). Briefly, an overnight culture of the test organism 
was diluted 1:200 in fresh media (BHI or BHI supplemented with 4% NaCl or 1% 
glucose as appropriate). From this suspension 100 μl was used to inoculate the 
microtitre plate wells prior to static incubation at 37ºC for 24 h. Microtitre plates 
were washed three times with sterile distilled H2O and dried for 1 h at 65ºC prior to 
staining for 10 min with a 0.4% (w/v) crystal violet solution (prepared in water). 
After staining, the plates were washed a further three times with sterile distilled 
H2O. The absorbance of the adhered, stained cells was measured at 492 nm using 
a thermo Multiskan Ex plate reader (Thermo Fisher, U.K.). Each experiment was 
performed in triplicate. Strains were determined to be biofilm-positive when the 
mean biofilm optical density (OD) was greater than 0.17 (10). Assays were 
performed in triplicate and data presented represents mean OD ± standard 
deviation (SD). 
2.5.2 Biofilm assay using RPMI-1640 and a human plasma coating 
Blood (approximately 40 ml) was drawn from a healthy volunteer using the S-
Monovette system (Sarstedt) (407). Blood was transferred into 15 ml tubes and 
centrifuged at 150 x g for 10 min. After centrifugation, plasma (from the upper layer 
of the centrifuged sample) was collected and used immediately or frozen at −20 
°C. The plasma was diluted to a 20% (v/v) concentration in carbonate buffer 
(NaHCO3, Na2CO3 pH 9.6), which promotes immobilisation of the matrix protein to 
the plate surface (408). A volume of 100 μl of the plasma was added to the 
individual wells of a 96-well plate (Nunc, Denmark) and incubated at 37 °C for 2h. 
Plasma was then withdrawn from wells. An overnight culture of the test organism in 
RPMI was diluted 1:2 in warmed sterile media (RPMI). From this suspension, 100 
μl was used to inoculate the test wells of the microtitre plate prior to incubation at 
37ºC for 24 h, 3 d or 5 d as indicated. RPMI-1640 media in each well was changed 
daily for three and five day biofilm experiments. Microtitre plates were washed 
three times with sterile distilled H2O and dried for 1 h at 65ºC prior to staining for 
10 min with a 0.4% (w/v) crystal violet solution (prepared in water). After staining 
the plates were washed a further three times with sterile distilled H2O. The 
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absorbance of the adhered, stained cells was measured at 492 nm. Each 
experiment was performed in triplicate. Strains were biofilm-positive when the 
mean biofilm OD was greater than 0.17 (10). Assays were performed in triplicate 
and data presented represents mean OD ± SD. 
2.6 Measurement of anti-biofilm activity of catheter lock solutions under 
static growth conditions 
Biofilms were prepared as described above with the following modifications. 
Following the initial incubation (24 h, 3 d or 5 d) and washing, 100 μl of the test 
antimicrobial solution was added to each test well and incubated again at 37ºC for 
a defined period of time (range 5 min - 24 h). The antimicrobial solutions used 
were prepared according to Table 2.2. Plates were then washed twice with sterile 
distilled water. Following this, 100 µl of Alamar blueTM, a redox indicator dye, (20% 
(v/v) Alamar blue, BHI/RPMI broth) (Biosource, Invitrogen, U.K.) or 100 µl of 
resazurin solution (88 µM resazurin, water) was added to each well. Resazurin is 
converted to bright red–fluorescent resorufin (from blue to pink) via the reduction 
reactions of metabolically active cells. The amount of fluorescence produced is 
proportional to the number of living cells present (the higher the fluorescent unit the 
higher level of actively metabolising live cells present). Plates were incubated in 
the dark for a further 60 min at 37ºC. Biofilm viability was determined using a 
fluorimeter with an excitation at 544 nm and an emission value of 590 nm. After 
measuring redox activity, the plates were washed and the level of stained adhered 
biofilm was measured as described above. Each experiment was performed in 
triplicate, three times and results represent mean fluorescent intensity ± SD. 
2.7 Measurement of anti-biofilm activity of catheter lock solutions under flow 
conditions 
2.7.1 Biofilm assay in enriched growth media 
A flow cell and pump was used to develop a microfluidic assay, system is shown in 
figure 2.1 (Cellix Ltd., Ireland). The flow cell consisted of eight microfluidic 
chambers to which bacteria were inoculated and the media pumped through. One 
in ten dilutions of overnight cultures were prepared in BHI supplemented with 4% 
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NaCl or 1% Glucose. A 20 µl volume of these were added to each of eight lanes in 
the tissue culture treated chip (Cellix Ltd., Ireland). Each chamber was filled with 
an additional 50 µl BHI and incubated statically at 37ºC for 4 h to allow for initial 
attachment. The pump was switched on and supplemented BHI was perfused 
through the chip, under constant flow, at an infusion rate of 200 µl/min for 7 – 24 h. 
The inoculated chip was then placed on an inverted microscope with a heated 
stage, set at 37ºC. Following incubation, antimicrobial agents were injected into 
each of the chambers and allowed to act statically for a further 24 h. The effect of 
each agent on biofilm was examined visually using brightfield and confocal 
microscopy (Section 2.7.3).  
 
Figure 2.1 Cellix Ltd. iKima microfluidic pump. System comprises of media bottle, microfluidic 
pump, connector tubing and eight chamber chip (image from Cellix Ireland Ltd.).  
2.7.2 Biofilm assay using RPMI -1640 and a human plasma coating 
To more closely mimic the in vivo environment our laboratory developed and 
modified the above protocol (2.7.1) (126). Briefly, bacteria were grown overnight on 
solid media (BHI). From this, one colony was taken and used to inoculate 5 ml of 
RPMI-1640, that was then incubated at 37ºC for 6 h with shaking. The chamber of 
each chip was coated with 100% human plasma for 2 h at 37ºC. Chambers were 
flushed through with sterile PBS before each chamber was inoculated. The 
bacteria were then allowed to attach for 1 h. The pump was switched on and 500 
ml of RPMI-1640 was infused into the chip, at a rate of 200 µl/min under constant 
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flow for 24 h. Chambers were treated as described above (2.7.1). Brightfield and 
confocal microscopy were used to analyse the effect of each agent on biofilm as 
described below (2.7.3). This assay was only used for growth of S. aureus bioflms 
under flow conditions. 
2.7.3 Biofilm imaging 
An inverted light microscope (Zeiss, Wexford, Ireland) was used to examine biofilm 
formation in flow chambers. Zen image analysis software was used to visualise 
biofilm formed in flow chambers under 10 X and 20 X magnification. Biofilm 
structure and treatment efficacy were also analysed using an inverted confocal 
microscope (Zeiss, LSM 510 Meta) for which the image capture software LSM510 
was used. Bacterial cells within the biofilm were visualised using Syto S green, 
3.34 mM, (Life technologies, Invitrogen) and Propidium iodine 20 mM (Life 
technologies, Invitrogen). Optimised lasers (argon (488 nm) and HeNe (632.8 nm)) 
were used to excite the dyes and capture the fluorescence emitted from the cells, 
under a 40 X magnification. The argon laser operated in the blue/green part of the 
visible spectrum, while the HeNe laser emits a red beam. Confocal imagine 
acquisition was carried out by adjusting the focus manually until the biofilm clusters 
were visible, autofocus was then used until clear images were obtained. Laser 
strength and detector gain were selected before capturing the first image and not 
adjusted for the duration of the experiment. ImageJ software was used to calculate 
fluorescent intensity for each chamber.  
2.8 Animal Studies 
2.8.1 Husbandry and care 
Male Sprague-Dawley rats, with a preimplanted jugular vein central venous 
catheter (polyurethane, 0.025-in. internal diameter, and 40-μl volume), were 
obtained from Charles River Labs (Kent, U.K.). Initial weights were 200 -250 g per 
rat. Rats received water and Agway rodent chow ad libitum throughout the 
experiments. Laboratory Animal Science and Training (LAST) Ireland certification 
was obtained (appendix 01). All animal protocols were reviewed and approved by 
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the RCSI Research Ethics Committee (appendix 02), a personal and project 
licence was obtained from the health products regulatory authority (HPRA) 
(appendix 03). All work was performed in accordance with S.I. No. 543 (2012). 
Animals were held in quarantine for one week on arrival to monitor health status, 
animals were examined for signs of illness, pains and infection at the end of this 
week.  Catheters were flushed with heparin saline (500UI) every second day of the 
quarantine week to maintain patency. 
2.8.2 Rat intravascular catheter (IVC) model of infection 
A rat IVC-model of infection was developed as described previously by Ulphani 
and Rupp (409), van Praagh et al. (2011) (410) and Chauchan et al. (2012) (411, 
412) with the following modifications. An initial pilot experiment was performed to 
optimise the technique, which was followed by main experimental work. Briefly, 
rats were anesthetised with isoflurane (5% induction and 2% maintenance) for all 
catheter manipulations. Jugular vein central venous catheters were inoculated by 
the instillation of 0.2 ml of saline containing 1 x 106 CFU/ml (high inoculum) or 1 x 
104 CFU/ml (low inoculum) S. aureus USA300 lux. This strain was used due to its 
ability to produce luminescence and subsequently indicate bacterial viability using 
an IVIS® imaging system. The bacteria remained in the lumen of the catheter for 
one or four days. After one or four days of infection (early and mature biofilm, 
respectively), 50 µl of each treatment agent (ML:8 or Citrox) was instilled into the 
lumen of the catheter daily for a further five days. Subcutaneous injections of 
vancomycin (50 mg/kg) were administered every 12 h for the duration of the 
experiment. Measurement of bioluminescence intensity at the site of infection was 
determined using the IVIS® imaging system on each day of treatment.  
2.8.3 Terminal harvest and analysis of results 
Rats were anesthetised. Measurement of bioluminescence intensity was measured 
using IVIS® imaging system. Cardiac blood was collected via cardiac puncture, 
serially diluted, and the CFU count determined. Rats were euthanised by cervical 
dislocation. Catheters were removed and bioluminescent intensity of catheters was 
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analysed via IVIS imaging system. Catheters were then transferred into sterile 
tubes. Biofilms were harvested from the lumens of the catheters using TrpLE TM 
(1X) (Gibco). Bacterial numbers were determined using a broth dilution and spread 
plate method on tryptone soya agar (TSA) (Fannin, LIP, Ireland). 
2.9 Measurement of cytotoxicity of ML:8 and Citrox 
2.9.1 Storing and reviving mammalian cells 
Frozen stocks of cells were thawed rapidly before use, by placing at 37°C. 
Contents of the cryovials were then transferred to a cell culture flask with 5ml of 
pre-warmed cell culture media. All cells were maintained at 37°C in a humidified 
5% CO2 incubator in appropriate media. Cells were stored in a freezing mix of 90% 
(v/v) fetal bovine serum (FBS) and 10% DMSO at a cell density of 1 x 106 cells per 
ml in cryovials. These were then frozen at -20°C for 4 h, -80°C overnight and finally 
in liquid nitrogen. 
2.9.2 Culturing mammalian cells 
HaCaT cells, a human keratinocyte cell line were a gift from Prof. Hugh Byrne, 
Dublin Institute of Technology (DIT). Cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Bio-Sciences, Ireland) with 2 mM L-glutamine 
supplemented with 10% FBS. THP-1 cells, a human acute monocytic leukemia cell 
line were provided by Prof. Catherine Greene, RCSI. Cells were cultured in RPMI-
1640 (Bio-Sciences, Ireland) supplemented with 10% FBS. Before treatment, cells 
were washed with serum free media. Cells were passaged as described in section 
2.9.3.  
2.9.3 Tissue culture 
2.9.3.1 Culture of HaCaT cells 
Following incubation, media from cell culture flasks was removed. HaCaT cells 
were washed with 1ml serum free DMEM, 2ml TrypLETM (lifescience, Invitrogen) 
was used to treat cells at 37°C for approximately 3 min. Following this 8 ml of 
DMEM was added to each flask, cells in media were transferred to 15 ml conical 
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tubes and centrifuged at 150 x g for 5 min. Pellet was retained and resuspended in 
1 ml fresh pre-warmed DMEM. Cell density was determined by diluting 10 µl of cell 
suspension in 90 µl of media / Trypan blue and using a haemocytometer to count 
numbers of viable cells.    
2.9.3.2 Culture of THP-1 cells 
THP-1 cells are a non adherent cell line. Following incubation, media from cell 
culture flasks was collected and transferred to 15 ml conical tubes and centrifuged 
at 150 x g for 5 min. Pellet was retained and resuspended in 1 ml fresh pre-
warmed RPMI-1640. Cell density was determined by diluting 10 µl of cell 
suspension in 90 µl of media / Trypan blue and using a haemocytometer to count 
numbers of viable cells.    
2.9.4 MTT assay for assessing cytotoxicity 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay is a 
colorimetric assay used to measure the mitochondrial metabolism of the cell 
through the activity of the mitochondrial oxidoreductase enzyme; these enzymes 
reduce the tetrazolium dye (413). For the MTT assay, cells were seeded in 96-well 
microtitre plates (Nunc, Denmark) at a density of 1 x 105 cells/ml in 100 μl of 
respective media. THP-1 cells were cultured in RPMI-1640 with increasing 
concentrations of test agents for 24h. HaCaT cells were incubated in DMEM with 
10% (v/v) FBS prior to treatment for 24 h to allow for cell attachment, plates were 
washed with 100 μl PBS and HaCaT cells were treated with increasing 
concentrations of each test agent for 24 h. Control wells were treated with triton X-
100 (1%) or media free of test agent. After 24 h exposure, whole cell suspensions 
of THP-1 cells were taken from each well and centrifuged 4 min at 650 x g, cell 
pellets were retained. Medium for the control and test wells of HaCaT cells was 
removed. The wells were then washed with PBS.  
Following this, 100 μl of freshly prepared MTT in media (5 mg/ml of MTT in media 
(without FBS or supplements)) was added to each well / eppendorf. After the 4 h 
incubation, the medium was discarded and the cells were washed once with PBS. 
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Then 100 μl of MTT fixative solution (isopropanol) was added to each well and the 
plates were fixed for 4 min with shaking. The absorbance was then measured at 
595 nm in a thermo Multiskan Ex plate reader (Thermo Fisher, U.K.). All 
incubations were performed at 37°C in a 5% CO2 humidified incubator. Three 
technical replicates as well as three biological replicates were tested, mean data ± 
SD are presented.  
2.9.5 Haemolysis assay 
The potential for haemolytic activity of our novel antimicrobials, ML:8 and Citrox, 
was determined using fresh human erythrocytes from healthy donors in a modified 
version of the method originally described by Cantisani et al., (2013) (414). Briefly, 
blood (approximately 20 ml) was drawn from a volunteer into EDTA using the S-
Monovette system (Sarstedt) (concentration 1.6 mg/ml). Blood was centrifuged at 
110 x g for 5 min. Plasma was removed and the remaining erythrocytes were 
washed three times with PBS. Erythrocytes were diluted in 40 ml PBS and 50 µl 
was added to a 96-well plate. Test agents were prepared in RPMI at a 
concentration twice that used in testing. Then, 50 µl of each solution was added to 
erythrocytes. Plates were incubated at 37 ºC for 24 h. Following this, 50 µl of the 
supernatant was withdrawn from top of each well and placed in a new plate. The 
release of haemoglobin was monitored by measuring the absorbance of the 
supernatant at 490 nm. Negative and positive controls consisted of erythrocytes 
suspended in RPMI-1640 and erythrocytes in RPMI-1640 with 1% triton X-100 
respectively. 
2.10 Investigation into immune response to ML:8 and Citrox                  
2.10.1 Cytokine production in whole human blood 
Blood was drawn from healthy volunteers into EDTA (concentration 1.6 mg/ml) 
using the S-Monovette system (Sarstedt). Whole blood was exposed to either 
ML:8, Citrox or an untreated media control for two hours at 37°C in 96-well 
microtitre plates (Nunc, Denmark). Exposed blood was collected into eppendorfs 
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and centrifuged at 150 x g for 10 min. After centrifugation, serum (the upper layer) 
was collected and used immediately or stored at -20°C.  
2.10.2 Cytokine measurement assays 
Cytokine concentrations were determined using a Bio-Plex 200 system (Bio-Rad, 
Lifescience, Leopardstown Dublin) and the DuoSet enzyme-linked immunosorbent 
assay (ELISA) (R & D Systems, Abingdon, U.K.). 
A Bio-Plex Pro™ Human Cytokine 8-plex assay plate containing eight cytokines 
was used, these included both proinflammatory and anti-inflammatory cytokines 
and chemokines (IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α and IFN-γ). Serum samples 
were diluted 1:4 and the plate was analysed according to manufacturer’s 
instructions. Briefly, magnetic bead solutions were vortexed and transferred to the 
vacuum filter plate. Beads were washed twice in assay buffer. Assay buffer acts as 
a blocking agent to the polystyrene surfaces of the plate and the beads and 
reduces background interference. Serum samples were centrifuged at 1400 x g for 
30 min at 4º C and added to wells in triplicate. Three donors were examined for 
each group. Supplied standards were hydrated and diluted using standard diluents 
to create a standard curve. These were added to wells of the plate in duplicate. 
Plates were sealed, protected from light and placed on a platform shaker set to 
110 x g. After 10-15 s, speed was reduced to 10 x g for 30 min.  
Detection antibody mix provided was diluted to 1:25 and added to wells. Plates 
were again sealed, protected from light and placed on a plate shaker set to 110 x 
g. After 10-15 s, the speed was reduced to 10 x g for 30 min. Streptavidin-
Phycoerythrin (SAPE) was added to bind to biotin on the detection antibody. The 
plate was incubated again with shaking at 10 x g for 10 min; the speed was 
increased to 110 x g for 30 s. The plate was read to assess fluorescence using a 
Bio-Plex 200 plate reader.   
DuoSet IL-8 and TNF-α ELISA kits were used to validate cytokine results. ELISAs 
were carried out in accordance with manufacturer’s instructions. Briefly, 100 µl of 
primary antibody was coated onto wells of a 96-well (Nunc, Denmark) plate 
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overnight at room temperature (RT). The primary antibody was removed and test 
wells were washed with 300 µl of wash buffer three times. Then 300 µl of blocking 
buffer was added to each test well for 1 h. Following this, test wells were washed 
again with 300µl of wash buffer a further three times. Samples and standards were 
prepared in kit diluents, serum samples were diluted 1:4 as before, and added to 
plates in triplicate for 2 h. Test wells were then washed with 300 µl of wash buffer 
three times. Following this, 100 µl of the secondary antibody was added to each 
well and incubated for two hours at RT. Plates were again washed with 300 µl of 
wash buffer three times. A 100 µl of Streptavidin-HRP, was added to plates for 20 
min at RT. After this incubation test wells were washed with 300µl of wash buffer 
three times, as before. A 100 µl volume of substrate solution was added to plates 
for 20 min at RT. Fifty microliters of stop solution was then added to each well and 
shaken gently. The plate was read to determine the optical density of each well 
immediately after the addition of the stop solution; plates were read at 450 nm 
using a thermo Multiskan-Ex plate reader (Thermo Fisher, U.K.).  
2.11 Investigation of potential of ML:8 and Citrox to induce antimicrobial 
resistance             
Antimicrobial resistance testing was performed using Mueller Hinton agar plates 
supplemented with novel antimicrobial agents at concentrations of 0.125 & 0.0625 
% v/v for ML:8  and 0.015 & 0.0075 % v/v for Citrox. S. aureus strain SH1000 was 
adjusted to a 0.5 McFarland standard, 100 µl was plated in triplicate onto plates of 
various concentrations (Table 2.3). Plates were incubated for 48 h at 37 ºC and 
were then transferred to 4 ºC for 48 h to allow bacterial cells to recover from the 
challenge. Bacterial cells were harvested, adjusted to a 0.5 Mc Farland standard 
and cultured onto fresh agar plates with test agents added. This process was 
repeated in triplicate twice weekly for 12 weeks.  
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Table 2.3 Preparation of Plates for Resistance Testing 
Agent MIC Sub-MIC 
 
ML:8 
 
0.125% (v/v) 
 
0.0625% (v/v) 
Citrox 0.015% (v/v) 0.0075% (v/v) 
 
2.12 Harvesting and preparation of RNA 
2.12.1 Growth and preparation of cells for RNA extraction 
All work with RNA was done in RNase free plastic-ware using RNase free filter 
tips. Benches and pipettes were cleaned with RNase Zap (Ambion). Any water 
used was incubated at 37 °C with 0.1 % (w/v) diethyl pyrocarbonate overnight prior 
to sterilisation by autoclaving (DEPC-treated water). 
Overnight cultures were adjusted to an OD600 of 0.5 using BHI. Then 2 ml of the 
diluted culture was used to inoculate 50 ml of sterile BHI in 250 ml flasks. Flasks 
were incubated with shaking at 37 ˚C until an OD600 of 0.5 was reached. Then BHI 
and ML:8 (0.0625% v/v), BHI and Citrox (0.0075% v/v) or equivalent volume of BHI 
(control) was added to the representative flask. After 20 min treatment, cells were 
harvested by centrifugation of 0.5 ml of culture for 5 min at 10,000 x g and 4 °C. 
Pellets were resuspended in 1 ml of RNAlater (Qiagen) to ensure maintenance of 
RNA integrity prior to purification and incubated overnight at 4 °C.  
Bacterial biofilms were developed in supplemented BHI for 24 h as previously 
described in section 2.5.1. TypLE® was used to harvest biofilm from 96-well plates 
and cells were centrifuged at 10,000 x g for 3 min to remove TrypLE®, cells were 
resuspended in BHI, BHI and ML:8 (0.0625% v/v) or BHI and Citrox (0.0075% v/v). 
After 20 minutes treatment cells were harvested by centrifuging, resuspended in 
RNAlater (Qiagen) and stored overnight at 4 °C as above.  
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2.12.2 Lysis of cells for RNA extraction 
A method adapted from Tatham (2011) was used to lyse cells for RNA extraction 
(415). Briefly, the protocol was; 3 ml of the S. epidermidis strain RP62A 
preparation or 1 ml of the S. aureus strain SH1000, BH48 or BH1CC preparation 
was used. The bacteria were centrifuged at 5000 x g for 5 min at 4 °C, and 
resuspended in 50 µl Tris-EDTA (TE) containing 6 mg/ml-1 lysostaphin and 400 U 
ml-1 mutanolysin. The solution was incubated at 37 °C for 15 min for S. aureus and 
30 min for S. epidermidis, mixing every 5 min. Bacteria were incubated for a further 
30 min at 37 °C following the addition of 25 µl of Proteinase K (Qiagen). 
2.12.3 RNA extraction 
RNA was extracted using the RNeasy kit (Qiagen), with slight alterations to the 
manufacturer’s protocol. Briefly, the method was as follows: 350 µl kit buffer RLT 
containing 1 % (v/v) β-mercaptoethanol was added to the lysed cells and mixed 
before the addition of 250 ml of 100% ethanol. This suspension was centrifuged 
through the RNeasy column for 15 s at 8000 x g. The column was washed twice 
with 700 µl kit buffer RW1 for 15 sec at 10000 x g. The column was then washed 
three times with 500 µl kit buffer RPE for 15 s at 10000 x g. Collection tubes were 
changed between buffers. The column was centrifuged in a clean collection tube 
for 1 min with the column lid off and the column was then air dried for 2-5 min. 
RNA was eluted twice with 30 µl water prewarmed to 45 °C. RNasin (Promega) 
was added according to the manufacturer’s instructions. A 2 µl aliquot of the 
sample was used for total RNA quantification using Qubit RNA assay kit 
(Invitrogen) according to manufacturer’s protocol. 
2.12.4 DNase treatment of RNA 
Samples with > 3 µg total RNA were DNase treated using turbo DNase (Ambion) 
according to manufacturer’s instructions. DNase was removed using the RNeasy 
MinElute clean up kit (Qiagen) according to manufacturer’s instructions, with the 
addition of 1 % beta-mercaptoethanol to the buffer RLT and elution was in 20 µl 
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water.  An aliquot of 4 µl was taken for quality control analysis whilst the rest was 
frozen at -80 °C.  
2.13 Real time quantitative polymerase chain reaction (q-PCR) 
RNA was harvested and DNase treated as described in section 2.12.4. RNA 
integrity was assessed by gel electrophoresis prior to conversion to cDNA for 
qPCR. Agarose gels were made to a concentration of 1 % (w/v) agarose in TAE 
buffer. Ethidium bromide or Midori green (Nippon Genetics) were mixed into 
molten agarose at 4 µl or 2 µl per 100 ml, respectively. When necessary, a loading 
dye was added to samples before loading samples into the gel. Samples were run 
in TAE buffer at 80-100 v for between 45 min and 1.5 h. Complementary DNA 
(cDNA) was generated from messenger RNA (mRNA) using the NEB First Strand 
Synthesis kit in accordance with the manufacturer’s instructions using random 
hexamers primers.  
Real-time PCR (q-PCR) was performed on a LightCycler instrument using the RNA 
amplification kit Sybr Green I (Roche Biochemicals, Switzerland) following the 
manufacturer's recommended protocol. RT-cycle was run using a denaturation 
step at 95°C for 5 min and 45 amplification cycles of 95°C for 10 s, 58°C for 20 s 
and 72°C for 20 s. Melting curve analysis was performed at 45°C to 95°C 
(temperature transition, 0.1°C per second) with stepwise fluorescence detection. 
For LightCycler q-PCR, RelQuant software (Roche Biochemicals) was used to 
measure relative expression of target genes. Primers used are shown in table 2.4. 
The expression of gyrB was used as an internal standard. Each experiment was 
performed at least three times. Fold difference in expression between control and 
treated were determined and average data with standard deviations presented. 
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Table 2.4 RT-PCR primers used in this study 
Target Gene Primer Name Primer sequence 5’ – 3’ 
gyrB GyrB_For TTATGGTGCTGGGCAAATACA 
 GyrB_Rev CACCATGTAAACCACCAGATA 
sdrC SdrC_for TTGACATACATCAGCGAAAACA 
 SdrC_rev TCAATTTCGTTGTTTGCTTCA 
coa Coa_for GCATACGACAATCAAACTGGTGT 
 Coa_rev ACCTTTAACTTCACGTGCAGC 
esxB Esx_for CGCACTCAATCAAGGCATTA 
 Esx_rev CCAGCAAGTGTCTGACTTCG 
cap5E Cap5E_for AATACGCCTGAGGAATTTTCTG 
 Cap5E_rev CCAAATTTTTGCGAAAAGGA 
2.14 RNA sequencing 
2.14.1 RNA quality control 
Quality control analysis was conducted using a Qubit (Qubit RNA BR assay kit, 
Life Technologies, Invitrogen) for quantification, 2100 Bioanalyser (Agilent 
technologies) to assess degradation levels and Nanodrop (Thermoscientific) to 
assess protein or solvent contamination. Tests were carried out according to 
manufacturer’s instructions for bacterial RNA. Samples with a paired control and 
test condition sample with Qubit read indicating ≥ 3 µg RNA, Bioanalyser RIN ≥ 
7.0, Bioanalyser trace indicating good integrity, Nanodrop 260/280 and 260/230 ≥ 
1.8 were determined to be suitable for sequencing.  
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2.14.2 RNA library preparation 
Library preparation was performed at the Centre for Genome Research (CGR), 
University of Liverpool. Total RNA samples were rRNA depleted using Ribo-Zero 
magnetic kit for Gram-positive bacteria (Epicentre); this was repeated for samples 
with poor initial rRNA removal. The concentration of RNA was normalised, then 
libraries were then prepared using strand specific ScriptSeq kits (Epicentre). 
Samples were sequenced using paired-end sequencing on the HiSeq platform 
(Illumina).  
2.14.3 RNA sequencing differential expression analysis 
Bowtie (416) and Edge R (74, 417) were used to map reads and determine the 
differentially expressed (DE) genes, respectively. A significance value of P≤0.0001 
was set for DE analysis. Genes with mapped transcripts that had a false discovery 
rate > 0.05, as determined by Benjamin and Hochberg analysis, were filtered out of 
the dataset (418). The remaining gene set was considered differentially expressed 
between control and test conditions. This analysis was produced by the CGR, 
Liverpool, United Kingdom. Changes in gene expression in biosynthetic pathways 
were assessed using DE gene sets with KEGG mapper- search and color (419). 
Gene ontology (GO) terms were attached to DE genes using Uniprot, 2014. 
2.14.4 Staphylococcus aureus microarray meta-database (SAMMD) analysis 
Prior to SAMMD analysis, the gene names in the DE gene list were converted to 
their homologue in S. aureus N315 using a bespoke Perl script 
(convert_to_SA_homologs.pl) which utilises the Basic Local Alignment Search 
Tool (BLAST) (420). The top hit from BLAST was selected using Excel (Microsoft), 
this list was used to create lists of homologous up or down regulated genes using a 
bespoke Perl script (lists_for_SAMMD.pl). The DE homologue gene list was then 
submitted to SAMMD (421) as an advanced search and the resulting data was 
turned into Venn diagrams using Inkscape. The genes that were up- and down-
regulated in both ML:8 and Citrox were determined using a bespoke Perl script 
(sammd_compare.pl). 
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2.15 Statitistical analysis 
Two-tailed, paired Student’s t-tests were used to determine statistical significance 
of data. Significance was defined as a P value of ≤0.05 (*). For the animal 
experiments descriptive statistics (including mean and standard deviation) values 
were calculated for each test agent. Log10 transformation of CFU data from 
catheters were used to ensure normal distribution. A two-sample t-test was 
conducted to compare the log-transformed CFU values. 
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Chapter 3: Evaluation of antiseptics and 
antibiotics for the treatment of IVC-related 
staphylococcal biofilm infections 
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3.1 Introduction  
The use of IVCs in modern healthcare has increased over the last number of 
decades (422).  It is likely that this trend will continue with an ageing population 
and the need for increased medical and surgical interventions. Colonisation of 
these devices by surface-adhering bacteria, such as staphylococci, can result in 
CRIs that in turn are associated with increased patient morbidity and mortality, 
prolonged hospitalisation and excess hospital-related costs. CRIs now represent 
one of the most common causes of HCAI in Ireland. A mortality rate of between 
12-25% among critically ill patients with a BSI associated with a CRI has been 
attributed by the centre of disease control (CDC) (423).  
As discussed, staphylococci are recognised as the most frequent cause of biofilm-
associated infections leading to CRI (424, 425). A large proportion of 
staphylococcal bloodstream infections are due to IVCs. In Ireland, the HPSC 
record and report on the number of patients with S. aureus bloodstream infections 
and over 1,100 cases were reported in 2014 (11). Irish data from 2014 revealed 
that 18% of all MRSA BSIs were catheter-related, while 26% of MSSA BSIs were 
associated with an implanted catheter (11). S. aureus is regarded as the most 
virulent species of staphylococcus due to its wide array of secreted and cell 
surface associated virulence factors, mechanisms of immune evasion and toxin 
production (89). Over recent decades, CoNS, notably S. epidermidis, have become 
increasingly recognised as opportunistic pathogens in patients with medical 
devices in situ.  Irish surveillance data does not record the incidence of S. 
epidermidis infection rates. However, previous studies have indicated up to 65% of 
IVC infections are caused by S. epidermidis (426, 427).  
These biofilms are highly resistant to both the action of the innate and adaptive 
immune response, and to the action of systemically administered antimicrobial 
agents. As a result such infections are often associated with treatment failure when 
the source of infection, namely the IVC, is left in situ. For the treatment of 
suspected CRI involving staphylococci, numerous guidelines have been published 
(349, 350, 356). For example, in the IDSA and Irish guidelines the use of a CLS 
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has been recommended for the prevention of CRI. These solutions have also been 
indicated as a potential treatment option. In this study we have focused on the 
treatment of CRI using various potential and established CLSs.  
A range of antibiotics, including vancomycin, daptomycin, gentamicin, rifampicin 
and linezolid have been used in studies investigating their effectiveness as CLSs in 
patients with CRI due to staphylococci (363, 428, 429). Similarly, various antiseptic 
agents including ethanol, EDTA and sodium citrate derivatives have been studied, 
with significant variations in their effectiveness being reported (430-432). Due to 
the variation between models used as well as concentrations of agents, there is 
little consistency in the findings of these studies. This makes it difficult to draw any 
sound conclusions on which agent, or agents, would be most effective for the 
treatment of staphylococcal biofilm infections. Many in vitro studies investigating 
the effectiveness of CLSs are flawed, as they do not attempt to mimic in vivo 
conditions. This can be addressed by attempting to replicate blood flow and 
incorporating serum proteins into the model of infection. Many studies use nutrient 
enriched media on a small number of reference strains in static polystyrene biofilm 
assays, this is not representative of in vivo conditions. 
The link between in vitro biofilm susceptibilities and in vivo results is not always 
clear. This may be in part due to the current in vitro models used, particularly in 
cases where biofilm is present. An in vivo relevant model for biofilm formation has 
recently been developed in our laboratory (126). This model involves growing 
biofilms in RPMI-1640 media, which is routinely used in the culture of blood cells, 
and on surfaces that have been coated with human plasma. Current models for 
biofilm formation often involve culturing bacteria in nutrient enriched media, such 
as BHI or tryptic soya broth (TSB). 
The aim of this chapter is to investigate which of the currently available treatment 
options for CRIs due to staphylococcal biofilm are most effective. Here a 
combination of in vitro staphylococcal biofilm models of IVC infection are used to 
assess the effectiveness of the various CLSs in current use. Commonly used 
methodology involving nutrient enriched media will be used and compared to newly 
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designed assays that aim to mimic the in vivo environment. Testing will be carried 
out against a selection of reference strains and clinical staphylococcal isolates of 
varying genetic backgrounds and methicillin susceptibility to determine the 
optimum agent required to eradicate biofilm formed by S. aureus and S. 
epidermidis within the catheter.  
3.2 Aims 
 To compare the effect of conventional antiseptics and antibiotics on 
staphylococcal planktonic cells. 
 
 To analyse the effectiveness of these antiseptics and antibiotics on 
staphylococcal biofilm formed by a number of clinical and reference isolates 
of varying genetic lineages. 
 
 To use a clinically relevant static biofilm model of CRI to assess the efficacy 
of antiseptics and antibiotics.  
 
 To develop an in vivo like model of biofilm formation under conditions of 
flow, compare it to commonly used models and use it to assess the 
antimicrobial effect of antiseptics and antibiotics. 
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3.3 Results 
3.3.1 Determining minimum inhibitory concentrations (MIC) 
The MICs of a range of commonly used antiseptics and antibiotics for a range of 
MSSA and MRSA strains and an S. epidermidis strain were determined. Results 
were then compared to determine if greater resistance patterns were evident 
between MRSA, MSSA and S. epidermidis strains. 
Assays to determine MIC included E-test® and broth microdilution methods, as 
described in section 2.3. After 24 h exposure at 37°C, the results were interpreted 
and are described in Table 3.1. The MIC for each isolate tested fell below the 
EUCAST clinical breakpoints for susceptibility deeming them sensitive to all 
antibiotics tested. Guidelines are not currently available for the antiseptics tested. 
No differences in MIC values can be seen for the antiseptics ethanol, EDTA and 
Taurolodine in each of the strains tested. However, S. aureus strains were more 
resistant to sodium citrate compared to the S. epidermidis strain RP62A.  
Table 3.1 Minimum inhibitory concentrations of antiseptics and antibiotics 
Agent SH1000 BH48 BH1CC USA300 Je2 RP62A 
Antiseptics      
Ethanol % (v/v) 30 30 30 30 30 
Sodium Citrate % 
(v/v) 
 
25 
 
25 
 
25 
 
25 
 
12.5 
Taurolodine 
(µg/ml) 
>250 >250 >250 >250 >250 
EDTA (mg/ml) 1.87 1.87 1.87 1.87 1.87 
Antibiotics      
Vancomycin 
(µg/ml) 
1 0.25 1 1 0.5 
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Agent SH1000 BH48 BH1CC USA300 Je2 RP62A 
Gentamicin 
(µg/ml) 
1 0.5 1 1 1 
Daptomycin 
(µg/ml) 
0.25 0.25 0.25 0.125 0.125 
Linezolid (µg/ml) 1 0.5 1 1 1 
Fosfomycin 
(µg/ml) 
2 1 1 2 1 
Rifampicin (µg/ml) 0.6 1.25 1.25 0.6 0.6 
Tigecycline 
(µg/ml) 
0.125 <0.016 0.094 0.094 0.125 
 
3.3.2 Measurement of antimicrobial activity of antiseptics and antibiotics 
against planktonic cells 
Following the MIC testing, it was important to determine the optimum time to 
achieve a complete kill of a culture of bacteria. To examine this, suspension testing 
was performed. The activity of each agent against bacterial cell suspensions was 
measured as described in section 2.4. The optimum time required, as well as the 
concentration required, to achieve a complete kill was determined and the results 
are shown in table 3.2. The antiseptics ethanol, EDTA, Duralock-CTM and 
TaurolockTM all resulted in a complete kill of the bacterial suspension within 20 min. 
The antibiotics tested took substantially longer than this with the time taken to kill 
planktonic bacteria ranging from 12 h to 48 h. 
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Table 3.2 Optimum time to achieve total kill of planktonic bacteria 
Agent Concentration SH1000 BH48 BH1CC USA300 
Je2 
RP62A 
Antiseptics       
Ethanol 30% (v/v) 6 min 6 min 13 min 11min 3 min 
Duralock-C TM 46.7% (v/v) 20 min 20 min 20 min 20min 20 min 
Taurolock TM  1.25% (v/v) 17 min 18 min 17 min 18min 16 min 
EDTA 32 mg/ml 20 min 20 min 19 min 20min 17 min 
Antibiotics       
Vancomycin 4 µg/ml 48 h 48 h 48 h 48h 48 h 
Gentamicin 4 µg/ml 48 h 48 h 48 h 48h 24 h 
Daptomycin 4 µg/ml 48 h 48 h 48 h 48h 48 h 
Linezolid 4 µg/ml 48 h 48 h 48 h 48h 48 h 
Fosfomycin 4 µg/ml 48 h 48 h 48 h 48h 48 h 
Rifampicin  4 µg/ml 24 h 24 h 24 h 24 h 24 h 
Tigecycline 4 µg/ml 12 h 12 h 12 h 12h 12 h 
3.3.3 Analysis of biofilm formation by S. aureus and S. epidermidis strains 
Osmotic stress induced by NaCl is known to activate ica expression and biofilm 
development in most MSSA and some S. epidermidis strains (180). Acidic stress, 
induced by the addition of glucose, has been shown to increase biofilm production 
on most MRSA strains (406). Conditions for optimum biofilm formation for the five 
lead strains used in this study were found to be consistent with these previous 
findings. The level of biofilm formation was assessed using a static, nutrient 
enriched media biofilm assay described in section 2.5.1. SH1000, BH48 and 
RP62A biofilm was grown in BHI supplemented with 4% (w/v) NaCl. BH1CC and 
USA 300 Je2 were grown in BHI supplemented with 1% (w/v) glucose. Plates were 
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incubated and examined as described in section 2.5. Results are illustrated in 
figure 3.1. All five strains were deemed to be biofilm-positive with an OD492 greater 
than 0.17. The MSSA strain SH1000 and the MRSA strain BH1CC were the 
strongest biofilm formers.  
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Figure 3.1: Biofilm formation of S. aureus and S. epidermidis lead strains. SH1000, BH48 and 
RP62A biofilm was grown in BHI supplemented with 4% (w/v) NaCl. BH1CC and USA 300 Je2 
were grown in BHI supplemented with glucose (1% w/v). Optical density (OD) was measured at 
490nm. Assays were performed in triplicate and data represents mean OD ± SD. 
Biofilm testing was expanded to include thirteen strains from eight clonal 
complexes that are prevalent in European hospitals. Biofilm forming capacity was 
first examined as above. Each of the strains tested was determined to be biofilm-
positive. This is illustrated in figure 3.2. Dar strains 70, 113, 141 and 217 (figure 
3.2 A) as well as strains from Beaumont Hospital (BH), 40(04), 49(04) and 10(03) 
(figure 3.2 C), were determined to be strong biofilm formers with OD492 readings 
greater than 1.9 for all strains. Strains shown in figure 3.2 B are weaker biofilm 
formers; however these strains were still determined to be biofilm-positive.  
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Figure 3.2: Biofilm formation of S. aureus strains. Dar strains 70, 113, 141, 217 and BH 10(03)  
were grown in BHI with glucose (1% w/v), remaining BH strains were grown in BHI with NaCl (4% 
w/v). Optical density (OD) was measured at 490nm. Assays were performed in triplicate and data 
represents mean OD ± SD. 
3.3.4 Effect of antiseptics on static biofilm formed in nutrient enriched media 
All the antiseptics tested proved effective at killing the bacterial cell suspensions, 
however, it remained to be determined if the antiseptic agents would also be 
effective against the bacteria in a biofilm. Biofilms were formed, treated and 
analysed as described in section 2.5.1 and 2.6. High fluorescent readings indicate 
high levels of viable bacteria while low readings are indicative of low metabolic 
activity and cell death. The results are illustrated in figure 3.3.  
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Figure 3.3 Effect of antiseptics on biofilm viability following treatment for 24 h. SH1000, 
BH48 and RP62A biofilm was grown in BHI supplemented with NaCl (4% w/v). BH1CC and USA 
300 Je2 were grown in BHI supplemented with glucose (1% w/v). Test wells were either left 
untreated or treated with antiseptics ethanol (A), EDTA (B), sodium citrate (C) or commercial CLSs  
(D) for 24 h. Assays were performed in triplicate and data represents mean fluorescent units ± SD. 
Statistically significant results are indicated (two tailed student t-tests, P ≤ 0.05 *). 
D 
C 
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Ethanol treatment at concentrations of 30% (v/v), and above, resulted in a 
significant decrease in biofilm viability to levels suggestive of complete eradication. 
Treatment with 15 and 7.5% (v/v) was found to result in a significant reduction in 
viability for all five strains tested, however, a complete kill was not seen with these 
concentrations (figure 3.3 A). Ethanol at a concentration of 30% (v/v) was found to 
be the lowest dose to eradicate biofilm and was used in all future testing. EDTA 
treatment was examined at 32 mg/ml and lower as this was the highest 
concentration published and deemed to be suitable for use as a CLS (376). EDTA 
at concentrations of up to 32 mg/ml were not effective at killing biofilm cells within 
this model (figure 3.3 B).  
Sodium citrate was analysed as it is a main component of the commercial CLSs 
Duralock-CTM and TaurolockTM. Concentrations up to 50 % (w/v) were examined. 
Susceptibility differences between strains were evident. Sodium citrate significantly 
reduced the viability of biofilms produced by the MSSA strain BH48 at 
concentrations of 25% (w/v) and 50 % (w/v) (figure 3.3 C). As expected, Duralock-
CTM treatment resulted in similar reduction as that seen with 50 % (w/v) sodium 
citrate. In contrast to sodium citrate treatment, Duralock-CTM significantly reduced 
viability of biofilm produced by the MRSA strain BH1CC (figure 3.3 D). SH1000, 
RP62A and USA300 Je2 were observed to be the most resistant strains to 
treatment (figure 3.3 D). Treatment with TaurolockTM resulted in a significant 
reduction in biofilm viability in all strains tested. 
Results illustrated in this section indicate the optimum concentrations of antiseptic 
and agents that should be used in future testing. Concentrations were selected 
based on the agents’ performance against the five lead strains. Agents that proved 
effective in treating biofilm were used at the lowest effective concentration, while 
agents that did not prove effective were used at the highest concentration available 
and recommended for use. Concentrations of antiseptic agents chosen for use in 
future testing are summarised in table 3.3.  
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Table 3.3 Concentration of antiseptic agents chosen for biofilm testing 
Agent Concentration 
Ethanol 30 % (v/v) 
Duralock-CTM 46.7% (as sold) 
TaurolockTM 4% (as sold) 
EDTA 32 mg/ml  
 
3.3.5 Determining optimum exposure time for treatment of biofilms with 
antiseptic agents.  
Testing was expanded to determine an optimum treatment time for antiseptic 
agents against biofilm formed over 24 h. Treatment times of 4, 8, 16 and 20 h were 
examined. Both MRSA strain BH1CC and S. epidermidis strain RP62A were 
significantly (P≤0.05) affected by treatment with ethanol at a concentration of 30% 
(v/v) in all treatment times examined. Treatment for 4 (figure 3.4 A) and 8 h (figure 
3.4 B) did not result in a significant reduction in biofilm viability with any other 
treatment agents. MRSA strain Je2 was significantly affected by ethanol treatment 
after exposure for 16 h (figure 3.4 C). Treatment for 20 h resulted in a significant 
reduction in biofilm viability for all strains treated with ethanol (30% v/v). A 
significant reduction (P≤0.05) was also observed for BH48, BH1CC and RP62A 
after treatment with TaurolockTM for 20 h (figure 3.4 D). Duralock-CTM treatment for 
20 h resulted in a significant reduction in viability for BH1CC. EDTA treatment did 
not have any significant affect on biofilm viability in the times examined.  
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16h treatment
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Figure 3.4 Effect of antiseptics on biofilm over time. SH1000, BH48 and RP62A biofilm was 
grown in BHI supplemented with NaCl (4% w/v). BH1CC and USA 300 Je2 were grown in BHI 
supplemented with glucose (1% w/v). Test wells were either left untreated or treated with 
antiseptics for 4 (A), 8 (B), 16 (C) or 20 h (D). Assays were performed in triplicate and data 
represents mean fluorescent units ± SD. Statistically significant results are indicated (two tailed 
student t-tests, P ≤ 0.05 *). 
C 
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The results in figure 3.4 show a significant reduction in bacterial viability with some 
treatments after a 20 h exposure. However, this reduction is less than that seen 
previously following a 24 h treatment (figure 3.3). From this we can determine the 
minimum treatment time for our antiseptic agents should be 24 h. This treatment 
time will be used in all future experiments. This is consistent with previous 
research recommending the use of CLSs for up to 24 h (433, 434).  
3.3.6 Effect of antibiotics on static biofilm formed in nutrient enriched media  
High concentrations (several thousand times the MIC) of antibiotics were used to 
treat established biofilm produced in nutrient enriched media. Antibiotics tested 
were shown to be effective at killing planktonic bacterial cells (table 3.1, 3.2). To 
establish their efficacy against sessile cells measurement of anti-biofilm activity 
was carried out as described in section 2.6. Treatment was carried out for 24 h; 
biofilm was then assessed for viability using a redox indicator dye. Results are 
shown in figure 3.5. 
There was no significant (P≤0.05) reduction in the viability of biofilm produced by 
each of the five lead strains, following treatment with vancomycin (figure 3.5 A), 
gentamicin (figure 3.5 B), daptomycin (figure 3.5 C) or fosfomycin (figure 3.5 E) at 
concentrations up to 50 mg/ml. Rifampicin (figure 3.5 F) was analysed at 
concentrations up to 10 mg/ml, there was no significant reduction in biofilm viability 
following 24 h treatment. Similarly, linezolid did not result in a significant reduction 
in biofilm viability at concentrations up to 4 mg/ml. The effect of tigecycline 
treatment at concentrations up to 10 mg/ml is shown in figure 3.4 G. The clinical 
isolates BH48 and BH1CC were most affected by tigecycline at concentrations 
above 1.25 mg/ml, where a significant decrease (P≤0.05) in biofilm cell viability can 
be seen. The strains SH1000, RP62A and USA300 Je2 remained unaffected by 
tigecycline treatment at concentrations up to 10 mg/ml.  
108 
 
A B
C D
FE
 
D 
109 
 
G
 
Figure 3.5 Effect of antibiotics on biofilm viability following treatment for 24 h. SH1000, BH48 
and RP62A biofilm was grown in BHI supplemented with NaCl (4% w/v). BH1CC and USA 300 Je2 
were grown in BHI supplemented with glucose (1% w/v). Test wells were either left untreated or 
treated with antibiotics vancomycin (A), gentamicin (B), daptomycin (C), linezolid (D), fosfomycin 
(E), rifampicin (F) or tigecycline (G) for a further 24 h. Assays were performed in triplicate and data 
represents mean fluorescent units ± SD. Statistically significant results are indicated (two tailed 
student t-tests, P ≤ 0.05 *). 
As the antibiotics examined were not fully effective at any of the concentrations 
tested against all five strains, the highest concentrations achievable in a clinical 
setting, were selected for use in future testing. Concentrations chosen are 
summarised in table 3.4. 
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Table 3.4 Summary of concentration of antibiotic agents for future biofilm 
testing 
Agent Concentration (mg/ml) 
Vancomycin 50  
Gentamicin 40  
Daptomycin 50  
Fosfomycin 50  
Linezolid 4  
Tigecycline 10  
Rifampicin 10  
3.3.7 Determining the effect of antiseptics and antibiotics on S. aureus 
strains of different genetic background 
The variance, if any, in the susceptibility of biofilms produced by different clonal 
complexes (CCs) of S. aureus to treatment was also examined. Ethanol treatment 
significantly (P≤0.05) reduced biofilm viability against S. aureus strains from eight 
CCs. Greater than 87% reduction in biofilm viability was seen in all cases (figure 
3.6). Treatment with Duralock-CTM resulted in a significant reduction in biofilm 
viability against three strains, BH3, BH4 and BH10 (figure 3.6 C). All other strains 
remained minimally effected by Duralock-CTM treatment. The effect of TaurolockTM 
on biofilm viability in all CCs was variable (figure 3.6). CCs 15 (BH4), 121 (BH3) 
and 398 (BH10) were all significantly affected by TaurolockTM treatment. Within 
CCs there was further strain to strain variation. Biofilm produced by CC22 strains 
BH10 (03) and BH21 were significantly (P≤0.05) reduced after TaurolockTM 
treatment, whilst Dar 113 was not. Bacterial biofilm was not significantly affected 
by EDTA.  
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Figure 3.6 Effect of antiseptics on biofilm formed by different clonal complexes of S. aureus 
following 24 h treatment.   Dar strains 70, 113, 141, 217 and BH 10(03) were grown in BHI with 
glucose (1% w/v), remaining BH strains were grown in BHI with NaCl (4% w/v).Test wells were 
either left untreated or treated with antiseptics for a further 24 h. Assays were performed in triplicate 
and data represents mean fluorescent units ± SD. Statistically significant results are indicated (two 
tailed student t-tests, P ≤ 0.05 *). 
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The effect of antibiotics on biofilm formed by 13 S. aureus isolates covering a 
range of eight CCs was examined. Antibiotics had previously been shown to be 
ineffective at reducing bacterial viability within a biofilm (figure 3.5). Similar results 
are shown in figure 3.7, when testing was expanded to include biofilms formed by 
all CCs. Of the antibiotics tested, none significantly (P≤0.05) reduced the viability 
of biofilms produced by strains representing the different CCs (figure 3.7). This was 
in keeping with earlier findings shown in figure 3.5 for all antibiotics, except 
tigecycline. Surprisingly viability, of the 13 S. aureus clinical isolates tested, was 
not significantly reduced by tigecycline treatment (figure 3.7).  
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Figure 3.7 Effect of antibiotics on biofilm formed by different clonal complexes of S. aureus 
following 24 h treatment.   Dar strains 70, 113, 141, 217 and BH 10(03) were grown in BHI with 
glucose (1% w/v), remaining BH strains were grown in BHI with NaCl (4% w/v).Test wells were 
either left untreated or treated with antibiotics for a further 24 h. Assays were performed in triplicate 
and data represents mean fluorescent units ± SD. Statistically significant results are indicated (two 
tailed student t-tests, P ≤ 0.05 *). 
Taken together these results indicate that while some strain to strain variation was 
evident, there was no significant (P ≤ 0.05) variation between strains exposed to 
either antiseptics or antibiotics.  
3.3.8 Examining the effect of therapeutic agents in combination on biofilm 
viability 
To investigate if our antibiotics and antiseptics had a synergistic effect and 
enhanced biofilm killing we examined the effect of agents in combination against 
pre-established biofilm. Biofilm was formed, treated and analysed as described in 
section 2.5.1 and 2.6. Antibiotics were examined at a concentration of 5 mg/ml, 
with the exception of linezolid, which was used at a concentration of 2 mg/ml. 
These concentrations were choosen based on cinical advice. The concentrations 
of antiseptics included in the combinations are described in table 3.5.  
C 
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The summary in table 3.5 indicates no combination of antiseptic/antibiotic or 
antibiotic/antibiotic had a synergistic effect or significantly increased killing of 
biofilm produced by S. aureus strain SH1000. A benefit was observed for five 
combinations; however the reduction in biofilm viability was too low when 
compared to monotherapy to be considered significant (P≤0.05). These included 
gentamicin in combination with daptomycin, rifampicin and tigecycline, as well as 
rifampicin in combination with daptomycin and tigecycline. Both gentamicin and 
rifampicin are commonly used in combination therapies for patients with 
staphylococcal infections. Combination therapy was compared to monotherapy 
against the same strain in the same nutrient enriched growth conditions. 
Table 3.5 Summary of potential benefit of combination therapies. 
Agent 1 Agent 2  
 Vancomycin Gentamicin Daptomycin Fosfomycin Linezolid Rifampicin Tigecycline 
Antiseptics        
Ethanol 
(15%) 
X X X X X X X 
Duralock-C 
TM 
X X X X X X X 
TauroLockTM X X X X X X X 
EDTA 
(32mg/ml) 
X X X X X X X 
Antibiotics        
Vancomycin ― X X X X X X 
Gentamicin X ―  X X   
Daptomycin X  ― X X  X 
Fosfomycin X X X ― X X X 
Linezolid X X X X ― X X 
Rifampicin X   X X ―  
Tigecycline X  X X X  ― 
Symbol is indicative of benefit () or no benefit (X) of the combination examined when compared to 
monotherapy.   
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3.3.9 Analysis of biofilm formation in novel in vivo like conditions 
An in vivo relevant assay for biofilm formation has recently been developed in our 
laboratory (126). Biofilm was developed as described in section 2.5.2. Biofilm was 
allowed to develop for 24 h on plasma coated surfaces in nutrient limited 
conditions before wells were washed and biofilm density was assessed using 
crystal violet. The four S. aureus lead strains used in this study are shown, in figure 
3.8, to be strong biofilm formers in this model, with biofilm ODs greater than 1.6 
demonstrated. S. epidermidis strain RP62A growth is limited in RPMI-1640 media 
on plasma coated surfaces, this resulted in low biofilm levels of OD492 0.29.  
S
H
10
00
B
H
48
B
H
1C
C
Je
2
R
P6
2A
0.0
0.5
1.0
1.5
2.0
2.5
O
D
4
9
2
 
Figure 3.8: Biofilm formation of S. aureus lead strains on plasma coated surfaces in RPMI 
1640. SH1000, BH48, BH1CC, USA 300 Je2 and RP62A were grown in RPMI-1640. Crystal violet 
was used to determine biofilm levels. Assays were performed in triplicate and data represents mean 
optical density at 492nm ± SD. 
3.3.10 Effect of antiseptics and antibiotics on static biofilm formed in minimal 
media 
To investigate if there is a difference in susceptibility of biofilms produced in 
nutrient limited conditions to those produced in nutrient enriched conditions 
biofilms were generated using two protocols (nutrient enriched and nutrient limited 
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media as described in section 2.5), and subjected to treatment for 24 h with agents 
under investigation. Results are illustrated in figure 3.9. Antibiotic and antiseptic 
concentrations used are described in Table 3.3 and 3.4. 
Bacterial biofilms grown in the nutrient limited assays were more susceptible to 
treatment than those formed using the nutrient enriched assay. Antiseptic 
treatment is shown in figure 3.9 A to be more effective against biofilms formed in 
nutrient limited conditions on plasma. The efficacy of Duralock-CTM against biofilm 
in RPMI-1640 increases by approximately 25% when compared to biofilms grown 
in BHI. A similar trend can be seen with EDTA (32 mg/ml) treatments with them 
being 45% more effective over a 24 h period. This was found to be a significant 
difference between the two assays. Antibiotic treatment was also shown to be 
more effective against biofilm formed in RPMI-1640, with several antibiotics 
resulting in a more that 70% difference in biofilm viability between the two assays 
(figure 3.9 B). Daptomycin (50 mg/ml), vancomycin (50 mg/ml), tigecycline (10 
mg/ml) and rifampicin (10 mg/ml) all proved significantly more effective against 
biofilm formed in the minimal media on plasma coated surfaces, with a minimal 
reduction of 80% in bacterial viability when compared to the untreated control. It 
can be seen from figure 3.9 that gentamicin has significantly increased activity 
against biofilms of over 40% in the RPMI-1640 assay when compared to the 
nutrient enriched assay.   
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A B
Figure 3.9 Susceptibility of S. aureus SH1000 biofilm to antibiotics and antiseptics using two 
biofilm models. SH1000 biofilm was grown in either BHI supplemented with NaCl (4% w/v) or 
RPMI-1640 (indicated) and treated with antiseptics (A) or antibiotics (B) at 37
o
C for 24h. Viability of 
biofilms was measured using the resazurin conversion assay. Percentage viability was calculated, 
untreated control was considered 100% viable. Assays were performed in triplicate and data 
represents mean % viability ± SD. Statistically significant results are indicated (two tailed student t-
tests, P ≤ 0.05 *). 
3.3.11 Effect of antiseptics and antibiotics on static biofilm in minimal media 
To investigate if S. aureus biofilm maturity had an impact on the efficacy of 
treatment agents, biofilms were developed for one, three and five days as 
described in sections 2.5.2 in RPMI-1640 on plasma coated surfaces. Due to its 
limited biofilm growth in this assay, the S. epidermidis strain RP62A, was not 
included in this testing. Results are shown in figure 3.10. 
The antiseptics, ethanol and TaurolockTM were the most effective agents, at 
eradicating biofilm produced by strains, at each of the three time points 
investigated. The effect of EDTA and Duralock-CTM however, was limited to 
biofilms formed over 24 h, where both treatment agents resulted in a significant 
(P≤0.05) reduction in viability. EDTA was shown to reduce biofilm viability by 64%, 
whilst Duralock-CTM reduced viability by 46%. A significant reduction in biofilm 
viability on more mature biofilms formed over three and five days was not seen for 
Duralock-CTM and EDTA treatment (figure 3.10).  
* 
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Figure 3.10: Susceptibility of mature S. aureus biofilm to antiseptics. MRSA and MSSA biofilm 
(indicated) were grown in RPMI-1640 for 1, 3 or 5 days and treated with antiseptics at 37°C for 24 
h. Viability of biofilms was measured using the Resazurin conversion assay. Assays were 
performed in triplicate and data represents mean fluorescent intensity unit ± SD. Statistically 
significant results are indicated (two tailed student t-tests, P ≤ 0.05 *). 
Day One 
Day Three 
Day Five 
121 
 
Biofilms were formed as described above and treated with antibiotics at 
concentrations outlined in table 3.4. Results are presented in figure 3.11. 
Daptomycin, vancomycin, tigecycline and rifampicin all resulted in an almost 
complete eradication of biofilm formed over 24 hours. Gentamicin resulted in a 
significant reduction in bacterial viability against SH1000 and BH48; fosfomycin 
also resulted in a significant reduction (P≤0.05) in BH48 biofilm (figure 3.11, day 
one). Testing was then expanded to determine the effect of antibiotics on three and 
five day biofilm. Daptomycin, tigecycline and rifampicin all remained very effective 
in treating mature biofilms. Daptomycin resulted in an 89-91% reduction in viability 
of biofilms, formed over one, three and five days. Rifampicin yielded a 90-94% 
reduction, while tigecycline reduced biofilm viability by 74-90%. The efficacy of 
gentamicin, vancomycin and fosfomycin was greatly reduced, with no significant 
reduction in viability observed against three or five day biofilm (figure 3.11, day 
three, day five). Results suggest that biofilm resistance or tolerance to some 
antibiotics developed in the more mature biofilm.   
3.3.12 Development of biofilm using venous shear 
Bacteria in the lumen of a catheter are exposed to fluid flow and shear stress. Two 
assays of biofilm formation were developed involving a microfluidic device and 
venous shear of 6.25 dynes/cm. The first was a nutrient enriched media assay and 
the second involved forming biofilm in nutrient limited conditions on plasma coated 
surfaces; similar to the static assays previously described (section 3.3.3, 3.3.9). 
Biofilm formation with MSSA, MRSA and S. epidermidis strains under conditions of 
flow were examined using both assays. Biofilm was formed over 24 hours, with the 
exception of SH1000 in nutrient enriched conditions, for which biofilm formed in 
seven hours due to rapid growth of biofilm produced. An inverted light microscope 
was used to monitor biofilm formation.  
 
122 
 
U
nt
re
at
ed
Li
ne
zo
lid
G
en
ta
m
ic
in
D
ap
to
m
yc
in
V
an
co
m
yc
in
Ti
ge
cy
cl
in
e
Fo
sf
om
yc
in
R
ifa
m
pi
ci
n
B
la
nk
0
5000
10000
15000
20000
****
******** ****
*
SH1000
BH48
BH1CC
Je2
F
lu
o
re
s
e
n
t 
in
te
n
s
it
y
 u
n
it
s
 
U
nt
re
at
ed
Li
ne
zo
lid
G
en
ta
m
ic
in
D
ap
to
m
yc
in
V
an
co
m
yc
in
Ti
ge
cy
cl
in
e
Fo
sf
om
yc
in
R
ifa
m
pi
ci
n
B
la
nk
0
5000
10000
15000
20000
****
****
****
SH1000
BH48
BH1CC
Je2
F
lu
o
re
s
e
n
t 
in
te
n
s
it
y
 u
n
it
s
 
U
nt
re
at
ed
Li
ne
zo
lid
G
en
ta
m
ic
in
D
ap
to
m
yc
in
V
an
co
m
yc
in
Ti
ge
cy
cl
in
e
Fo
sf
om
yc
in
R
ifa
m
pi
ci
n
B
la
nk
0
5000
10000
15000
20000
**** ****
****
SH1000
BH48
BH1CC
Je2
F
lu
o
re
s
e
n
t 
in
te
n
s
it
y
 u
n
it
s
 
Figure 3.11: Susceptibility of mature S. aureus biofilm to antibiotics. MRSA and MSSA biofilm 
were grown in RPMI-1640 for 1, 3 or 5 d and treated with antibiotics at 37°C for 24 h. Viability of 
biofilms was measured using the Resazurin conversion assay. Assays were performed in triplicate 
and data represents mean fluorescent intensity unit ± SD. Statistically significant results are 
indicated (two tailed student t-tests, P ≤ 0.05 *). 
Day One 
Day Three 
Day Five 
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In nutrient enriched conditions MSSA strains SH1000 and BH48 were observed to 
form biofilm in a non-confluent manner, the visible clumps resemble a typical 
schematic of biofilm formation (figure 3.12 A & C). When grown on plasma coated 
surfaces the formation of biofilm was uniform throughout the chamber (figure 3.12 
B & D). Cellular aggregation and accumulation were shown to be visibly reduced 
when compared to nutrient enriched growth conditions. MRSA strains BH1CC and 
Je2 formed an even layer of confluent biofilm in both assays (figure 3.12 E, F, G & 
H). S. epidermidis strain RP62A biofilm formed biofilm aggregates in nutrient 
enriched conditions (figure 3.12 I), as seen with MSSA strains. Biofilm formation by 
RP62A in nutrient limited conditions had been shown in figure 3.8 to be impaired, 
however, biofilm was observed under conditions of flow in these conditions (figure 
3.12 J).  
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Figure 3.12. Biofilm formed by staphylococcal strains under constant shear stress. Biofilm 
was developed in nutrient enriched media (A, C, E, G & I) and minimal media (B, D, F, H & J) under 
shear stress of 6.25 dynes/cm
2
. Images were captured after treatment using bright-field 10 x 
magnifications. Three individual points on each chamber were analysed, representative images are 
shown. 
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3.3.13 Treatment of biofilm formed under venous shear 
After confirming the ability of each of our strains to form biofilm under conditions of 
venous shear (6.25 dynes/cm2) in both assays, testing was carried out to assess 
the effect of treatment agents on biofilm formed in this manner. Biofilms grown 
under conditions of shear have previously been shown to be more tolerant to 
treatment than static biofilms (435).  
Data presented in figure 3.13 show the results for S. aureus SH1000, BH48, 
BH1CC, Je2 and S. epidermidis RP62A biofilm formed in nutrient enriched 
conditions under condition of flow and treated statically with antiseptics. Upon 
visual inspection, treatment with ethanol results in the most significant decrease in 
the number of live cells when compared to the media control. In contrast to static 
microtitre assays, TaurolockTM does not result in a substantial reduction in biofilm 
viability in nutrient enriched conditions. EDTA at 32 mg/ml and Duralock-CTM did 
not appear to reduce the number of live cells within the biofilm after 24 h treatment. 
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Figure 3.13. Effect of antiseptic treatment on biofilm formed under flow. Biofilm formed by S. 
aureus strains  SH1000 (A), BH48 (B), BH1CC (C), Je2 (D) and S. epidermidis RP62A (E) were 
grown for 24 h under constant shear stress (200 µl/min) in BHI with 1% Glucose or BHI with 4% 
NaCl before being treated with antiseptics for 24 h. Confocal microscopy (40x) images represent 
live/dead (green/red) staining of biofilm. Three individual points on each chamber were analysed, 
representative images are shown. 
Testing was expanded to determine the effect of antiseptics on biofilm formed in 
nutrient limited media, on plasma coated surfaces, under conditions of shear 
stress. As seen in static testing, biofilms are more susceptible to treatment than 
nutrient enriched conditions. Ethanol proved very effective in killing biofilm cells for 
all strains tested. TaurolockTM was effective against biofilm formed in these 
conditions. Duralock-CTM appeared to result in a reduction in bacterial cell viability, 
while EDTA (32 mg/ml) did not have an effect on biofilm formed in these 
conditions.  
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Figure 3.14. Effect of antiseptic treatment on biofilm formed under flow. Biofilm formed by S. 
aureus strains  SH1000  (A), BH48 (B), BH1CC (C), Je2 (D) and S. epidermidis RP62A (E) were 
grown for 24 h under constant shear stress (200 µl/min) in RPMI media before being treated with 
antiseptics for 24 h. Confocal microscopy (40x) images represent live/dead (green/red) staining of 
biofilm. Three individual points on each chamber were analysed, representative images are shown. 
The effect of antibiotic treatment for 24 hours on biofilm formed in nutrient enriched 
conditions, under shear, is illustrated in figure 3.15. Concentrations used were 
described in table 3.4. As was seen with their effect on static biofilms antibiotics 
tested failed to have an effect on biofilm formed under flow in BHI media. Upon 
visual inspection daptomycin appeared to have a minimal effect on cell viability 
within the biofilm. Remaining antibiotics did not result in a visible reduction in 
biofilm cell viability.  
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Figure 3.15. Effect of antibiotics treatment on biofilm formed under flow. Biofilm formed by S. 
aureus strains  SH1000  (A), BH48 (B), BH1CC (C), Je2 (D) and S. epidermidis RP62A (E) were 
grown for 24 h under constant shear stress (200 µl/min) in BHI with 1% Glucose or BHI with 4% 
NaCl before being treated with antibiotics for 24 h. Confocal microscopy (40x) images represent 
live/dead (green/red) staining of biofilm. Three individual points on each chamber were analysed, 
representative images are shown. 
As seen in the microtitre biofilm results, daptomycin (50 mg/ml) and rifampicin (10 
mg/ml) were very effective against established biofilm in nutrient limited conditions. 
Vancomycin (40 mg/ml) and tigecycline (10 mg/ml) resulted in a decrease in 
biofilm cell viability. Remaining antibiotics gentamicin (50mg/ml), linezolid (4 
mg/ml) and fosfomycin (50 mg/ml) did not effect viability of biofilm formed in this 
assay.  
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 Figure 3.16. Effect of antibiotics treatment on biofilm formed under flow. Biofilm formed by S. 
aureus strains  SH1000  (A), BH48 (B), BH1CC (C), Je2 (D) and S. epidermidis RP62A (E) were 
grown for 24 h under constant shear stress (200 µl/min) in RPMI-1640 media before being treated 
with antibiotics for 24 h. Confocal microscopy (40x) images represent live/dead (green/red) staining 
of biofilm. Three individual points on each chamber were analysed, representative images are 
shown. 
Z-stacking analysis was carried out on biofilms treated with antiseptic and antibiotic 
agents; differences were not observed in the treatment efficacy throughout layers 
of attached biofilm. Quantitative evaluation of the effect of antiseptics and 
antibiotics on biofilm formed under shear stress was carried out. Fluorescent 
images were analysed to determine the signal intensity of both live and dead 
bacteria, this was used to quantify the percentage of viably cells for each treatment 
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group. Data presented in figure 3.17 show results for quantitative analysis of S. 
aureus SH1000 biofilm in nutrient enriched and nutrient limited conditions after 
exposure to antiseptics and antibiotics.  
A B
C D
 
Figure 3.17 Quantative evaluation of confocal microscopy. Images from confocal microscopy of 
biofilm treated with antiseptics in nutrient enriched (A) and limited conditions (B) or biofilm treated 
with antibiotics in nutrient enriched (C) or limited conditions (D) were analysed using image J 
software. Fluorescent intensity values were used to determine percentage live/ dead biofilm. Three 
images were analysed for each treatment group, data represents mean percentage ± SD. 
Significant decrease in live cells compared to media control is shown (two tailed student-T test 
P≥0.5). 
Untreated controls had a biofilm viability level of approximately 70% in all growth 
conditions. Ethanol (30% v/v) was the most effective antiseptic tested; 80% and 
96% of biofilm cells were killed after 24 h exposure in nutrient enriched and limited 
conditions respectively (figure 3.17 A & B). TaurolockTM resulted in 60% of biofilm 
* 
* 
* 
* * 
* * 
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cells formed in nutrient limited conditions being eradicated (figure 3.17 B). It was 
not shown to be effective on biofilm formed in nutrient enriched media (figure 3.17 
A). Duralock-C and EDTA (32 mg/ml) did not result in a reduction in biofilm viability 
when compared to the untreated control (figure 3.17 A & B). Similar results were 
obtained for the other strains examined in this study, results are presented in figure 
3.18 and 3.19.  
The antibiotics tested in these experiments did not result in a reduction of biofilm 
viability in nutrient enriched conditions (figure 3.17 C). Visual analysis of images 
had indicated increased activity of some antibiotics in nutrient limited conditions on 
plasma coated surfaces; this was confirmed in figure 3.17 D. Daptomycin and 
rifampicin were shown to kill 94-98% of biofilm cells, vancomycin and tigecycline 
were also observed to eradicate 71-77% of biofilm after 24 hours exposure.  
Linezolid, gentamicin and fosfomycin were not observed to be effective at reducing 
bacterial viability in this testing. Remaining strains were also examined to assess 
the percentage viability of cells post treatment, similar results were seen and are 
presented in figure 3.18 and 3.19. 
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Figure 3.18: Quantative evaluation of confocal microscopy. Images from confocal microscopy 
of biofilm treated with antiseptics (A, C & E) and antibiotics (B, D & F) in nutrient enriched 
conditions were analysed using image J software. Fluorescent intensity values were used to 
determine percentage live/ dead biofilm. Three images were analysed for each treatment group, 
data represents mean percentage ± SD. Significant decrease in live cells compared to media 
control is shown (two tailed student-T test P≥0.5). 
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Figure 3.19: Quantative evaluation of confocal microscopy. Images from confocal microscopy 
of biofilm treated with antiseptics (A, C & E) and antibiotics (B, D & F) in nutrient limited conditions 
were analysed using image J software. Fluorescent intensity values were used to determine 
percentage live/ dead biofilm. Three images were analysed for each treatment group, data 
represents mean percentage ± SD. Significant decrease in live cells compared to media control is 
shown (two tailed student-T test P≥0.5). 
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3.4 Discussion 
Significant progress has been made in recent years in enhancing our 
understanding of the complexity of staphylococcal biofilm formation and associated 
treatment strategies (436). The use of CLSs, in addition to systemic treatment with 
an appropriate antibiotic, has been suggested as one such treatment strategy 
(356). However, an effective CLS appropriate for use in the treatment of CRI 
caused by staphylococci has not been determined. This may be due to the lack of 
experimental evidence to support their use, which has resulted in widely varied 
clinical practice. This chapter aimed to assess the in vitro antimicrobial effects of 
currently available antibiotics and antiseptics upon S. epidermidis and S. aureus to 
determine optimal therapeutic options for clinical use within a CLS. 
The committee on antimicrobial testing, EUCAST, created a European wide, 
harmonised set of breakpoints for antimicrobials. Examination of our antibiotics 
and antiseptics began with analysing their effect on planktonic bacteria. The five 
lead strains used in our study were determined to be susceptible to all of the 
antibiotics included, as MIC values were below the EUCAST break points. It should 
be noted that there are currently no breakpoints for antiseptics used in this study. 
Variation between species to sodium citrate was evident, S. epidermidis strain 
RP62A was shown to be more susceptible than the S. aureus strains investigated. 
No variation between strains or species in susceptibility to other antiseptics was 
evident. MRSA strains Je2 and BH1CC as well as MSSA laboratory strain SH1000 
were more resistant to treatment with antibiotics under investigation in planktonic 
testing. This is in keeping with previous studies that have indicated MRSA strains 
to be more resistant to antibiotic treatment (437).  
Conventional MIC results are often used to guide treatment of infections. Our 
evaluation of antiseptics and antibiotics has shown that these MIC results are 
much lower than concentrations required to effect sessile cells. This is consistent 
with previous studies showing large variance in the MIC and biofilm susceptibility 
levels. The difference is likely to be due to altered antibiotic penetration and altered 
metabolic activity of bacterial cells within a biofilm (63).  
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Initial biofilm testing was carried out on five lead strains in nutrient enriched media 
to determine an optimum concentration for use in future testing. The antiseptic 
agent ethanol was found to be effective at concentrations of 30% (v/v) and higher, 
against each of the five strains tested. In agreement with our results, 30% ethanol 
was previously suggested for use as a CLS, by Sherertz et al., (2006) (438). 
However, this group did not examine the effect of ethanol on sessile bacteria. 
Ethanol has previously been reported to be effective at concentrations of 70% (v/v) 
in a clinical setting (439). Our results suggest this high concentration may not be 
required to eradicate staphylococcal biofilm. Previous reports have highlighted the 
potential for sodium citrate solutions to be used as CLSs (378). Both Duralock-CTM 
and TaurolockTM had previously been shown to be effective against biofilm (431, 
440). Our results, generated from biofilm testing in nutrient enriched media, 
showed a >50% reduction in biofilm viability after treatment with TaurolockTM. 
However, Duralock-CTM only showed a significant reduction in bacterial viability for 
one strain, BH1CC. The use of EDTA has previously been suggested as a 
potential CLS (377, 432). Concentrations of up to 32 mg/ml have previously been 
used in a clinical setting (432). EDTA was not found to be effective in our biofilm 
testing at this concentration. A range of exposure times were examined to 
determine the optimum treatment time of the antiseptics to pre-established 
staphylococcal biofilm. This testing revealed that a treatment time of 24 h was 
required for the antiseptics to exert maximum effect. Various treatment times have 
reportedly been used in a clinical setting including 24 h treatment. Current 
guidelines in the US state that dwell times of CLS should not exceed 48 h and 
ideally should be reinstalled every 12-24 h (349, 441). 
Of the antibiotics tested most, with the exception of tigecycline, were not effective 
against biofilm formed by staphylococci in nutrient enriched media conditions. 
Tigecycline treatment did result in a significant reduction in biofilm viability at 
concentrations above 0.625 mg/ml for two strains. The clinical isolates BH1CC and 
BH48 (04) were shown to be most susceptible to treatment while other strains 
remained relatively unaffected by treatment with tigecycline. This antibiotic has 
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been shown previously to be effective against S. aureus and CoNS, such as S. 
epidermidis (364, 442).   
Efforts to investigate effective therapeutics for biofilm-associated infections have 
been underpinned by studies investigating the mechanisms of staphylococcal 
biofilm formation on polystyrene surfaces in nutrient rich bacteriological growth 
media using mainly reference strains of staphylococci (237, 428, 429). However, 
the rapid coating of implanted materials by plasma and extracellular matrix 
proteins, including fibronectin, fibrinogen and collagen, raise questions on the in 
vivo relevance of mechanisms of biofilm expressed under these in vitro conditions. 
To address this concern, in this chapter we used our recently described in vitro 
method that more closely mimics the in vivo formation of S. aureus biofilm during 
colonisation of an artificial surface inserted intravenously and investigated the 
effects of our chosen antibiotics and antiseptic agents (443). This assay involves 
growing biofilms in nutrient limited conditions on plasma coated surfaces. S. 
aureus reference and clinical strains formed high levels of biofilm in this assay. S. 
epidermidis strain RP62A formed low levels of biofilm when compared to levels in 
nutrient enriched conditions; growth was observed to be impaired in RPMI-1640. 
This is a limitation of the assay and suggests S. epidermidis may require additional 
nutrients to S. aureus to form biofilm. The reason for this difference in growth is not 
known, however previous studies have also noted differences in growth rates of S. 
aureus and S. epidermidis in different growth conditions (444).  
Many previous studies have examined the effect of antibiotics as a CLS against 
infections caused by staphylococcal biofilm. These studies often use in vitro 
conditions and bacteriological media not mimicking the in vivo environment. 
Unsurprisingly, this has resulted in widely varied results between in vitro and in 
vivo efficacy. The effectiveness of antibiotics such as vancomycin, daptomycin and 
rifampicin have been shown in some studies (359, 428, 442, 445); whilst others 
have demonstrated the opposite effect (446, 447). Variable results in the 
effectiveness of linezolid, gentamicin, and oxacillin have also been shown (447). 
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A comparison of biofilm response to treatment in nutrient enriched and nutrient 
limited conditions was shown for S. aureus SH1000. Large differences in biofilm 
susceptibility were evident between assays. Some antiseptics and antibiotics were 
shown to be significantly more effective in the RPMI-1640 and plasma coating 
assay. Ethanol and TaurolockTM were very effective in eradicating biofilm viability in 
both models. Both agents have constantly been shown in our testing to be effective 
against staphylococcal biofilm formed statically. Duralock-CTM and EDTA (32 
mg/ml) both resulted in increased efficacy in the nutrient limited assay.  Antibiotics 
had proved relatively ineffective in nutrient enriched media conditions against 
SH1000 biofilm. When examined in a nutrient limited assay daptomycin, 
vancomycin, tigecycline and rifampicin were shown to result in a more than 80% 
reduction in biofilm viability. Gentamicin also proved significantly more effective in 
the minimal media assay, showing an approximate 50% reduction in viability. 
Biofilms formed under these nutrient limited conditions have previously been 
shown to be more susceptible to treatment (126). 
After this initial comparison, testing was expanded using this newly described 
assay to examine the effect of test agents on biofilm formed by other strains. In the 
clinical environment, biofilms will develop on an IVC over a number of days. To 
mimic this testing the effect of antiseptics and antibiotics was examined on biofilm 
formed over one, three and five days. Previous studies have observed an 
increased resistance of bacterial biofilm to treatment when formed over a number 
of days (443, 448, 449). Ethanol and TaurolockTM were shown to be effective on 
biofilm formed over one day by all strains tested. Both agents remained effective 
against biofilm formed over three and five days.  The previously discussed 
increase in activity of EDTA and Duralock-CTM against biofilm was shown for all 
strains tested. However, this was only evident against biofilms grown over 24 
hours. When used to treat biofilms formed over three and five days a significant 
reduction in biofilm viability was not observed using either agent.  
The antibiotics daptomycin and rifampicin were found to remain effective against 
mature biofilm, with a reduction in biofilm viability of up to 95% seen. This 
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sustained efficacy of daptomycin may be in part due to the structure of the drug. 
The C10 fatty acid which forms part of daptomycin may aid in the penetration of 
this antibiotic into mature biofilms (450). Tigecycline (10 mg/ml) resulted in a 
significant reduction in the viability of early and mature biofilms produced by all 
strains. Vancomycin, although very effective against one day old biofilm was 
shown to be ineffective against three and five day biofilm. The molecular mass of 
vancomycin is greater than rifampicin and tigecycline, with a molecular mass of 
1449.3 g/mol (451). This may affect the antibiotics ability to penetrate biofilm and 
may contribute to its poor effect against denser, more mature biofilm. This is 
clinically relevant data as in an in vivo, real life setting, biofilm form over a number 
of days before symptoms of infection become evident. Therefore, when treatment 
is commenced the biofilm may have been developing for a number of days. 
Biofilms formed in minimal nutrient conditions on plasma coated surfaces have 
been shown to have a lower cell density, with 1-2 log differences in the CFUs 
harvested when compared to nutrient enriched media conditions such as BHI 
(126). This may be a contributing factor to the differences in susceptibility levels 
between the two models. Importantly, it has also been shown that bacterial 
numbers increase as the biofilm matures, with CFU levels after five days in RPMI-
1640 similar to that of biofilm formed over one day in enriched laboratory media 
(443). Results discussed here highlight the importance of developing an 
appropriate in vitro assay to determine the potential of therapeutic treatments. 
Under conditions of flow ethanol, followed by TaurolockTM were the most effective 
agents in eradicating this type of in vitro biofilm. This is in contrast to previous 
publications where the use of Duralock-CTM and EDTA has been recommended to 
use in the treatment of biofilm-related device infections (25-27).  
Of the antibiotics tested daptomycin, rifampicin and tigecycline were shown to be 
the most effective. This is in keeping with earlier findings. Daptomycin resulted in 
the most dramatic reduction in viability, with only 2% viability being observed post 
treatment. Rifampicin and tigecycline were shown to result in an approximate 
reduction in biofilm viability of 90%. Previous studies have indicated that biofilms 
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formed under conditions of shear are more resistant to treatment (435); this was 
also evident in our testing. 
S. aureus strains have been shown, for the most part, to belong to one of ten 
genetic lineages (452). Methicillin resistance has been detected in six of these 
(CC1, CC5, CC8, CC22, CC30 & CC45) (401). S. aureus strains from different 
lineages have been shown to exchange genetic material at a lower rate than those 
from within the same clonal complex (CC) (453). It was important to ensure that 
our initial results were not confined to the five lead strains included. To determine if 
S. aureus strains from different genetic backgrounds were equally susceptible to 
treatment, testing was expanded to include a wide range of CCs commonly 
isolated from patients in Irish hospitals. The most prevalent CCs isolated in Irish 
hospitals are CC 22 and CC 8. Between 2003 and 2011 over 80% of all MRSA 
BSIs were caused by MRSA CC22 (454). The strains included in our testing 
included CC groups 5, 8, 12, 15, 22, 30, 45 and 398. We did not observe a 
significant difference in activity of treatment agents to different CC groups.  
Combination treatments involving antibiotics are often used in the clinical setting. 
Use of agents in combination has been shown to improve efficacy as some 
combinations have synergistic properties. There is also a reduced risk of the 
emergence of resistance associated with combination therapy (455). We examined 
a total of 58 combinations in our testing; we did not observe a synergistic effect 
with any of those tested (synergism was defined using a checkerboard method). 
Despite combination data not resulting in a synergistic or additive effect, a benefit 
was observed in the cases of five combinations. This benefit was evident when 
combination therapy was compared to monotherapy for two strains, S. epidermidis 
strain RP62A and MRSA strain BH1CC. The increased activity of combinations 
was not found to be significant when compared to monotherapy. Previous studies 
have demonstrated increased antimicrobial effects when antibiotics are combined 
with either gentamicin or rifampicin in the treatment of staphylococcal infections 
(456-459).  
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Although this chapter represents findings from an in vitro study we have replicated 
in vivo like conditions by using iron-deficient media and human blood plasma 
coating. If staphylococci gain access to the catheter they can adhere to a 
conditioning film, pre-coated on the device and accumulate to form biofilm. 
Bacteria growing in this environment are exposed to iron limited conditions, to 
represent this we have used iron depleted media RPMI-1640. We believe the 
growth conditions used in our assay in combination with the conditioning film do 
represent the in vivo environment better than previously discussed nutrient 
enriched conditions on polystyrene surfaces. Differences in biofilm susceptibility to 
treatment between assays as shown in this chapter highlight the importance of 
using the correct method when assessing therapeutic agents versus 
staphylococcal biofilm. Further work is needed to develop an in vitro model of 
infection that supports growth of S. epidermidis to the same levels as S. aureus in 
conditions that mimic the in vivo situation. 
Although the current best treatment for patients with CRI caused by staphylococci 
involves the removal of the IVC, this is not always possible. Often, an underlying 
diagnosis or a lack of alternative vascular access prevents removal. Therefore, an 
alternative treatment such as combination of CLS and systemic treatment may be 
required. Whilst many antimicrobial agents kill bacteria in a planktonic state only a 
limited number of agents are effective in treating staphylococcal biofilm.  Our 
findings from novel in vivo relevant assays of infection have identified the 
antiseptics and antibiotics in regular clinical practice that have the potential to allow 
rapid clearance of staphylococci from an infected IVC. These evaluations of 
antiseptics and antibiotics have shown the two most effective antiseptics to be 
ethanol at concentrations of 30% as well as the commercially available CLS 
TaurolockTM.  The antibiotics daptomycin, rifampicin and tigecycline were shown to 
be the most effective antibiotics examined. These agents have to potential to be 
used in the salvage of IVCs with a confirmed MSSA, MRSA or S. epidermidis 
infection. 
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Chapter 4: Evaluation ML:8 and Citrox for the 
use as a catheter lock solution in the 
treatment of staphylococcal biofilm IVC-
related infections 
 
 
 
 
 
 
 
 
 
 
 
143 
 
4.1 Introduction 
The effective treatment of staphylococcal CRIs is a significant challenge clinically 
and this is mainly due to the ability of staphylococci to form biofilm (177). The 
surfaces of IVCs can rapidly become coated with host matrix proteins, such as 
fibronectin, fibrinogen and collagen (25). Staphylococci contain numerous surface 
proteins that can bind to these host matrix proteins, as described in chapter one 
(460). Current treatment for staphylococcal IVC infection involves device removal; 
however this is not always possible. Numerous research groups have 
demonstrated the ineffectiveness of antibiotics against bacteria within a biofilm 
compared to their effectiveness versus the planktonic counterparts. Hence, 
antibiotics have limited success in achieving device sterility and the resolution of 
biofilm and infection (299, 300). In the previous chapter, we demonstrated the 
ineffectiveness of several commonly used antibiotics against staphylococcal 
biofilm, leaving only a small number of options for the treatment IVC infections 
involving staphylococci, as well as other staphylococcal biofilm-related infections. 
There are concerns over the use of antibiotics routinely as CLSs as there is the 
potential for this to lead to the selection of resistant organisms. To date, this has 
limited their application in the treatment of CRIs.  However, some studies have 
shown the benefit of CLSs in the treatment of IVC infections (446). The IDSA 
guidelines on the management of CRIs recommend the use of CLSs for the 
salvage of an IVC associated with CRI (349). There is as of yet no consensus on 
an appropriate agent for use as a CLS in the treatment of staphylococcal CRIs. As 
current options are limited, the need for novel therapeutic agents for use as a 
CLSs, or as an anti-staphylococcal biofilm treatment option, is of great clinical 
importance (436). In this chapter, we have performed a series of investigations to 
determine the therapeutic potential of two novel treatment agents, ML:8 and Citrox. 
This includes a range of in vitro testing to determine antimicrobial efficacy, 
cytotoxicity and cytocompatibility as well as in vivo testing in a rat IVC model of 
infection.   
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ML:8 is a solution comprising of components previously approved for parenteral 
nutrition; caprylic acid being one of the main components. Caprylic acid is a 
medium chain fatty acid. The antimicrobial properties of ML:8 have long been 
known, with numerous studies demonstrating an efficacy against a range of Gram-
positive and Gram-negative bacteria (383-385, 461). Recent research has also 
noted its efficacy against biofilm (386).  The effect of ML:8 on periodontal 
pathogens has also recently been reported (380). The effect on staphylococcal 
biofilm has also been investigated (382). 
Citrox is an antimicrobial comprising of flavonoids. Flavonoids are secondary 
metabolites, found in a variety of plants. They are polyphenolic molecules, with a 
15 carbon structure. They are reported to be important for pigment production, UV 
filtration and nitrogen fixation (462). The antimicrobial activities of flavonoids have 
previously been shown against a wide variety of bacterial species (391). To date 
studies examining their effect on cells within a biofilm have been limited (395). The 
exact formulation of Citrox is unknown, however patent applications have revealed 
the flavonoids included to be neoeriocitrin, isonaringin, naringin, hesperidin, 
neohesperidin, neodiosmin, naringenin, poncirin and rhiofolin (388). Citrox is 
primarily used for agricultural purposes, however, an antimicrobial effect on human 
pathogens associated with oral infections has been demonstrated (389). It has also 
been shown to eradicate S. aureus on a range of surfaces commonly colonised in 
a hospital setting (390). The reported antimicrobial properties of both ML:8 and 
Citrox have lead to their inclusion in this study. 
CRIs involve complex interactions between the host, the microbe and the 
implanted biomaterial that are impossible to fully replicate in vitro. A number of 
models to examine CRIs have been developed (463, 464). One such model is the 
rat IVC infection model used in this study (360). The use of animal models of CRI 
is invaluable in the evaluation of novel therapeutics against staphylococcal biofilm. 
This model mimics conditions such as blood flow, serum proteins as well as innate 
and humoral immunity. In this model, a polyurethane catheter is inserted via the 
right jugular vein with the tip sitting just outside the right atrium. The catheter is 
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tunnelled to the scapular region and secured in place with a single wound clip. 
After placement a quarantine period is undertaken to ensure infection caused by 
contamination of the device during surgery has not developed. The IVC can then 
be injected with a known number of bacteria and treatment agents analysed. 
Catheters are salvageable at the end point of the study, making it an ideal model of 
infection for the analysis of CLSs. This was used as the basis for in vivo studies 
described in this chapter. 
4.2 Aims  
 To determine the effect of ML:8 and Citrox on staphylococcal planktonic 
cells.  
 To examine the effectiveness of ML:8 and Citrox on staphylococcal biofilm 
produced by a range of clinical isolates and reference strains of varying 
genetic backgrounds.  
 To optimise/develop an in vitro biofilm model of CRI that mimics in vivo 
growth conditions and use it to assess the efficacy of ML:8 and Citrox. 
 To investigate the suitability of ML:8 and Citrox for in vivo use within a CLS 
by examining their cytotoxicity, potential to cause haemolysis and potential 
to induce an innate immune response in vitro.  
 To investigate the efficacy of ML:8 and Citrox in the treatment of an in vivo 
IVC-infection involving S. aureus biofilm.  
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4.3 Results 
4.3.1 Determining the minimum inhibitory concentration of ML:8 and Citrox  
A microbroth dilution assay was used to determine the MIC of ML:8 and Citrox as 
described in section 2.3. Bacteria prepared to a 0.5 McFarland standard were 
exposed to serially diluted test agents. Results were read after 24 h exposure at 
37°C and are presented in table 4.1. The MIC of ML:8 was determined to be 
0.125% (v/v) for all strains. For Citrox, the MIC is 0.015% (v/v) for all strains. 
Table 4.1 Minimum inhibitory concentrations of ML:8 and Citrox 
 MSSA MRSA S. epidermidis 
 SH1000 BH48 BH1CC USA300 Je2 RP62A 
ML:8 0.125% (v/v) 0.125% (v/v) 0.125% (v/v) 0.125% (v/v) 0.125% (v/v) 
Citrox 0.015% (v/v) 0.015% (v/v) 0.015% (v/v) 0.015% (v/v) 0.015% (v/v) 
4.3.2 The measurement of antimicrobial activity of ML:8 and Citrox against 
planktonic cells 
Suspension testing was carried out to determine the concentration of test agent 
required to kill a planktonic bacterial suspension. This testing was carried out as 
described in section 2.4. The optimum treatment time and concentration of ML:8 
and Citrox required to kill was determined and the results are presented in table 
4.2. Both ML:8 and Citrox can eradicate planktonic bacterial suspensions of 
MSSA, MRSA and S. epidermidis strains within 1 min at concentrations of 0.5% 
(v/v) and 1% (v/v). S. epidermidis was shown to be more susceptible than S. 
aureus strains when treated with ML:8 at a concentration of 1% (v/v) with cells 
being eradicated after 30 s exposure. At a concentration of 0.25% (v/v) both 
agents proved effective within 3 min against all strains tested. S. aureus strain 
SH1000 and S. epidermidis strain RP62A were shown to be eradicated in a shorter 
time than other S. aureus strains BH48, BH1CC and USA300 Je2 after treatment 
with ML:8 and Citrox at concentrations of 0.25% (v/v).  
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Table 4.2 Optimum time to achieve total kill of planktonic bacteria 
Agent Concentration 
(v/v) 
SH1000 BH48 BH1CC USA300 Je2 RP62A 
ML:8 1% 
0.5% 
0.25% 
1 min 
1 min 
2 min 
1 min 
1 min 
3 min 
1 min 
1 min 
3 min 
1 min 
1 min 
3 min 
30 s 
1 min 
2 min 
Citrox 1% 
0.5% 
0.25% 
1 min 
1 min 
2 min 
1 min 
1 min 
3 min 
1 min 
1 min 
3 min 
1 min 
1 min 
3 min 
1 min 
1 min 
1 min 
4.3.3 The effect of ML:8 and Citrox on static biofilm formed in nutrient 
enriched media 
The activity of ML:8 and Citrox on bacterial cells within a biofilm was also 
examined. Biofilms were formed in nutrient enriched media and treated with ML:8 
or Citrox, as described in section 2.5.1. An alamar blue conversion assay (section 
2.6) was used to determine bacterial cell viability for which high fluorescent 
readings indicated viable bacteria. 
ML:8 at concentrations of 0.25% (v/v), and above, are shown in figure 4.1 (A) to be 
significantly (P≤0.05)  effective at completely eradicating biofilm viability. Lower 
concentrations of 0.13% (v/v) did not fully eradicate biofilm viability but did result in 
a significant (P≤0.05) reduction in biofilm viability against all strains tested. Citrox is 
shown in figure 4.1 (B) to be effective in complete eradication of biofilm viability at 
concentrations of 0.25% (v/v) and above. A significant reduction (P≤0.05) in biofilm 
viability can be seen following treatment with Citrox at concentrations of 0.13% 
(v/v) and 0.06% (v/v). Both ML:8 and Citrox proved effective against biofilms 
produced by all of the five strains examined, with Citrox being more effective than 
ML:8 at lower concentrations of  0.06% (v/v).  
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Figure 4.1 The effect of ML:8 and Citrox on biofilm viability following treatment for 24 h.  
SH1000, RP62A and BH48 biofilms were grown in BHI supplemented with NaCl. BH1CC and 
USA300 Je2 biofilms were grown in BHI supplemented with Glucose. Biofilms were grown in 96 
well plates at 37°C for 24 h.  Test wells were either left untreated or treated with ML:8 (A) or Citrox 
(B) for a further 24 h. Assays were performed in triplicate and data represents mean fluorescent 
units ± SD. Statistically significant results are indicated (two tailed student t-tests vs untreated, 
P≥0.05 *) 
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These data indicate that concentrations of 0.25, 0.5 and 1 % (v/v) of ML:8 and 
Citrox are effective against staphylococcal biofilms. To expand on this, 
staphylococcal biofilms were exposed to either ML:8 or Citrox at concentrations 
previously identified to be effective for 4 h, 8 h, 16 h and 20 h. This testing was 
carried out to determine an optimum treatment time for future testing.  
Biofilm viability of MRSA strains BH1CC and USA300 Je2 are shown to be 
significantly (P≤0.05) affected after treatment for four and eight hours with 1% (v/v) 
Citrox. No other strains were shown to be affected by treatment in this time (figure 
4.2 A & B). Treatment for 16 h with 1 % (v/v) Citrox resulted in a significant 
reduction (P≤0.05) in biofilm viability for all five strains tested. Treatment with ML:8 
at a concentration of 1% (v/v) resulted in a significant reduction (P≤0.05)  in 
viability for biofilms produced by both MRSA strains and S. epidermidis RP62A 
after 16 h treatment (figure 4.2 C). Exposure to Citrox at concentrations of 1% and 
0.5% (v/v) resulted in a significant reduction in biofilm viability in all strains tested. 
Similar results are shown for ML:8 at concentrations of 1% (v/v) (figure 4.2 D). 
ML:8 at a concentration on 0.5% (v/v) is shown to significantly (P≤0.05) affect 
biofilm viability of both MRSA strains and the S. epidermidis strain RP62A after a 
20 h treatment. Other concentrations of either treatment agent were not shown to 
be effective in this time. 
Full eradication had previously been seen after 24 h treatment with both ML:8 and 
Citrox (figure 4.1). As a result, a 24 h treatment time was determined to be the 
most favourable exposure time.  
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Figure 4.2 The effect of ML:8 and Citrox treatment over time on biofilm produced by 
staphylococci. SH1000, RP62A and BH48 biofilms were grown in BHI supplemented with NaCl. 
BH1CC and USA 300 Je2 biofilms were grown in BHI supplemented with Glucose. Biofilms were 
grown in 96 well plates at 37°C for 24 h.  Test wells were either left untreated or treated with ML:8 
or Citrox for 4 (A), 8 (B), 16 (C) or 20 h (D). Assays were performed in triplicate and data represents 
mean fluorescent units ± SD. Statistically significant results are indicated (two tailed student t-tests 
vs untreated, P≥0.05 *). 
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4.3.4 Determining the effect of ML:8 and Citrox on different clonal complexes 
of S. aureus 
To ensure our treatment times and doses were not limited to a small number of S. 
aureus strains, a larger group of biofilm-positive isolates representing varying 
genetic backgrounds were also included in the study. These strains and isolates 
represent clonal complexes commonly associated with S. aureus infection within 
Ireland, namely, CC5, CC8, CC15, CC22, CC30, CC45, CC122 and CC398. S. 
epidermidis was not included in this testing as less variation in CC type has 
previously been reported (465). Results are shown in figure 4.3. 
The biofilms produced by all CCs examined were significantly (P≤0.05) affected by 
treatment with both ML:8 and Citrox at all concentrations tested. A reduction 
greater than 90% in biofilm viability is shown for all strains treated with 1% (v/v) 
ML:8. Some variation in susceptibility is evident between CCs and the strains 
exposed to ML:8 at concentrations of 0.5 and 0.25% (v/v). ML:8 at concentrations 
of 0.5 % (v/v) is shown to reduce biofilm viability by 90% for BH4, a strain 
belonging to CC4. In contrast to this, the viability of biofilms produced by strains 
belonging to CC22 is shown to be reduced by between 77-88%. Further variation 
within CC types was evident in our testing. Viability of biofilm formed by strains 
BH40 and Dar 217 (both belonging to CC5) was reduced by 90% and 73% 
respectively, following treatment with 0.5% ML:8 (v/v) for 24 h. 
Biofilm viability is shown to be reduced by a minimum of 95% after treatment with 
1% (v/v) Citrox; this can be seen for all strains and CCs tested. The effect of Citrox 
at concentrations of 0.5 and 0.25% (v/v) on biofilm viability varied between the 
CCs; further variation within CCs was also evident.  Treatment with 0.5% Citrox 
(v/v) of the CC298 strain BH10 is shown to reduce biofilm viability by 95%, 
however, treatment of CC22 strain Dar 113 results in an 82% reduction in biofilm 
viability. Variation between strains within CC45 is shown (figure 4.3 A,D); BH18 
biofilm viability is reduced by 90% whilst the viability of Dar70 biofilms were 
reduced by 84%.  
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Figure 4.3 The effect of ML:8 and Citrox on biofilm formed by range of clonal complexes 
following 24 h treatment.   Dar strains 70, 113, 141, 217 and BH 10(03) were grown in BHI with 
glucose (1% w/v), remaining BH strains were grown in BHI with NaCl (4% w/v). Biofilms were grown 
in 96 well plates at 37°C for 24 h.  Test wells were either left untreated or treated with ML:8 or 
Citrox  for a further 24 h. Assays were performed in triplicate and data represents mean fluorescent 
units ± SD. Statistically significant results are indicated (two tailed student t-tests vs untreated, 
P≥0.05 *) 
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From this testing it is clear both agents at concentrations of 1% (v/v) are very 
effective in the treatment of S. aureus biofilm. This efficacy is not shown to be 
dependent on the genetic background of the strain. However, treatment with ML:8 
and Citrox at lower concentrations revealed variation in susceptibility of the CCs 
and strains to treatment. 
4.3.5 Examining the anti-biofilm effect of ML:8 and Citrox in combination 
The effect of ML:8 and Citrox against staphylococcal biofilms in combination with a 
range of commonly used antibiotics was examined to determine if synergistic 
effects could be seen. Biofilm was grown and treated as described in section 2.5 
and 2.6. Results did not show a benefit in combining ML8 (0.06% v/v) or Citrox 
(0.06% v/v) with any of the antibiotics tested. A synergistic or additive effect was 
not observed for any combination tested when compared to treatment with a single 
agent.    
4.3.6 Effect of ML:8 and Citrox on static biofilm in minimal media 
To determine the effect of treatment on biofilm formed in conditions closely 
representing an in vivo setting, ML:8 and Citrox were exposed to biofilms as 
described in section 2.5. This was investigated as results from chapter three had 
revealed differences in susceptibility of biofilm formed during longer incubations. 
Growth conditions used in this testing was not sufficient to support the growth of S. 
epidermidis and it was therefore not included in this testing.  
The results in figure 4.4 indicate that ML:8 and Citrox are equally as effective 
against biofilms formed over the three time points by each strain tested.  A 
significant reduction of biofilm viability, suggesting complete eradication, can be 
seen for biofilms formed over 1 d, 3 d and 5 d following a treatment for 24 h. This 
complete eradication can be seen in all S. aureus strains and isolates tested.  
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Figure 4.4 Susceptibility of mature S. aureus biofilm toML:8 and Citrox.  MRSA and MSSA 
biofilm were grown in RPMI-1640 for 1 (A), 3 (B) or 5 days (C) and treated with ML:8 (1% v/v) or 
Citrox (1% v/v)  at 37°C for a further 24h. Viability of biofilms was measured using the resazurin 
conversion assay. Assays were performed in triplicate and data represents mean fluorescent units 
± SD. Statistically significant results are indicated (two tailed student t-tests vs untreated, P≥0.05 *) 
C 
A B 
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4.3.7 Effect of ML:8 and Citrox on biofilm formed under shear stress 
To investigate the efficacy of ML:8 and Citrox on biofilm formed under shear, a 
microfluidic flow model in nutrient enriched and limited conditions, described in 
section 2.7, was used. Confocal laser scanning microscopy and live/dead staining 
was used to assess biofilm viability after treatments.  Results are illustrated in 
figure 4.5 for biofilm formed in nutrient enriched conditions and figure 4.6 for biofilm 
formed in minimal media on pre-conditioned surfaces.  
Upon visual inspection ML:8 and Citrox both at concentration of 1% (v/v) are 
shown to result in eradication of staphylococcal biofilm formed under condition of 
flow in nutrient enriched conditions (figure 4.5).  This is indicated by the 
predominantly red staining in images of treatment groups. No strain to strain 
variation was observed. Similar results for all strains and isolates were seen 
following treatment with Citrox (1% v/v).  
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Figure 4.5 Effect of treatment with ML:8 and Citrox on biofilm formed under flow. Biofilms of 
SH1000 (A), BH48 (B), BH1CC (C), Je2 (D) and RP62A (E) were grown under constant shear 
stress (200 µl/min) in BHI with 1% Glucose or BHI with 4% NaCl before being treated with novel 
agents for 24 h. Images, captured by confocal microscopy (40x), represent live/dead staining of 
biofilm treated with Citrox (1% v/v) and ML:8 (1% v/v) as well as an untreated BHI control. Three 
individual points on each chamber were analysed, representative images are shown.  
Similar results were shown for biofilm formed under shear stress in minimal media 
on pre-conditioned surfaces. Upon visual inspection treatment with ML:8 and 
Citrox, both at concentration of 1% (v/v) resulted in predominantly red cells,  
indicating cell death. This result is shown for biofilm produced by all strains tested 
and is illustrated in figure 4.6.  
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Figure 4.6 Effect of treatment with ML:8 and Citrox on biofilm formed under flow in minimal 
media. Biofilms of SH1000 (A), BH48 (B), BH1CC (C), Je2 (D) and RP62A (E) were grown under 
constant shear stress (200 µl/min) in RPMI media before being treated with ML:8 (1% v/v) or Citrox 
(1% v/v) for a further 24 h. Images, captured by confocal microscopy (40x), represent live/dead 
staining of biofilm treated with Citrox (1% v/v) and ML:8 (1% v/v) as well as an untreated RPMI-
1640 control. Three individual points on each chamber were analysed, representative images are 
shown.  
 
Z-stacking analysis was carried out on biofilms treated with ML:8 and Citrox; 
differences were not observed in the treatment efficacy throughout layers of 
attached biofilm. This reduction in biofilm viability was quantified using Image J 
software analysis as described in section 2.7.  
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Figure 4.7 Effect of treatment with ML:8 and Citrox on biofilm formed under flow. Biofilms of 
SH1000 were grown under constant shear stress (200 µl/min) in nutrient enriched media (BHI) (A) 
or nutrient limited (RPMI-1640) media on surfaces coated with 20% human plasma (B) before being 
treated with ML:8 or Citrox (1% v/v) for 24 h. Image J software was used to calculate intensity 
fluorescence for each image, from this percentage viability was calculated. Three individual points 
on each chamber were analysed, data represents % live/dead cells ±SD. Significant decrease in 
live cells compared to media control is shown (two tailed student-T test P≥0.5). 
A 
B 
* * 
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Results shown in figure 4.7 illustrate the percentage of live and dead cells post 
treatment for SH1000. Similar results were shown after treatment in either growth 
condition. ML:8 (1% v/v) results in a 97% reduction in biofilm viability after 24 h 
treatment (figure 4.7). A reduction in biofilm viability greater than 98% was 
observed after 24 h treatment with Citrox (1% v/v). Similar results were observed 
for other strains tested. Both agents have strong antimicrobial effects against 
biofilm formed under conditions of flow in both growth conditions tested. This is of 
significant clinical and in vivo relevance as within an IVC, biofilm forms under these 
conditions of shear stress. 
4.3.8 Investigation of possible adverse effects of ML:8 and Citrox on the host 
4.3.8.1 Cytotoxicity testing 
Cytotoxicity is an important consideration for any new treatment option. To assess 
the cytotoxicity in this study, cell lines were exposed to various concentrations of 
test agents for 24 hours and an MTT assay was used to assess metabolic activity 
as described in section 2.9. Antiseptic agents ethanol and Duralock-CTM are 
currently used as CLSs and were used as a comparator to ML:8 and Citrox; all 
agents were compared to a media control of cell culture media (vehicle control).  
The effect of ML:8, Citrox, ethanol and Duralock-CTM on HaCaT cells can be seen 
in figure 4.8. This effect was dose dependent with increasing cytotoxic effects 
being seen at higher concentrations of all agents examined. Concentrations of 
0.25% (v/v) and above of ML:8 were shown to be cytotoxic. At lower 
concentrations of ML:8 only mild cytotoxic effects can be seen (figure 4.8 A). Citrox 
was shown to be cytotoxic at concentrations of 0.03% (v/v) and above, lower 
concentrations showed reduced cytotoxic effects with 0.001% (v/v) showing similar 
metabolic activity to the vehicle control (figure 4.8 A). The IC50 of ML:8 was 
calculated to be 0.149% (v/v). Citrox was shown to be more cytotoxic than ML:8, 
resulting in an IC50 value of 0.011% (v/v).Ethanol was shown to be highly cytotoxic 
at all concentrations over 7.5% (v/v) (figure 4.8 B). The IC50 of ethanol was 
determined to be 1.7% (v/v). Duralock-CTM concentrations above 1.45% were 
deemed to be cytotoxic (figure 4.8 C), with an IC50 of 0.21% (v/v). 
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Figure 4.8 Cytotoxicity testing for ML:8, Citrox, ethanol and Duralock-C
TM
 on HaCaT cells. 
HaCaT cells were seeded onto 96 well plates for 24 h and treated for a further 24 h with ML:8 
(0.0009-1% v/v), Citrox (0.0009-1% v/v), ethanol (0.05-30% v/v) or Duralock-C
TM
(0.09-46.7% v/v). 
Media control was DMEM and tritonX-100 was considered a positive control. MTT assay was 
conducted to determine metabolic activity of HaCaT cells after treatment. Assays were performed in 
triplicate and data represents mean absorbance (595nm) ± SD. Significant toxicity compared to 
media control is shown (two tailed student-T test P≥0.5). 
The human monocytic THP-1 cell line was also used to examine the cytotoxicity 
levels of test agents against a cell line derived from human blood. These results 
can be seen in figure 4.9. A similar cytotoxicity pattern to that seen in HaCaT cells 
was observed. ML:8 at concentrations above 0.25% (v/v) were shown to be 
cytotoxic while THP-1 cells did not appear to be effected by concentrations of less 
than 0.03% (v/v) (figure 4.9 A). An IC50 value of 0.058% (v/v) was determined. 
Citrox was found to have an IC50 value of 0.021% (v/v) with concentrations greater 
* * * 
* 
* * * * * * 
* * 
** ** ** * * * 
* 
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than 0.06% (v/v) being highly cytotoxic (figure 4.9 A). Ethanol exposure resulted in 
almost 100% cell death at all concentrations over 7.5% (v/v) (figure 4.9 B). All 
concentrations below 1.8% (v/v) did not appear to have an effect on cell viability, 
the IC50 was found to be 2.4% (v/v). Duralock-C
TM was shown to be cytotoxic to 
THP-1 cells at concentrations of 7.5% (v/v) and higher (figure 4.9 C). An IC50 value 
of 0.48% (v/v) was found (figure 4.9 C). 
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Figure 4.9 Cytotoxicity testing of ML:8 and Citrox on THP-1 cells. THP-1 cells were incubated 
in 96 well plates for 24 h and then treated for a further 24 h with ML:8 (0.007-1% v/v), Citrox (0.007-
1% v/v), ethanol (0.9-30% v/v) or Duralock-C
TM
(0.03-46.7% v/v). Media control was RPMI-1640 and 
tritonX-100 was considered a positive control. MTT assay was conducted to determine metabolic 
activity of HaCaT cells after treatment. Assays were performed in triplicate and data represents 
mean absorbance (595nm) ± SD.  Significant toxicity compared to media control is shown (two 
tailed student-T test P≥0.5). 
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4.3.8.2 Haemolysis testing 
Haemolytic activity of our novel agents was determined using fresh human 
erythrocytes from healthy donors as described in section 2.9.3. When erythrocytes 
are exposed to an agent that causes haemolysis they lyse, this results in an 
increased absorbance reading. Both agents were found to cause haemolysis at 
high concentrations (figure 4.10). ML:8 was found to be non-haemolytic at 
concentrations lower that 0.125% (v/v). Citrox was found to be non-haemolytic at 
concentrations below 0.06% (v/v).  
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Figure 4.10 Haemolysis testing of ML:8 and Citrox using erythrocytes. Human erythrocytes 
and test agents ML:8 or Citrox (0.0015-0.25%) were incubated in 96 well plates at 37ºC for 24 h. 
Supernatant from each well was transferred to a new plate and the absorbance was read at 490nm. 
The media control consisted of erythrocytes suspended in RPMI, 1% tritonX-100 was used as a 
positive control for haemolysis. Assays were performed in triplicate and data represents mean 
absorbance (490nm) ± SD. Significant haemolysis compared to media control is shown (one tailed 
student-T test P≥0.5). 
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4.3.8.3 Immunogenic effects of ML:8 and Citrox 
To investigate if exposure to ML:8 or Citrox results in an induction of cytokines and 
chemokines from host cells, a Bio-Plex Pro™ Human Cytokine 8-plex assay was 
used. This assay enabled rapid analysis of the relative expression of a range of 
human cytokines and chemokines including IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α and 
IFN-δ. Blood was drawn from three healthy donors and exposed to ML:8 and Citrox 
for 2 h. Results are shown in figure 4.11 A. No significant induction of the cytokines 
by ML:8 or Citrox was seen when compared to a media control. This indicates that 
ML:8 and Citrox do not trigger an immune response in the exposure time 
examined. Results for IL-8 and TNF-α were confirmed by ELISA, where a similar 
trend was observed (figure 4.11 B). Neither ML:8 or Citrox resulted in an induction 
of IL:8 or TNF-α compared to the lipopolysaccharide (LPS) control. 
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Figure 4.11 Cytokine responses to exposure to ML:8 and Citrox . Human blood and test agents 
ML:8, Citrox (0.06% v/v and 0.03% v/v respectively), media control, S. aureus biofilm cells or LPS 
were incubated for 2 h. Samples were centrifuged and serum harvested. Cytokine response was 
examined using a bioplex-pro assay (A) and an IL8 and TNF-α elisa (B). Data represents mean 
pg/ml concentrations of cytokines ± S.D, three donors were used for each experiment. Significant 
induction compared to media control is shown (one tailed student-T test P≥0.5). 
4.3.9 Effect of ML:8 and Citrox in vivo using an animal model of infection 
An in vivo model of S. aureus catheter-related biofilm infection was developed to 
further investigate ML:8 and Citrox as potential CLSs. Using three animals a pilot 
study was carried out to confirm conditions appropriate for the development of 
infection and biofilm formation in vivo (data not shown). For the main study, biofilm 
was formed over five days following inoculation of USA300lux containing 106 
CFU/ml. Figure 4.12 shows a representative image of a Sprague-Dawley rat five 
days post infection of IVC with S. aureus. This image was captured prior to the 
initiation of CLS treatment and high levels of luminescence are shown within the 
implanted catheter.  
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Figure 4.12 Monitoring development of in vivo infection. Optimised doses of 10
6 
CFU MRSA 
USA300lux in 40 µL were injected into catheters; infection was allowed to develop over 5 d. IVIS 
imaging system was used to monitor development of infection. Bioluminescence activity was 
acquired using an IVIS 100 camera of Sprague-Dawley rat 5 d post infection. Colour scale indicates 
degree of luminescence from high (red) to low (purple). A representative animal is shown (N=3). 
Vancomycin at 50 mg/kg was administered every 12 hours to prevent BSI for the 
duration of the experiment. Animals were euthanised and catheters, blood and 
organs were harvested. CFU counts of blood were carried out; results are shown in 
figure 4.13. Bacteria were not detected in the harvested blood for any treatment 
group, indicating vancomycin had successfully prevented the development of BSI. 
Animals organs were examined under IVIS imaging system, no luminescence was 
detected indicating no bacteria were present (data not shown). 
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Figure 4.13 Determination of Log10 CFU/ml in blood post infection with 10
6 
cfu/ml S. aureus. 
Catheter inoculation and dissemination into blood in a rat IVC infection model. Optimised doses of 
10
6 
CFU MRSA USA300lux in 40 µl were injected into catheters; infection was allowed to develop 
over 5 d, this was followed with a 4 d treatment of ML:8 or Citrox. Animals were euthanised at day 
nine and blood was harvested. Log
10
 CFU counts were determined. Assays were performed in 
triplicate and data represents mean Log10 CFU/ml ± SD.  
Images of explanted catheters were captured using IVIS imaging. Assays were 
performed in triplicate and representative images are shown in figure 4.14 (A) for 
the untreated, as well as ML:8 and Citrox treated catheters. High level 
luminescence is evident in the untreated catheter; whilst luminescence is also 
shown in the ML:8 treated catheter, this appeared to be less than the untreated 
control. The Citrox treated catheter did not have any detectable luminescence. The 
CFU/ml was calculated for each explanted catheter. Results are presented in 
figure 4.14 (B). ML:8 (1% v/v) treatment did not result in a significant reduction in 
the viability of bacterial biofilm cells harvested from the catheters. However, Citrox 
(1% v/v) was shown to result in eradication of all biofilm cells within the treated 
catheter. 
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Figure 4.14 Effect of ML:8 and Citrox on in vivo high inoculum biofilm formed over five days. 
Optimised doses of 10
6 
CFU MRSA USA300lux in 40 µl were injected into catheters; infection was 
allowed to develop for 5 d. This was followed by treatment for 4 d with saline (control), ML:8 (1%) or 
Citrox (1%). Animals were euthanised at day 9. Catheters were explanted, bioluminescence activity 
was acquired using an IVIS 100 camera (A) and Log
10
 CFU counts were determined (B). 
Representative catheters are shown. Assays were performed in triplicate and data represents mean 
Log10 CFU/ml ± SD. Statistically significant results are indicated (two tailed student t-tests vs 
untreated, P≥0.05 *) 
ML:8 was shown to be ineffective against high inoculum (106 CFU/40µl) biofilms 
formed over five days (4.14). The effect of ML:8 on low inoculum (104 CFU/40µl) 
biofilms formed over one day was also investigated. An inoculum of 104 CFU/ml 
USA300lux was inoculated into IVCs of rats and allowed to develop for one day. 
Treatment with ML:8 or saline was carried out for four days following initial 
inoculation, the animals were euthanised and catheters were harvested as before. 
Images were captured and are shown in figure 4.15 (A). High level luminescence 
ML:8 Citrox Untreated A 
B 
* 
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was observed in the untreated catheter. No detectable luminescence was 
observed for the ML:8 treated catheter. Luminescence levels correlated with a 
CFU count of 9 x 1010 CFU/catheter for the untreated control. No bacteria were 
detected for the ML:8 treatment group (figure 4.15 B).  
 
 
Figure 4.15. Effect of ML:8 on in vivo low inoculum biofilm formed over one day. Optimised 
doses of 10
4 
CFU MRSA USA300lux in 40 µl were injected into catheters; infection was allowed to 
develop over 24 h. This was followed by treatment for 4 d with saline (control) or ML:8 (1%). 
Animals were euthanised at day 9. Catheters were explanted, bioluminescence activity was 
acquired using an IVIS 100 camera (A) and Log
10
 CFU counts were determined (B). Representative 
catheters are shown. Assays were performed in triplicate and data represents mean Log10 CFU/ml 
± SD. Statistically significant results are indicated (two tailed student t-tests vs untreated, P≥0.05 *) 
 
Untreated ML8 
A 
B 
* 
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4.4 Discussion 
Suspension testing, static biofilm assays and flow biofilm assays were employed to 
give an insight into the efficacy of ML:8 and Citrox, both independently and in 
combination with antibiotics, against S. aureus and S. epidermidis biofilms in vitro. 
Investigations were also carried out to determine the potential for in vivo use by 
analysing the cytotoxic profile of ML:8 and Citrox and determining if an immune 
response was stimulated by exposure. Finally the effect of these novel therapeutic 
agents was examined in an animal model of CRI involving biofilm.  
Previous studies have found large variation between MICs for planktonic cells and 
concentrations effective against cells embedded in a biofilm (63). This was also 
observed in earlier testing outlined in chapter three. In contrast to this, 
concentrations of 0.125% (v/v) ML:8 proved effective in not only inhibiting 
planktonic growth but also significantly reducing biofilm viability. This was observed 
against the two MRSA, two MSSA and one S. epidermidis strain tested. Despite 
0.125% (v/v) significantly reducing biofilm viability, concentrations of 0.25% (v/v) 
were required for complete eradication of biofilms formed by the five strains tested. 
Differences in susceptibility of planktonic and sessile bacterial cells were observed 
when treated with Citrox.  MICs were found to be 0.015% (v/v) against planktonic 
cells, while the concentration required to fully kill cells within a biofilm were higher 
at 0.25% (v/v). Concentrations of 0.125 and 0.06% (v/v) were shown to yield a 
significant (P≤0.05) reduction in biofilm viability.  
Concentrations of 0.25, 0.5 and 1 % (v/v) of ML:8 and Citrox were examined over a 
series of time points on biofilm produced by our five lead strains. This was carried 
out to determine an optimum treatment time for each agent. Twenty four hours was 
found to be the minimum treatment time required for both ML:8 and Citrox against 
the five strains tested. This time had previously been recommended for treatment 
of staphylococcal-related IVC infection, using a number of treatment agents 
including ethanol and antibiotics (438, 466).  Interestingly, biofilm formed by MRSA 
strains BH1CC and USA300 Je2 were more susceptible to treatment with ML:8 
and Citrox than the MSSA and S. epidermidis strains tested. This was an 
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unexpected finding as MRSA strains are typically considered more difficult to treat 
in the clinical setting, with MRSA infection often non responsive to antibiotics in 
common use (467, 468). The mortality associated with MRSA bloodstream 
infection, often stemming from a colonised IVC, has been reported to be twice that 
of MSSA bloodstream infection (469). These results indicate the potential for ML:8 
and Citrox to be used in the treatment of IVC infections caused by both MRSA and 
MSSA stains as well as S. epidermidis.  
Again it was important to ensure that our initial results were not confined to limited 
genetic backgrounds, SH1000, BH48, BH1CC, USA300 Je2 and RP62A. To 
investigate this we introduced a wide range of S. aureus clonal complexes (CC) 
commonly isolated from patients within Irish hospitals, in particular CC 22. In this 
study, we have included MRSA strains from five CC and MSSA strains from eight 
different CC groups. Previous studies have shown an association between S. 
aureus clonality and invasive disease, with strains from CC5 and CC30 reported to 
be associated with increased severity of infections (470, 471). Some 
staphylococcal clonal complexes are more commonly associated with bacterial 
resistance than others. Variation in susceptibility of biofilms produced by strains 
from varying genetic lineages was not shown after treatment with 1% (v/v) of ML:8 
or Citrox. However, differences were observed between CCs and strains treated 
with lower concentrations of ML:8 and Citrox. ML:8 and Citrox at concentrations of 
0.5 and 0.25% (v/v) were not shown to be fully effective in eradicating biofilm 
produced by S. aureus from varying genetic lineages. CC4 and CC298 were 
observed to be more susceptible to treatment than CC22; this difference was not 
shown to be significant. A difference in susceptibility of strains to treatment has not 
been shown to be dependent on CC type in previous studies. From this testing 
concentrations of 1% (v/v) of both ML:8 and Citrox was chosen for use in future 
testing.  
The successful treatment of complex CRI involving staphylococci can often involve 
a combination of therapies. Testing was carried out to investigate the effect of 
ML:8 and Citrox in combination with commonly used antibiotics. This was done to 
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determine if synergistic or additive effects were seen by combining agents but also 
to ensure antagonism was not evident. No additive or synergistic benefit was found 
in the combination of low doses of ML:8 or Citrox with commonly used antibiotics. 
In contrast to our findings, previous studies examining combinations of antibiotics 
with flavonoids have shown synergistic and additive effects (394, 472, 473). 
Combinations of fatty acids at low doses have previously been shown to have 
increased activity on staphylococcal biofilms in combination with antibiotics (474). 
It should also be noted combination of antibiotics with ML:8 or Citrox did not result 
in antagonism.  
Previous research by our group, and others, had shown differences in 
susceptibility of biofilms formed in different nutrient conditions (443, 475). To 
elucidate the effect of ML:8 and Citrox in an assay more closely representing in 
vivo conditions, testing was expanded into a nutrient limited (RPMI-1640) and pre-
conditioning assay. The data from these experiments demonstrated that both 
agents are very effective against biofilm formed under these biomimetic conditions. 
Efficacy of treatment agents at concentrations of 1% (v/v) was confirmed under 
conditions of flow. Our investigations using this model were limited in static assays 
to S. aureus strains, as S. epidermidis growth was not supported in the RPMI-1640 
media used for longer than one day.   
CLSs should be withdrawn after completion of treatment for the required duration 
due to potential leak into systemic circulation. It is important to consider patient 
safety when investigating potential CLSs. Solutions must be deemed as safe and 
non-toxic before they can be used as a CLS. It was therefore essential to analyse 
the cytotoxicity of ML:8 and Citrox on human cells, especially those cells to which 
the agents may come into contact with the host. For these reasons, we chose to 
use HaCaT cells and THP-1 cells initially in our experiments. These two cell lines 
were chosen as they represent the two cell types a CLS would encounter in clinical 
use. The method chosen to assess the cytotoxic properties of agents against the 
above mentioned cell lines, was an MTT assay. Cells were treated and analysed in 
serum-free media. Serum components can have a protective effect on cells and 
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can result in differences in sensitivity to toxic solutions. Results obtained show that 
while ML:8 and Citrox are toxic at concentrations effective at killing bacterial 
biofilms, they are no more toxic than solutions currently available that were 
included in our testing. Ethanol has previously been used in CLS at concentrations 
of up to 70% (371). We have demonstrated at this level that its cytotoxicity levels 
are very high, with concentrations ten times lower that what is in use clinically 
showing toxicity. Duralock-CTM was also demonstrated to have cytotoxic properties 
seven times lower than the clinically used concentration. ML:8 showed a cytotoxic 
profile at concentrations over 0.125%, which is three-fold lower than the working 
concentration. Citrox was shown to be cytotoxic at concentrations five-fold lower 
than the working concentration. Both ML:8 and Citrox were shown to be haemolytic 
at concentrations over 0.125 and 0.06% (v/v), respectively. This indicated they 
have caused lysis of the erythrocyte cell membrane.  Interestingly, neither ML:8 or 
Citrox resulted in an induction of cytokines. This is an important finding as severe 
reactions have been reported previously for drugs that elicit an immune response 
(476). It would be interesting to determine if ML:8 or Citrox would dampen the 
immune response to different bacterial cellullar components. Some flavonoids 
have previously been shown to inhibit expression of the pro-inflammatory cytokine, 
TNF-α (477).  
The in vitro data presented offer a strong justification for the use of ML:8 and Citrox 
as CLSs. Testing was expanded to investigate their effect on in vivo biofilm. A 
striking reduction in the viability of biofilm formed over five days within catheters 
treated with Citrox was observed. This provides further justification for the use of 
Citrox in treatment of IVC infection caused by S. aureus. Surprisingly ML:8 
treatment did not result in a significant reduction in biofilm viability in this five day 
infection assay. Previous in vitro testing had shown ML:8 to be very effective 
against established S. aureus biofilm under all growth conditions. Testing was 
expanded to determine if biofilm formed over one day using a lower initial inoculum 
would prove more susceptible to ML:8 treatment. This inoculum may, in fact, be 
more likely to represent the in vivo environment. ML:8 was shown to eradicate 
biofilm viability in this assay, indicating the efficacy of ML:8 in vivo may be 
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dependent on the cell density. Another possible explanation for the enhanced 
effect is the maturity of the biofilm. Differences in S. aureus biofilm have previously 
been reported as the biofilm matures (478). Thicker biofilm structures, with the 
cells tightly knitted together in a uniform manner may play a role in protecting the 
cells within the deeper layers from ML:8 treatment. This has previously been 
reported for treatment with some antibiotics (479, 480). Further in vivo testing 
would be required to determine the effectiveness of ML:8, on mature biofilms using 
the lower 104 inoculum. Notably biofilms formed over five days in this in vivo model 
contain numbers of viable bacteria similar to that previously reported in biofilms 
recovered from infected catheters in vivo (360). Perhaps limiting the potential use 
of ML:8 to early stage biofilm infection. Vancomycin (50mg/kg) was administered 
systemically for the duration of the experiment to prevent systemic infection from 
developing. Terminal harvest of blood was not shown to be infected; indicating 
vancomycin was effective in the prevention of bloodstream infection. This is in 
agreement with previous studies that have shown vancomycin to be effective 
against S. aureus (456). In cases of CRIs associated with staphylococci, systemic 
antibiotic treatment should be administered in combination with an appropriate 
CLS (354).  
In this chapter, we aimed to investigate the therapeutic potential for two agents 
ML:8 and Citrox as CLSs. A range of investigations were used to examine the 
effect of each agent on S. aureus and S. epidermidis in planktonic and sessile 
conditions. Citrox (1% v/v) was shown to be very effective in testing against biofilm 
produced by all strains in an in vitro setting. This result was replicated during in 
vivo testing against biofilm formed over five days, with complete eradication of 
biofilm viability being observed. ML:8 was also shown to be effective in vitro 
against a range of S. aureus and S. epidermidis strains, however when examined 
in an in vivo setting ML:8 did not result in a significant reduction in cell viability 
against biofilms formed over 5 days. ML:8 did prove effective against in vivo biofilm 
formed over one day using a lower inoculum of bacterial cells. Citrox and ML:8 
were shown to have cytotoxic and haemolytic levels similar to that of currently 
used CLSs ethanol and Duralock-CTM.  Both agents were shown to be non 
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immunogenic. Overall, the results from this chapter indicate strong therapeutic 
potential for ML:8 and Citrox, both at concentrations of 1% (v/v), as CLSs for the 
treatment of CRI due to staphylococcal biofilm.  
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Chapter 5: Investigation into the development 
of resistance and the transcriptional response 
of S. aureus to ML:8 and Citrox exposure 
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5.1 Introduction 
Gene expression of virulence factors is regulated in a tightly controlled manner, so 
it is complementary to the biological life cycle of staphylococci.  Transcriptomics 
data from staphylococci has primarily focused on differential gene expression 
between normal and treated cells (64, 481-483). However, some reports have 
investigated differentially expressed (DE) genes between wild type and gene 
mutant cells (484), or between sensitive and resistant isolates whilst others have 
focussed on non-coding small RNAs (485, 486). 
The transcriptional response of bacteria to an antimicrobial can be used to indicate 
the antimicrobial’s mode of action (487). An example of this approach comes from 
the many reports that have noted the activation of a cell-wall-stress response upon 
treatment with antimicrobials, such as oxacillin and vancomycin, which are known 
or predicted to inhibit cell wall biosynthesis (487-489). This response includes 
upregulation of the vraRS, which encodes a two-component regulatory system, 
and its downstream regulon, that includes cell wall metabolism, proteases, protein 
chaperones and members of the heat shock regulon (487-489). Upregulation of the 
heat shock regulon also leads to downregulation of cell division and autolysins in 
this response, which is believed to further preserve the cell wall (489). Activation of 
the cell-wall-stress response has been used to indicate that an antimicrobial affects 
cell wall production (487). 
The emergence of resistance is a considerable clinical problem, with the number of 
drug resistance organisms steadily increasing (490). During the past ten to fifteen 
years, numbers of antibiotic resistant organisms has steadily increased (491). The 
use of antibiotics for prophylactic or therapeutic purposes in humans or for 
agricultural purposes has provided the selective pressure favouring the survival 
and spread of such organisms (492). The WHO have highlighted antimicrobial 
resistance as a global concern, stating that a post-antibiotic era is approaching, in 
which common infections and minor injuries could result in death (493). This 
further supports the critical need for novel therapeutics to which resistance does 
not develop (436).  
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In this chapter we investigated the response of S. aureus to ML:8 and Citrox 
exposure. The transcriptional response to challenge with either agent was 
determined and compared to an untreated control to determine the effect of each 
agent on bacterial gene expression. Results were also compared to transciptomic 
datasets from the literature, in an effort to determine a mode of action. The 
potential for resistance development of bacteria to ML:8 and Citrox was also 
investigated.  
5.2 Aims 
 To determine the effect of ML:8 and Citrox on the S. aureus transcriptome 
using RNA-sequencing, with particular focus on genes associated with 
virulence, including genes associated with biofilm. 
 To compare the transcriptional response of bacteria treated with ML:8 and 
Citrox to transciptomics datasets from the literature, and assess if 
similarities could be suggestive of a mode of action for each agent. 
 To investigate the potential of resistance development of S. aureus and S. 
epidermidis strains exposed to ML:8 and Citrox. 
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5.3 Results 
To determine the transcriptional response of S. aureus to ML:8 and Citrox, RNA-
Seq was performed on challenged and control samples of S. aureus SH1000. The 
sub-MIC concentration of ML:8 and Citrox were  0.0625% (v/v) and 0.0075% (v/v) 
respectively, as established in chapter four. RNA was then purified from cells as 
described in chapter two. 
5.3.1 RNA Quality control 
Prior to sequencing, RNA samples were tested to ensure they were at levels of 
sufficient quality and concentration (table 5.1). All RNA samples used for 
sequencing had low protein, salt and solvent contamination, as indicated by 
nanodrop 260/280 & 260/230 ratios over 1.7. All samples had sufficient 
concentration ( 30 ng ul-1) and yield of RNA ( 3 µg) as determined by Qubit 
analysis. Samples were determined as sufficiently un-degraded by RNA integrity 
(RIN) scores > 7.0 and low evidence of degradation on bioanalyser traces (figure 
5.1) as determined by the Agilent bioanalyser. 
Table 5.1 QC values of RNA samples for sequencing.  
Group Sample Nano-
Drop 
260/280 
Nano-
Drop 
260/230 
Concentration 
µg 
Sample 
volume 
(µl) 
RIN1 
Control B1 2.19 1.98 5.37 16 8.5 
 B2 2.2 1.74 17.6 16 8.8 
 B3 2.25 2.20 7.7 16 7.9 
ML:8 M1 2.26 2.24 10.3 16 9.7 
 M2 2.27 1.81 4.7 16 9.2 
 M3 2.22 1.90 4.9 16 8.9 
Citrox C1 2.25 2.05 7.2 16 9.5 
 C2 1.89 1.89 10.5 16 9.8 
 C3 2.25 2.26 5.76 16 8.9 
*Abbreviations: RIN = RNA integrity number, B = control condition, M = ML:8 challenge condition, C 
= Citrox challenge condition. 
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Figure 5.1 Bioanalyzer traces of RNA samples for sequencing. The Agilent bioanalyser visual 
output for the determined RNA integrity showing the levels of particular sizes of RNA. Large peaks 
are expected (from right to left) for 23S and 16S, with a small peak for the ladder and small RNAs, 
other peaks and/or smaller 23S or 16S peaks are indicators of degradation. Samples are: media 
treated control 1, 2 and 3 (A, B & C respectively), ML:8 treated 1, 2 and 3 (D, E & F respectively) 
and 1, 2 and 3 (G, I & K respectively) and sapeinic acid treated 1 2 and 3 (H, J & L respectively). 
A B
C
G
FE
D
H
I
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5.3.2 Comparison of S. aureus transcriptional response to ML:8 and Citrox 
challenge 
Sequence reads were analysed by the CGR, following sequencing, to produce a 
list of genes that were significantly (P≤0.0001) DE between control and challenge 
groups. Challenge groups included SH1000 cells exposed to ML:8 and Citrox for 
20 min as described previously (section 2.14).  
5.3.2.1 Assessing variation in the data set 
To assess the variation present in the data, raw read counts per gene were 
determined among all sample pairs. This information was displayed as a 
correlation heatmap (figure 5.2). These give an indication of variation both within 
and between treatment groups. The variations between sample groups and the 
variation within a sample group are shown.  
Variation within the ML:8 treated group was observed for one of the three 
biological replicates. This variation in this sample was determined to be too large to 
include in our data set. ML:8 sample, M1, was excluded and analysis was carried 
out on remaining samples by the CGR. Results revealed 315 genes to be DE after 
exposure to ML:8; 57 genes were down-regulated while 258 genes were observed 
to be up-regulated. The transcriptional response to Citrox treatment showed 378 
genes to be DE expressed when compared to untreated control group with 122 
genes down-regulated and 256 genes shown to be up-regulated. Large changes in 
genes associated with a number of bacterial processes were observed. The first 
bacterial process to be examined was virulence.  
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Figure 5.2 Heatmap of sample correlation. Samples from same group are correlated more 
closely than samples from different sample groups. Red indicated high levels of DE while blue 
represents lower levels of DE gene in the group.  
5.3.2.2 Assessing differentially expressed genes associated with virulence 
and resistance 
DE gene lists were screened for genes known to be associated with 
staphylococcal virulence; results are illustrated in table 5.2. Genes associated with 
bacterial adherence such as, eap/map, fnbA and sdrC, are observed to be down-
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regulated in both treatment groups. Exoenzymes produced by S. aureus, in 
particular Coa and Geh, are up-regulated after exposure to ML:8 and Citrox. 
Similarly genes involved in capsule formation, cap5D and cap5E, are up-regulated. 
The ESAT-6 secretion system is also up-regulated, this system encodes ESAT-6-
like proteins and the genes coding for their synthesis/secretion. Toxin production is 
up-regulated after exposure to both agents, with the exception of genes hlgA and 
hlgC that are down-regulated after exposure to Citrox and ML:8 respectively. 
Superantigen- like proteins are shown to be upregulated after Citrox exposure. 
Genes known to be involved in resistance mechanisms were found to be 
significantly (P≤0.0001) differentially expressed. Three genes involved in 
resistance to antimicrobial peptides including a zinc metalloproteinase aureolysin, 
aur, a sensor histidine kinase graS and dltC involved in LTA biosynthesis are up-
regulated. A sensor histidine kinase, SaeP was also up-regulated after ML:8 and 
Citrox exposure. 
Table 5.2 DE genes involved in virulence in S. aureus SH1000 after challenge 
with ML:8 and Citrox 
Ordered locus 
name 
Gene product Fold change 
ML:8
1 
Fold change 
Citrox
1 
Adherance    
SAOUHSC_02161 Eap/Map - -1.53 
SAOUHSC_02803 FnbA -1.42 - 
SAOUHSC_00544 SdrC -1.41 -1.14 
SAOUHSC_00816 Emp - -1.25 
Exoenzyme    
SAOUHSC_00300 Geh 3.7 2.5 
SAOUHSC_01936 SplE - 1.24 
SAOUHSC_01935 SplF - 1.3 
SAOUHSC_00192 Coa 2.1 3.50 
SAOUHSC_00818 Nuc  2.17 
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Ordered locus name Gene product Fold change ML:8
1 
Fold change Citrox
1 
Host immune evasion    
SAOUHSC_00117 Cap5D 2.6 2.5 
SAOUHSC_00118 Cap5E 2.34 2.1 
SAOUHSC_00120 UDP-N-
acetylglucosamine 2-
epimerase 
1.88 1.7 
Secretion system    
SAOUHSC_00258 EsaA 3.8 4.15 
SAOUHSC_00260 EsaB 1.44 1.55 
SAOUHSC_00261 EssB - 1.78 
SAOUHSC_00264 EsaC - -2.4 
SAOUHSC_00265 EsxB 2.9 2.2 
Toxin Production    
SAOUHSC_00384 set7 3.07 3.11 
SAOUHSC_00386 set8 2.11 2 
SAOUHSC_00390 set10 - 2.12 
SAOUHSC_00393 set12 2.14 3.75 
SAOUHSC_00399 set15 - 2.35 
SAOUHSC_02708 HlgA - -1.54 
SAOUHSC_02709 HlgC -1.55 - 
SAOUHSC_01955 LukE 3.6 - 
Protein coding    
SAOUHSC_00390 superantigen-like 
protein 5 
- 2.12 
SAOUHSC_00391 superantigen-like 
protein 
- 1.22 
SAOUHSC_00393 superantigen-like 
protein 
2.15 3.76 
SAOUHSC_00397 type I restriction-
modification system 
subunit M 
- 2.45 
SAOUHSC_00399 superantigen-like 
protein 11 
- 2.35 
Resistance 
mechanisms 
   
SAOUHSC_00871 DtlC 4.49 2.10 
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1 
Genes that were not DE in one species are indicated by a dash in the relevant fold change 
column. 
5.3.2.3 Comparison of DE metabolic pathways using Kyoto Encyclopedia of 
Genes and Genomes database 
Kyoto Encyclopedia of Genes and Genomes (KEGG) is a database that integrates 
genomic and systemic functional information. Lists of DE genes produced by the 
CGR were used in KEGG mapper version 2.1-search & color, an online 
programme that highlights the proteins within KEGG pathways based upon the 
users gene list (419). Analysis of these pathways enabled detection of metabolic 
processes with DE genes and speculative theories on the effect of ML:8 and Citrox 
on metabolism. 
Genes involved in pathways of amino acid production are observed, generally, to 
be up-regulated after challenge by ML:8 and Citrox (table 5.3). Histidine 
metabolism is up-regulated after ML:8 challenge, as is cystine and methionine 
metabolism and arginine and proline metabolism. Large fold increases are shown 
in valine, leucine and isoleucine biosynthesis, glycine metabolism and arginine and 
proline metabolism after Citrox exposure. A small number of genes are observed 
to be down-regulated after exposure to ML:8 and Citrox.  
Ordered locus 
name 
Gene product Fold change 
ML:8 
Fold change 
Citrox 
Resistance 
mechanisms 
   
SAOUHSC_02971 zinc metalloproteinase 
aureolysin 
2.97 2.63 
SAOUHSC_00666 GraS 2.26 - 
SAOUHSC_02972 immunodominant antigen B 3.07 2.76 
SAOUHSC_00717 SaeP 3.25 1.99 
SAOUHSC_01081 IsdA - 1.16 
SAOUHSC_02609 FosB - 2.81 
SAOUHSC_02305 Arl - 1.97 
SAOUHSC_01424 MurG 2.17 - 
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Table 5.3 DE genes involved in amino acid production1 in S. aureus SH1000 
after challenge with ML:8 and Citrox  
Ordered locus 
name 
Gene product Fold 
change 
ML:82
 
Fold 
change 
Citrox2
 
Enzyme 
name 
histidine 
metabolism 
  
SAOUHSC_02363 aldehyde dehydrogenase 3.03 - 1.2.1.3 
SAOUHSC_02606 imidazolonepropionase 4.81 - 3.5.2.7 
valine, leucine, 
iso biosynthesis 
  
SAOUHSC_02289 threonine dehydratase - 1.52 4.3.1.19 
SAOUHSC_02288 leuD 1.06 1.41 4.2.1.35 
SAOUHSC_02282 acetolactate synthase large 
subunit 
- 1.34 2.2.1.6 
SAOUHSC_02284 ketol-acid reductoisomerase 3.17 2.67 1.1.1.86 
SAOUHSC_00536 branched-chain amino acid 
aminotransferase 
- 2.12 2.6.1.42 
SAOUHSC_00914 2-isopropylmalate synthase - -4.39 2.3.3.13 
purine 
metabolism 
   
SAOUHSC_00101 phosphopentomutase 2.18 2.71 5.4.2.7 
SAOUHSC_01010 phosphoribosylaminoimidazole-
succinocarboxamide synthase 
- 1.22 6.3.2.6 
SAOUHSC_01107 nucleoside-triphosphatase - -1.78 3.6.1.66 
SAOUHSC_00442 DNA polymerase III subunits 
gamma and tau 
-1.28 -1.74 2.7.7.7 
SAOUHSC_01107 nucleoside-triphosphatase - -1.78 3.6.1.66 
cystine and 
methionine 
metabolism 
    
SAOUHSC_00075 hypothetical protein 2.47 2.09 2.5.1.47 
SAOUHSC_01394 aspartate kinase -1.77 -1.46 2.7.2.4 
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Ordered locus name Gene product Fold 
change 
ML:8 
Fold 
change 
Citrox 
Enzyme 
name 
cystine and methionine 
metabolism 
    
SAOUHSC_01395 aspartate semialdehyde 
dehydrogenase 
3.91 2.93 1.2.1.11 
SAOUHSC_00421 hypothetical protein 1.94 1.87 MccA 
arginine and proline 
metabolism 
    
SAOUHSC_02363 aldehyde dehydrogenase 3.03 - 1.2.1.3 
SAOUHSC_00150 ornithine aminotransferase 3.25 3.97 2.6.1.13 
SAOUHSC_00076 ornithine cyclodeaminase 2.29 2.14 4.3.1.12 
lysine biosynthesis     
SAOUHSC_01394 aspartate kinase -1.77 -1.46 2.7.2.4 
SAOUHSC_01395 aspartate semialdehyde 
dehydrogenase 
3.91 2.93 1.2.1.11 
SAOUHSC_02244 succinyl-diaminopimelate 
desuccinylase 
- -1.14 3.5.1.18 
SAOUHSC_00082 hypothetical protein 3.2 2.93 4.1.1.20 
glycine metabolism     
SAOUHSC_01394 aspartate kinase -1.77 -1.46 2.7.2.4 
SAOUHSC_01395 aspartate semialdehyde 
dehydrogenase 
3.90 2.93 1.2.1.11 
SAOUHSC_02289 threonine dehydratase - 1.52 4.3.1.19 
SAOUHSC_02933 betaine aldehyde dehydrogenase - -1.42 1.2.1.8 
SAOUHSC_00836 glycine cleavage system protein 
H 
3.42 - GCSH 
SAOUHSC_02289 threonine dehydratase - 1.52 4.3.1.19 
SAOUHSC_00756 hypothetical protein 3.00 1.99 2.7.1.31 
1 
Kegg mapper output pathways relevant to this table were histidine metabolism, valine, leucine and 
isoleucine biosynthesis, purine metabolism, glycine, cysteine and methionine metabolism, arginine 
and proline metabolism and lysine biosynthesis. 
2 
Genes that were not DE in one species are indicated by a dash in the relevant fold change 
column. 
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Energy production is shown to be generally upregulated after Citrox challenge. 
Particularly genes involved in pentose phosphate pathway and amino sugar 
metabolism, with fold increases of up to 3.8. ML:8 challenge however, resulted in 
mixed results with some genes involved in the production of some sugars being 
up-regulated and others being down-regulated. Starch and sucrose metabolism is 
generally down-regulated while pentose phosphate and butanoate metabolism are 
shown to be up-regulated. Galactose metabolism was both up- and down-
regulated in response to ML:8 challenge. The overall response of genes involved 
in glycolysis and sugar metabolism show a trend towards up-regulation of energy 
production after exposure to challenge with ML:8 and Citrox (table 5.4). 
Table 5.4 DE genes involved in energy production1 in S. aureus SH1000 after 
challenge with ML:8 and Citrox  
Ordered locus 
name 
Gene product Fold 
change 
ML:82 
Fold 
change 
Citrox2 
Enzyme 
name 
Galactose 
metabolism 
   
SAOUHSC_02450 PTS system lactose-specific 
transporter subunit IIBC 
-2.08 -1.44 2.7.1.69 
SAOUHSC_02455 galactose-6-phosphate 
isomerase subunit LacA 
- -1.93 5.3.1.26 
SAOUHSC_02801 UTP-glucose-1-phosphate 
uridylyltransferase 
-1.42 - 2.7.7.9 
SAOUHSC_00215 PTS system transporter 1.78 2.45 2.7.1.69 
SAOUHSC_00216 PTS system transporter 2.04 1.61 2.7.1.69 
SAOUHSC_00088 hypothetical protein 2.76 1.87 5.1.3.2 
SAOUHSC_00118 capsular polysaccharide 
biosynthesis protein Cap5E 
2.35 2.14 5.1.3.2 
fructose & 
mannose 
metabolism 
  
SAOUHSC_02403 mannitol-1-phosphate 5-
dehydrogenase 
 
- -1.23 1.1.1.17 
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Ordered locus 
name 
Gene product Fold 
change 
ML:8 
Fold 
change 
Citrox 
Enzyme 
name 
fructose & 
mannose 
metabolism 
    
SAOUHSC_02385 mannose-6-phosphate 
isomerase 
2.76 2.27 5.3.1.8 
SAOUHSC_00797 tpiA  -1.72 5.3.1.1 
SAOUHSC_00707 fructose 1-phosphate kinase 3.16 1.87 2.7.1.56 
starch and 
sucrose 
metabolism 
   
SAOUHSC_00158 PTS system transporter 3.16 3.34 2.7.1.69 
SAOUHSC_02662 PTS system sucrose-specific 
transporter subunit IIBC 
- -4.11 2.7.1.69 
SAOUHSC_02801 UTP-glucose-1-phosphate 
uridylyltransferase 
-1.42 - 2.7.7.9 
SAOUHSC_00437 hypothetical protein - -1.13 2.7.1.69 
glycolysis     
SAOUHSC_00236 6-phospho-beta-glucosidase 4.17 3.79 3.2.1.86 
glycolysis     
SAOUHSC_00797 tpiA  -1.72 5.3.1.1 
SAOUHSC_00113 bifunctional acetaldehyde-
CoA%2Falcohol dehydrogenase 
2.68 2.48 1.1.1.1 
SAOUHSC_02363 aldehyde dehydrogenase 3.03 - 1.2.1.3 
pyruvate 
metabolism 
    
SAOUHSC_02830 D-lactate dehydrogenase 1.72 - 1.1.1.28 
SAOUHSC_00914 2-isopropylmalate synthase - -4.39 2.3.3.13 
SAOUHSC_02363 aldehyde dehydrogenase 3.03 - 1.2.1.3 
pentose 
phosphate 
metabolism 
   
SAOUHSC_00101 phosphopentomutase 2.18 2.71 5.4.2.7 
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Ordered locus 
name 
Gene product Fold 
change 
ML:8 
Fold 
change 
Citrox 
Enzyme 
name 
pentose 
phosphate 
metabolism 
   
SAOUHSC_00239 Ribokinase 1.898 2.43 2.7.1.15 
SAOUHSC_01901 putative translaldolase 4.10 2.95 2.2.1.2 
SAOUHSC_01599 glucose-6-phosphate 1-
dehydrogenase 
3.74 3.05 1.1.1.49 
SAOUHSC_02808 gluconate kinase - -1.72 2.7.1.12 
amino sugar metabolism    
SAOUHSC_00157 murQ 3.49 3.59 4.2.1.126 
SAOUHSC_00295 N-acetylneuraminate lyase - -3.84 4.1.3.3 
SAOUHSC_02365 UDP-N-acetylglucosamine 1-
carboxyvinyltransferase 
3.23 3.81 2.5.1.7 
SAOUHSC_02385 mannose-6-phosphate isomerase 2.76 2.27 5.3.1.8 
SAOUHSC_02801 UTP-glucose-1-phosphate 
uridylyltransferase 
-1.42 - 2.7.7.9 
SAOUHSC_00088 hypothetical protein 2.76 1.87 5.1.3.2 
SAOUHSC_00118 capsular polysaccharide 
biosynthesis protein Cap5E 
2.35 2.14 5.1.3.2 
butanoate metabolism    
SAOUHSC_00086 acetoin reductase 3.66 2.85 1.1.1.76 
SAOUHSC_00086 acetoin reductase 3.66 2.85 1.1.1.304 
SAOUHSC_02282 acetolactate synthase large subunit - 1.34 2.2.1.6 
butanoate metabolism    
SAOUHSC_00113 bifunctional acetaldehyde-
CoA%2Falcohol dehydrogenase 
2.68 2.48 1.2.1.10 
SAOUHSC_00196 hypothetical protein 1.06 3.02 1.1.1.35 
1 
Kegg mapper output pathways relevant to this table were glycolysis/gluconeogenesis, pentose 
phosphate pathway, fructose and mannose metabolism, galactose metabolism, amino sugar and 
nucleotide sugar metabolism, pyruvate metabolism, propanoate metabolism, butanoate 
metabolism, glutathione metabolism. 
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Peptidoglycan biosynthesis in S. aureus was up-regulated after exposure to ML:8 
and Citrox. The fold change in regulation for both challenge groups is described in 
table 5.5. UDP-N-acetylglucosamine 1-carboxyvinyltransferase, an enzyme which 
catalyses the first stage of peptidoglycan biosynthesis (494), was up-regulated 
more than 3 fold after exposure to both ML:8 and Citrox. The gene murG was also 
shown to be up-regulated. This overall increase in peptidoglycan synthesis may 
suggest that ML:8 and Citrox are targeting the cell membrane. 
Table 5.5 DE genes involved in peptidoglycan biosynthesis in S. aureus 
SH1000 after challenge with ML:8 and Citrox  
Ordered locus 
name 
Gene product Fold 
change 
ML:8
 
Fold 
change 
Citrox 
Enzyme 
name 
SAOUHSC_02365 UDP-N-acetylglucosamine 
1-carboxyvinyltransferase 
3.23 3.81 2.5.1.7 
SAOUHSC_01424 murG 2.17 1.27 2.4.1.227 
SAOUHSC_01423 hypothetical protein 0.23 -1.77 3.6.1.27 
Membrane lipid biosynthesis was also observed to be upregulated after exposure 
to both agents (table 5.6). Glycerolipid biosynthesis, fatty acid degradation and 
terpenoid backbone biosynthesis were all shown to be up-regulated after exposure 
to ML:8 and Citrox. ML:8 treatment resulted in a greater than 3 fold increase in 
expression of genes associated with glycerolipid biosynthesis.  
Table 5.6 DE genes involved in membrane lipid biosynthesis1 in S. aureus 
SH1000 after challenge with ML:8 and Citrox  
Ordered locus 
name 
Gene product Fold 
change 
ML:82
 
Fold 
change 
Citrox2
 
Enzyme 
name 
glycerolipid     
SAOUHSC_00756 hypothetical protein 3.01 1.99 2.7.1.31 
SAOUHSC_02363 aldehyde dehydrogenase 3.03 - 1.2.1.3 
SAOUHSC_00300 lipase precurser 3.73 2.58 3.1.1.3 
SAOUHSC_00728 hypothetical protein 
 
3.96 3.65 2.7.8.20 
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Ordered locus 
name 
Gene product Fold 
change 
ML:82 
Fold 
change 
Citrox2 
Enzyme 
name 
fatty acid deg     
SAOUHSC_00198 hypothetical protein 3.21 1.97 6.2.1.3 
SAOUHSC_00196 hypothetical protein - 3.02 1.1.3.35 
SAOUHSC_00195 acetyl-CoA 
acetyltransferase 
- 2.78 2.3.1.16 
SAOUHSC_00113 bifunctional 
acetaldehyde-
CoA%2Falcohol 
dehydrogenase 
2.68 2.48 1.1.1.1 
SAOUHSC_02363 aldehyde dehydrogenase 3.03 - 1.2.1.3 
terpenoid 
backbone 
    
SAOUHSC_00220 2-C-methyl-D-erythritol 
4-phosphate 
cytidylyltransferase 
3.75 3.55 2.7.7.60 
SAOUHSC_00225 ispD 2.08 2.53 2.7.7.60 
SAOUHSC_01618 geranyltranstransferase - 3.65 2.5.1.1 
SAOUHSC_01618 geranyltranstransferase - 3.65 2.5.1.29 
1 
Kegg mapper output pathways relevant to this table were glycerolipid biosynthesis, fatty acid 
degradation and terpenoid backbone biosynthesis.  
2 
Genes that were not DE in one species are indicated by a dash in the relevant fold change 
column. 
5.3.2.4 Comparison of transcriptional response to other transcriptomic data 
sets. 
To help elucidate a mode of action of ML:8 and Citrox, the transcriptional response 
of S. aureus was compared to previously published transcriptome datasets. This 
technique has previously been used to indicate a mode of action for other chemical 
compounds (495) including the antibiotics, daptomycin and friulimicin B (487, 496). 
An online bioinformatics database, S. aureus microarray meta-database (SAMMD), 
was used to compare datasets.  Similarities and differences in transcriptional 
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response between both agents and a range of antibiotics and antiseptics were 
examined. 
ML:8 ML:8
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Daptomycin Vancomycin
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33 215
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Figure 5.3 SAMMD comparison of ML:8 transcriptome to S. aureus cell wall biosynthesis 
inhibitor transcriptomes. Comparison of gene regulation between ML:8 and cell wall active 
antibiotics daptomycin (A), vancomycin (B), oxacillin (C) and fosfomycin (D). Light grey circles 
represent ML:8 datasets, dark grey represents comparison data set, overlapping gene regulation is 
illustrated between the two circles, while oppositely regulated genes are located in individual circle. 
The active ingredient of ML:8 with suggested antimicrobial properties is caprylic 
acid; monocaprylate has previously been shown to work by targeting bacterial cell 
wall or membrane (387). To investigate this we compared the transcriptional 
response of ML:8 challenged cells to cell wall/membrane active antibiotics; results 
are shown in Venn diagrams (figure 5.3). The largest overlap in gene regulation is 
seen with ML:8 and daptomycin, however this overlap only amounts to 23%. The 
antibiotics vancomycin, oxacillin and fosfomycin are shown to result in an overlap 
of 14, 10 and 10 %, respectively. The results for vancomycin, oxacillin and 
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fosfomycin show a large number of genes oppositely regulated when compared to 
ML:8 transcription.   
While the mode of action of many antimicrobial fatty acids remains unclear, oleic 
and linoleic acid have been demonstrated to act on the bacterial cell membrane 
(483). Datasets from S. aureus treated with oleic and linoleic acid were compared 
to ML:8 and examined for similarities, results are illustrated in figure 5.4.Similarities 
between oleic (figure 5.4 A) and low dose linoleic acid (figure 5.4 B) were observed 
to be low when compared to the total number of genes affected by ML:8 challenge. 
However, when compared to the number of genes affected in the comparison 
dataset this overlap correlated with a much larger percentage similarity. A 42% 
overlap in gene regulation was observed between oleic acid and ML:8, while 
linoleic at concentrations of 0.01M resulted in 45% overlap between the two 
datasets. This high correlation was not seen in the higher dose linoleic acid 
treatment, with only an 18% overlap observed (figure 3.4 C). Tea tree oil has 
previously been shown to compromise the cytoplasmic membrane of S. aureus 
(497). To investigate if similarities could be seen between ML:8 activity and tea 
tree oil, gene response was examined. An overlap of 104 genes is shown (figure 
5.4 D) this represented a 33% overlap of genes affected when compared to total 
transcriptional affect of ML:8.  
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Figure 5.4 SAMMD comparison of ML:8 transcriptome to S. aureus cell membrane active 
transcriptomes. Comparison of gene regulation between ML:8 and cell membrane active fatty 
acids oleic acid (A), linoleic (0.01M) (B), linoleic (0.1M) (C) and tea tree oil (D). Light grey circles 
represent ML:8 datasets, dark grey represents comparison data set, overlapping gene regulation is 
illustrated between the two circles, while oppositely regulated genes are located in individual circle. 
The mode of action of Citrox is unknown. The solution comprises of a range of 
flavonoids. A number of flavonoids have previously been shown to induce cell lysis 
in S. aureus (498). This suggests flavonoids may target the bacterial cell 
wall/membrane. To further investigate this, Citrox gene regulation was compared 
to cell wall/membrane active antibiotics, results are shown in figure 5.5. Little 
similarities were observed in gene regulation for any of the cell wall/membrane 
active antibiotics and Citrox. The antibiotics daptomycin, vancomycin, oxacillin and 
fosfomycin were shown to have 9, 12, 7 and 9% overlap respectively when 
compared to overall Citrox transcriptional response. 
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Figure 5.5 SAMMD comparison of Citrox transcriptome to S. aureus cell wall biosynthesis 
inhibitor transcriptomes. Comparison of gene regulation between Citrox and cell wall active 
antibiotics daptomycin (A), vancomycin (B), oxacillin (C) and fosfomycin (D). Light grey circles 
represent Citrox datasets, dark grey represents comparison data set, overlapping gene regulation is 
illustrated between the two circles, while oppositely regulated genes are located in individual circle. 
As Citrox comprises of flavonoids extracted from oranges its transcriptional 
response was compared to that of orange oil. Results are shown in figure 5.6 A. A 
large number of genes were affected by exposure to orange oil, a total of 847, 
much higher than the 378 DE after Citrox exposure. A large overlap was observed 
between datasets when compared to the overall Citrox response, 42% of genes 
were shown to be similarly affected. Tea tree oil as discussed above has 
previously been shown to target cytoplasmic membrane. To determine if there was 
correlation between the genes affected by tea tree oil and Citrox transcriptional 
datasets were compared.  The regulation of 79 genes was observed to be the 
same between treatment groups. This correlated with a 20% overlap in gene 
regulation.  
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Figure 5.6 SAMMD comparison of Citrox transcriptome to S. aureus cell membrane active 
transcriptomes. Comparison of gene regulation between Citrox and orange oil(A) and tea tree oil 
(B). Light grey circles represent Citrox datasets, dark grey represents comparison data set, 
overlapping gene regulation is illustrated between the two circles, while oppositely regulated genes 
are located in individual circle. 
5.3.3 Quantitative PCR validation 
To confirm RNA-sequencing data, a small number of genes found to be DE in the 
dataset were examined using qPCR. As discussed in section 2.14 three biological 
and two technical qPCR replicates were used for each gene. RNA integrity was 
assessed by gel electrophoresis prior to conversion to cDNA for qPCR. Fold 
changes in gene expression were quantified and are illustrated in figure 5.6 and 
5.7. Results from qPCR were observed to be slightly lower than the fold expression 
determined by RNA-sequencing, this was not found to be a significant difference 
(P≥0.05). Overall, the same trend was observed in the bacterial response to 
challenge indicating the results from the RNA sequencing are accurate.   
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Figure 5.8 Comparison of differential expression of after challenge determined by RNA-seq 
and qPCR. Validation of RNA-seq data carried out using qPCR on genes geh, sdrC, coa, esxB and 
cap5E after treatment with ML:8 (A) and Citrox (B). Black bars indicate the fold change in gene 
expression from RNA-Seq data, grey bars indicate fold change in gene expression from qPCR data. 
Assay was carried out in triplicate, data represents mean fold change ± SD. Statistically significant 
results are indicated (two tailed student-T tests P≥0.05). 
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5.3.4 Investigation of effect of treatment on biofilm cells 
To determine if a similar trend was evident in biofilm exposed to ML:8 and Citrox, 
biofilm cells were harvested and exposed to treatment agents. The bacterial RNA 
was then harvested and examined using qPCR, as discussed in section 2.14. 
Results are shown in figure 5.9. While the fold change illustrated is lower than that 
of planktonic cells, a similar response to treatment is shown. No statistically 
significant differences were shown between planktonic and biofilm cell response. 
ge
h
sd
rC co
a
es
xB
ca
p5
E
-2
0
2
4
Citrox
ML:8
Biofilm response
Gene
F
o
ld
 C
h
a
n
g
e
 
Figure 5.9 Differential expression of biofilm cells after challenge determined by qPCR. 
Biofilms produced by S. aureus SH1000 were grown for 24 h and harvested using triple, cells were 
treated with ML;8 or Citrox for 20min and analysed. Analysis carried out using qPCR on genes geh, 
sdrC, coa, esxB and cap5E. Assay was carried out in triplicate, data represents mean fold change ± 
SD. Statistically significant results are indicated (two tailed student-T tests P≥0.05). 
5.3.5 Investigation into resistance development 
5.3.5.1 Assessing the development of resistance to ML:8 and Citrox 
The emergence of antimicrobial resistance is a considerable clinical problem, with 
the number of drug resistance organisms steadily increasing (490). The use of 
drugs to which bacteria can develop resistance in the treatment of biofilm 
infections is not advised as it poses many risks of further more complicated 
infections. To determine if S. aureus could develop resistance to ML:8 and Citrox, 
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SH1000 and BH1CC were passaged onto plates containing MIC and sub-MIC 
levels of each drug over a period of 90 days. With each passage, plates were 
examined for the development of any resistant colonies. After 90 days no growth 
was observed on plates containing the MIC levels of each drug. Therefore, 
resistance was not induced to either ML:8 or Citrox after 90 d. 
5.3.5.2 Investigation into potential induction of antibiotic resistance caused 
by ML:8 and Citrox 
Results from this chapter showed a 2.8 fold increase in fosB, a gene associated 
with fosfomycin resistance, after 20 min exposure to Citrox (0.007 % v/v). To 
further investigate the potential of ML:8 and Citrox to induce bacterial resistance to 
antibiotics, testing was expanded. S. aureus strains SH1000 and BH1CC were 
exposed to sub-MIC levels of ML:8 (0.06% v/v) and Citrox (0.007% v/v) for 24 h. 
MICs of antibiotics to bacterial cells was then examined. Results are shown in 
table 5.7.   
Table 5.7 Minimum inhibitory concentrations to novel agents post exposure 
to sub-MIC levels of ML:8 and Citrox 
 ML:8 pre-exposure Citrox pre-exposure 
Antibiotic (µg/ml) SH1000 BH1CC SH1000 BH1CC 
Vancomycin  1 1 1 1 
Gentamicin  1 1 1 1 
Daptomycin  0.25 0.25 0.25 0.25 
Linezolid  1 1 1 1 
Fosfomycin  2 1 2 1 
Rifampicin  0.6 1.25 0.6 1.25 
Tigecycline  0.125 0.094 0.125 0.094 
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MICs of antibiotics to strains pre-exposed to agents ML:8 and Citrox were shown 
to be the same as MICs previously determined for both SH1000 and BH1CC. 
Results indicate that ML:8 and Citrox do not induce resistance to antibiotics tested.  
5.4 Discussion 
Datasets were examined and DE genes were determined for treatment with ML:8 
and Citrox. Initial comparison of DE genes indicated large differences in the 
transcriptional response to ML:8 and Citrox. On further examination, similarities in 
the metabolic responses of S. aureus to both ML:8 and Citrox challenge were 
observed. Whilst the fold change in gene expression was not always comparable, 
correlation in the overall trend of regulation post exposure to ML:8 and Citrox was 
evident. The key focus in this chapter was the expression of virulence factors to 
investigate the mode of action of these novel agents.  
The ability of staphylococci to bind to host cells, implanted medical devices and 
other bacterial cells is a vital contributing factor to staphylococcal virulence. Genes 
involved in adherence were observed to be down-regulated after exposure to 
treatment agents used in our study. Eap/Map has been shown to bind neutrophil 
elastase (NE). NE is secreted by host cells, neutrophils and macrophages in 
response to infection. S. aureus is thought to be resistant to killing by NE, however, 
reports have shown a trend towards better killing by neutrophils in an eap deletion 
mutant. In a murine model of abscess formation, eap mutants were shown to have 
significantly lower bacterial loads than wild type strains, highlighting a role for eap 
in bacterial persistence (499). A role for Eap in facilitating attachment to 
biomaterials, such as those used for IVCs, has been shown previously (216). Eap, 
together with Emp, are reportedly involved in biofilm formation in iron depleted 
conditions (221). Exposure to Citrox results in reduced expression of eap and emp, 
this may lead to reduced biofilm forming capabilities amongst cells exposed to this 
agent. SdrC is known to be highly expressed in mature S. aureus biofilm (500). In 
addition to this, an SdrC mutant was previously shown to have reduced biofilm 
forming capacity, however this was shown to be strain dependent (501). 
Expression of sdrC was decreased in cells exposed to ML:8 and Citrox, this may 
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impair the ability of S. aureus cells exposed to either agent to form biofilm. 
Expression of SdrC in combination with expression of other Sdr proteins SdrD or 
SdrE, SdrC has been linked to bone infections (143). Decreasing SdrC expression 
may reduce the risk of these infections.  FnbA expression was decreased after 
exposure to ML:8. While this protein has previously been linked to biofilm 
formation, mutations in the fnbA gene do not result in impaired biofilm formation, 
leading us to believe the decrease in expression of this protein would have little 
impact on pathogenesis.  
A bacterial exoenzyme is a secreted enzyme that functions external to the bacterial 
cell. These were observed to be upregulated following exposure to our agents. 
Lipase, glycerol ester hydrolase (Geh) produced by S. aureus was upregulated 3.7 
fold after ML:8 expression and 2.5 fold post Citrox exposure. Lipase encoding 
genes, geh, have previously been shown to be upregulated during S. aureus 
biofilm formation (502, 503). Geh is an enzyme that hydrolyses emulsions of lipids 
with long chain fatty acids (504). It was perhaps unsurprising then, that Geh 
expression was increased after exposure to ML:8. The regulation mechanism of 
geh is not yet known (504). Spl are proteases, expression of these proteases has 
previously been shown to reduce biofilm formation (235). Spl proteins E & F are up 
regulated after exposure to Citrox. This may trigger release of pre-established 
biofilm in strains producing ica-independent biofilm. A theoretical role for coagulase 
in the pathogenesis of staphylococcal infection has been suggested but not 
elaborated on (127). An essential role for coagulase in biofilm formation has 
recently been shown in conditions that reflect the in vivo milieu (126). Coa 
expression was observed to be upregulated after ML:8 (2.09) and Citrox (3.50) 
exposure. Coa has previously been shown to trigger staphylothrombin activity, it 
binds prothrombin and induces thrombin-like activity (505). This in turn converts 
fibrinogen to fibrin (506).The increased expression of Coa, seen in our data, may 
lead to increased ability of bacterial cells to activate the fibrin formation cascade.  
As discussed in an earlier section, S. aureus is surrounded by a capsule this 
capsule protects the bacteria from phagocytosis. Vaccine development to S. 
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aureus has previously been examined through targeting the CP (507, 508). CP has 
previously been linked to attachment of bacterial cells to various biomaterials, such 
as those used for IVC production (165, 166). Expression of Cap 5E and D were 
both shown to be upregulated more than two fold following exposure to both ML:8 
and Citrox. This may increase the ability of S. aureus to attach and form biofilm on 
implanted IVCs. It may also suggest these agents are affecting the cell envelope, 
perhaps indicating a protective mechanism of bacteria to treatment. To further 
investigate this, MICs were determined to S. aureus SH1000 wild-type and Cap5E 
mutants. MICs were then compared for both strains to ML:8 and Citrox. Results 
revealed no differences in susceptibility between SH1000 strains examined.  
Secretion systems allow bacteria to respond to changing environmental conditions 
by facilitating translocation of several molecules, such as enzymes, toxins and 
proteins, across bacterial membranes. Analysis of the transcriptional response of 
S. aureus to ML:8 and Citrox revealed for the most part an up-regulation of genes 
involved in the ESTA-6 secretory system (Ess). This is similar to the type VII 
secretory system previously described in Mycobacterium tuberculosis (509). The 
Ess system is required for S. aureus pathogenesis, this locus consists of eight 
genes, three of which are esaC, esaB and esxB (510). EsaC is produced by 
staphylococci as they enter host tissues (511). EsaC production is regulated by 
EsaB. Bacteria lacking EsaB over produce EsaC. In our study, EsaB expression 
was upregulated and this in turn had a knock-on effect on EsaC, which was then 
down-regulated. EsaB has previously been linked to bacterial persistence in 
abscess formation, the decrease in expression seen in our study may impair the 
ability of S. aureus to invade host tissues and persist in the human host. EsxB was 
shown to be upregulated after exposure to both agents. The role EsxB plays in S. 
aureus is still unclear, however, it has been previously linked to abscess formation 
(510). Previous work carried out by Kenney et.al., (2009) showed a similar 
response of S. aureus after exposure to fatty acids, linoleic and oleic acid (483).  
A number of genes involved in toxin production were also up-regulated.  However, 
hlgA and hlgC were shown to be down-regulated. The virulence regulator RNAIII 
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was observed to be down-regulated but this was not deemed significant 
(P≥0.0001). However, this down-regulation may explain the effect on hlgA and 
hlgC, which have previously been linked to RNAIII expression. HlgA has previously 
been shown to be required for biofilm formation, with deletion mutants showing 
impaired biofilm production (512). IsdA production was increased in Citrox treated 
cells; this surface protein has previously been reported to reduce cell surface 
hydrophobicity and has previously been linked to bacterial resistance to long-chain 
unsaturated fatty acids.   
It is essential that bacteria can produce energy efficiently and respond rapidly to 
environmental changes or stresses if they are to survive. The availability of 
nutrients is ever changing and as a result a large amount of the bacterial genome 
codes for proteins involved in metabolism (513, 514). Energy production was up-
regulated; this may indicate increased cell growth.  This increase may also indicate 
an increased energy requirement of the bacterial cells in response to ML:8 and 
Citrox challenge. The up-regulation of virulence factors discussed above, such as 
capsule proteins, may have an additional fitness cost requiring larger amounts of 
energy. Many amino acid biosynthesis and metabolism pathways were observed to 
be up-regulated after challenge with ML:8 and Citrox including; histidine, valine, 
leucine, lysine, argentine and proline. The up-regulation of these systems has 
previously been shown to be induced in environments with low amino acid 
availability. However, in this instance bacteria were grown and challenged in 
enriched laboratory media, BHI, containing amino acids. The up-regulation may, 
therefore, be in response to the increased energy requirements of the bacterial 
cell, discussed above.  
Conditions of osmotic or acidic stress may also trigger increases in amino acid 
production. Citrox has a low pH and exposure to this agent may induce mild acidic 
stress. Arginine metabolism may serve to counter acidification or as an energy 
source in anaerobic conditions (515). Arginine metabolism was shown to be up-
regulated after exposure to Citrox; this may be in response to acidic stress. 
Bacterial metabolism is profoundly different between planktonic and sessile cells, 
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making it difficult to speculate the effect of ML:8 and Citrox exposure on sessile 
cells.  
Membrane phospholipids help S. aureus respond to environmental stress and 
antimicrobial challenge. Carotenoids are one component of the staphylococcal cell 
membrane. Carotenoid biosynthesis has been shown to be upregulated when 
membrane fluididty is increased (5). Genes associated with carotenoid 
biosynthesis were not DE after exposure to ML:8 or Citrox, indicating membrane 
fluidity may not be effected by either solution. However as changes in membrane 
fluidity can also be controlled at a protein level, further testing would be required to 
confirm this. DtlC expression was shown to be increased after ML:8 and Citrox 
challenge. This protein is involved in the D-alanylation of teichoic acids in the cell 
membrane (516). The modification of teichoic acids by the addition of D-alanine 
can decrease the negative charge of the bacterial membrane (517). This has been 
shown to be a survival mechanism when exposed to positively charged 
antimicrobial agents (516, 518). The pentose phosphate pathway has previously 
been shown to be upregulated to compensate for increased reduction of NADP 
and NADPH (519).  
The transcriptional response of S. aureus to ML:8 and Citrox challenge was 
compared to transcriptional responses of other datasets available on SAMMD. The 
response to ML:8 was compared to other fatty acids oleic and linoleic acid that 
have previously been shown to act on bacterial cell membrane. Comparison using 
SAMMD analysis revealed a 42% overlap in gene regulation was observed 
between oleic acid and ML:8, while linoleic at concentrations of 0.01M resulted in 
45% overlap between the two challenge groups. This high level of correlation 
between the treatment groups suggests ML:8 may be acting in a similar way to 
these cell membrane targeting agents. This is in agreement with a previous 
publication looking at the effect of monocaprylate on bacterial cell membranes 
(387). Tea tree oil has a similar mode of action to other fatty acids, targeting the 
cytoplasmic membrane of bacterial cells. An overlap in regulation of 104 genes 
was observed between tea tree oil and ML:8, strengthening the theory of ML:8 
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targeting the cell membrane. Little overlap in the response between ML:8 and the 
antibiotics daptomycin, vancomycin, oxacillin and fosfomycin was shown. Similar 
results were observed between the transcriptional response of Citrox and 
antibiotics, with little overlap evident. Citrox comprises of flavonoids extracted from 
citrus fruits, its transcriptional response was compared to that of orange oil. 
Orange oil has previously been shown to induce cell lysis (482). To investigate if 
similarities in gene regulation were present, SAMMD analysis was used to 
compare the transcriptional response. Results revealed that 42% of the genes 
differentially regulated in Citrox were also affected in orange oil, suggesting a link 
between the bacterial responses to both agents. Further study, including SEM 
imaging, is required to confirm the mode of action of ML:8 and Citrox being cell 
membrane targeting and lysis induction. 
The potential to induce or develop of resistance is a concern for any new 
antibacterial agent. Testing was carried out to investigate the potential of MSSA 
and MRSA strains SH1000 and BH1CC to develop resistance to ML:8 and Citrox. 
Over a period of three months, continuous culturing of bacterial cells in the 
presence of ML:8 or Citrox was performed. Encouragingly, bacterial resistance did 
not develop to either ML:8 or Citrox in this time. In contrast, bacterial resistance to 
antibiotics has previously been reported after 2-5 d exposure to sub-lethal 
concentrations (520). Resistance to agents such as tea tree oil have been shown 
to emerge within 90 d (521). These results suggest S. aureus bacteria may not be 
able to develop resistance to either ML:8 or Citrox.   
Transcriptional analysis revealed the gene product UDP-N-acetylglucosamine1-
carboxyvinyltransferase to be up-regulated more than 3 fold after exposure to both 
ML:8 and Citrox. This product is involved in peptidoglycan biosynthesis (522). 
Fosfomycin directly targets this gene product in E. coli and potentially in S. aureus 
(523). Taken together with the increased expression of fosB after Citrox challenge 
there is potentially an increased risk of fosfomycin resistance in bacterial cells 
treated with this agent. To further investigate this resistance testing was carried out 
to examine the MIC of S. aureus strains SH1000 and BH1CC to antibiotics 
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commonly used in the treatment of Gram-positive infections. MICs were examined 
post exposure to sub-MIC levels of ML:8 and Citrox for 24 h. Results revealed no 
increase in resistance to antibiotics, including fosfomycin, indicating that neither 
agent induced bacterial resistance to antibiotics tested.  
Overall, transcriptional results show a similar response of S. aureus to ML:8 and 
Citrox exposure.  Analysis revealed an increase in genes associated with energy 
production; this may be linked to increased expression of protective mechanisms in 
the bacterial cell. These protective mechanisms include capsule production and 
exoenzyme expression, which are up-regulated after ML:8 and Citrox challenge. 
Despite up regulation of genes that may aid in bacterial survival in conditions of 
stress, resistance was not shown to develop to either treatment agent. Based on 
comparison of transcriptional responses of ML:8 and Citrox to similar agents it can 
be suggested the mode of action is focused on the bacterial cell membrane. 
Further investigation into the exact mode of action is warranted. Taken together, 
the decrease in expression of a number of virulence genes such as those involved 
in bacteria adherence and toxin production as well as the failure to develop 
resistance, support the use of ML:8 and Citrox as potential CLSs. 
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6.1 Conclusions 
A significant risk factor in the development of hospital-acquired infections is the 
extensive use of implanted prosthetic biomaterials for diagnostic and therapeutic 
purposes. These devices can become colonised by pathogenic bacteria and give 
rise to infections. A study of over 14,000 patients, carried out by the European 
Centre for Disease Prevention and Control (ECDC), in 2010, found that of those 
with a healthcare-associated infection, 50.7% were IVC-related (524). Studies from 
the US have shown that over 250,000 BSIs associated with IVCs occur annually in 
the US with an attributable mortality ranging from 12% to 25% in critically ill 
patients, with an added cost ranging from US$3,000 to $56,167 per patient (490). 
IVCs are an essential lifeline for patients relying on treatments such as 
haemodialysis, chemotherapy and parenteral nutrition. Therefore, the prevention 
and treatment of infections associated with IVCs is of major clinical importance, it 
is for this reason that we have focused on existing and novel treatment of IVC 
infections using CLSs in this project. 
Biofilms are thought to be involved in 65-80% of microbial infections (3) and are an 
important virulence factor of staphylococci. Gram-positive cocci, particularly S. 
epidermidis and S. aureus, are the predominant organisms responsible for 
infectious complications following the implantation of IVCs due to the ability of 
these microorganisms to first adhere and subsequently form a biofilm. These 
biofilms are highly resistant to both the action of the innate and adaptive immune 
responses, and to the action of antimicrobial agents. These resistance 
mechanisms contribute to the development of persistent infections and to 
treatment failure. A major limitation of current chemotherapeutics for IVCs is that 
the antimicrobial drugs are selected for their ability to inhibit or kill planktonic cells 
and have limited effectiveness against bacteria within biofilms. As a result, there is 
an obvious need to determine the most appropriate available antimicrobial and to 
identify new biofilm-specific antimicrobial targets for the treatment of IVC-related 
BSIs. Conventional antimicrobial agents are frequently unsuccessful and the 
removal of the IVC is usually required. 
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The IDSA guidelines on the management of CRBSIs recommend the use of CLSs 
for the salvage of an IVC associated with a BSI (349). However, the choice of 
antibiotic to be used for CLS is often based on the in vitro susceptibilities using 
conventional susceptibility testing. This may not necessarily indicate that the 
antibiotic is active against the same organisms embedded in the biofilm. Currently, 
the decision to use antimicrobial lock prophylaxis/treatment as well as the choice of 
antimicrobial agent to be used is often made on the basis of the individual patient, 
their previous positive microbiology and is a decision made in conjunction with the 
infection and pharmacy specialists. There is as of yet no consensus on what is the 
best approach, partly because there is insufficient insight and knowledge about 
which agent, or combination of agents, is likely to be most efficacious in vivo 
against biofilm-forming bacteria. 
In this study, we examined the effect of commonly used antiseptics, antibiotics and 
two novel therapeutic agents, ML:8 and Citrox, on staphylococcal biofilm using a 
variety of in vitro and in vivo assays. Analysis of staphylococcal biofilm growth and 
eradication has previously been performed, in most cases, in nutrient enriched 
media. In keeping with this, initial investigations during the course of this project 
were performed in nutrient enriched conditions using an in vitro 96-well plate 
biofilm assay previously described by G. D. Christensen, et al.,(1985) (405). 
However, it is important to recognise the limitations of this assay. It does not take 
into account conditions of nutrient limitation and the interactions of bacteria with 
host extracellular matrix proteins that would be encountered in vivo.  
Recent research in our laboratory has led to the re-design of the commonly used 
96-well assay so that testing more closely represents the in vivo milieu (126). This 
new assay involves the coating of surfaces with plasma from healthy humans and 
the replacement of nutrient enriched media with iron-limited RPMI-1640 tissue 
culture media. This new assay was employed to examine the effect of our 
treatment groups on staphylococcal biofilm using conditions representing the in 
vivo environment. It is important to note the levels of biofilm formed by S. 
epidermidis in this assay are limited. These growth conditions do not support 
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growth of our S. epidermidis isolate to levels seen with S. aureus, the reason for 
this is not known. Recent investigations have revealed S. aureus to be better 
adapted to growth in iron limited, low nutrient media than CoNS (444). It was 
suggested in this study, by Krismer et al., (2014), that complex differences in 
metabolic and regulatory properties were responsible for the differences in growth 
rates, in these conditions. S. epidermidis has previously been shown to grow in low 
iron conditions (525), therefore this can be ruled out as the growth limiting factor in 
our study. Another important consideration when examining biofilm in vitro is the 
effect of shear stress, this is of particular importance in the case of biofilm formed 
in an IVC. To address this, an assay of biofilm formation under conditions of flow 
was developed. Biofilm formation and treatment in nutrient enriched and plasma 
coated conditions were examined under shear stress.  
Treatment of staphylococcal CRIs is complicated by the emergence of resistance 
by clinical isolates. Antibiotic resistance is an increasing problem with few new 
antimicrobial drugs in clinical trials. The use of non-antibiotic locks has been 
studied extensively as there are concerns that the prolonged use of antibiotics in 
catheters may lead to the development of antimicrobial-resistant microorganisms 
(526).  Guidelines on the treatment of CRIs published by the HPSC in August 2014 
recommend further investigation into the use of non-antibiotic lock solutions (350). 
Evaluations of the effect of commonly used antiseptics, previously shown to have 
potential in the treatment of CRIs, are presented in this thesis. Ethanol and 
TaurolockTM were both shown to be very effective against S. aureus and S. 
epidermidis biofilms formed in all growth conditions tested, indicating strong 
therapeutic potential. DuralockTM was also shown to have antimicrobial properties 
but this was to a lesser extent than the aforementioned antiseptics. The findings of 
this study on the efficacy of DuralockTM are not sufficient to justify its use for 
treatment of IVC infections caused by staphylococci. This is in contrast to previous 
work recommending its use in the treatment of CRIs (440). Although not examined 
in our study, it may be a suitable agent for the prevention of staphylococcal biofilm 
within a catheter. EDTA has previously been shown to be effective in the treatment 
of CRIs (432, 438), our results did not show any benefit of EDTA treatment on 
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staphylococcal biofilm. The differences observed in efficacy between our study and 
others may be linked to lower bacterial density of 1x 105, as that reported by 
Percival et al., (2005) (432). 
In a clinical setting, the occurrence of staphylococcal infection in an implanted IVC 
may not be immediately detected, allowing the biofilm to develop for a number of 
days before treatment is commenced. To reflect these conditions, testing was 
performed on S. aureus biofilms formed in nutrient limited conditions on plasma 
coated surfaces for one, three and five days. As RPMI-1640 media did not support 
the growth of mature S. epidermidis biofilm, it was not possible to continue 
antimicrobial testing using this species, in this assay. This highlights a limitation of 
this assay as a direct comparison of efficacies of treatment agents cannot be made 
between S. epidermidis and S. aureus. Both ethanol and TaurolockTM remained 
effective against biofilm formed over all time points tested, providing further 
support for the use of these antiseptic agents in the treatment of staphylococcal 
IVC infections involving biofilm. This is in keeping with previous studies 
recommending the suitability of ethanol and TaurolockTM for the treatment of IVC 
infections (430, 527). 
Although effective in eliminating circulating bacteria in a planktonic state, 
antibiotics frequently fail to sterilise an infected IVC where bacteria, such as 
staphylococci, exist in a biofilm. This leaves the patient at a continued risk of 
complications or the recurrence of infection. A range of antibiotics were examined 
in our testing to determine suitability for use in the treatment of CRIs caused by 
staphylococci. No correlation was observed between concentrations required to kill 
planktonic bacterial cells and those required to kill sessile cells. Biofilms have 
consistently been shown to be more resistant to treatment than planktonic cells, 
which is most likely due to the altered metabolic activity in bacterial cells within a 
biofilm. Previous studies have shown a large variation in susceptibility levels 
between planktonic cells examined in a laboratory setting and sessile bacteria 
found within the catheter (63). This finding may have important implications 
clinically as antibiotics, as well as the concentration chosen for use in a CLS, may 
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have little effect on sessile bacteria within the IVC and therefore may lead to 
treatment failure.  
Large variations in the efficacy of antibiotics were evident in our testing when 
biofilm assays were performed using different growth media.  This is consistent 
with other published research showing differences in bacterial susceptibility in 
different nutrient conditions (528). None of the antibiotics tested were shown to be 
effective against biofilms formed in nutrient enriched conditions either alone or in 
combination with other treatment agents. However, in the newly developed assay 
of nutrient limited conditions with plasma coating, some antibiotics proved more 
effective in the treatment of an established biofilm. The antibiotics daptomycin, 
vancomycin, tigecycline and rifampicin were all shown to be effective against 
biofilm formed over one day. This was further investigated under conditions of flow 
where a reduction in viability of up to 75-95% with each of the four antibiotics was 
found. The efficacy of vancomycin was limited to biofilm formed over one day as 
little reduction in viability was observed after treatment of three and five day old 
biofilm. Daptomycin, rifampicin and tigecycline had a sustained effect as they 
remained effective against more mature biofilms of three and five days. This 
sustained efficacy may be due in part to antibiotic structure or mode of action. As 
discussed, the C10 fatty acid that forms part of daptomycin may aid in the 
penetration of this antibiotic into mature biofilms (450). Rifampicin has previously 
been reported to successfully penetrate through staphylococcal biofilm, this may 
be in part due to its relatively small size (529). Differences in efficacy against 
biofilm at various levels of maturity may help to explain wide variation in reported 
efficacies of antibiotics, mature biofilms have previously been demonstrated to be 
more resistant to treatment (126).  
More mature biofilms are likely to represent the real life scenario in which biofilm 
develops on an IVC over a number of days before a CLS is used for treatment. 
Other antibiotics that have been commonly used as CLSs, such as linezolid, 
fosfomycin and gentamicin, were not shown to be effective at killing staphylococcal 
biofilms in the assays used in this study. These findings suggest that vancomycin, 
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as well as other anti-staphylococcal antibiotics linezolid, fosfomycin and gentamicin 
should not be used within a CLS to treat mature, staphylococcal, IVC-related 
infections. The antibiotics daptomycin, rifampicin and tigecycline were shown to be 
the most promising for the treatment of staphylococcal IVC-related infections 
involving biofilms. The work presented here prompts a re-evaluation of 
experimental methods used to investigate factors relevant for in vivo biofilm 
formation. Ultimately, in vitro assays that are more physiologically relevant should 
be adopted to augment traditional in vitro methods for studying biofilm formation. 
These are likely to aid in the discovery of novel therapeutic targets for treating 
CRIs caused by staphylococci. 
Previous work by Zapotoczna et al., (2015) revealed biofilm formed in nutrient 
limited conditions to have a lower cell density (126). Enhanced anti-biofilm activity 
of antibiotics in this model may be due to a lower bacterial cell density. Another 
contributing factor to the increased activity may be related to biofilm architecture 
(324). Differences were observed in biofilm structure when examined using a light 
and confocal microscope. Biofilm produced under nutrient enriched conditions 
formed in a non-confluent manner, whilst biofilm formed in nutrient limited 
conditions was observed to be a confluent layer of attached cells. Previous 
research has shown that ica-dependent biofilm produced in nutrient enriched 
conditions is encased in a polymeric slime (177, 530). Scanning electron 
micrograph images published by McCarthy et al., (2015) showed biofilm produced 
by S. aureus SH1000 to form in clumps or clusters (531). The differences in biofilm 
architecture observed between biofilms produced in the nutrient enriched and 
nutrient limited assays may contribute to the variation in treatment efficacy of 
agents used in our testing.  In keeping with this, previous studies have suggested 
that a PIA/PNAG coating may have a role in protecting biofilm cells from treatment 
agents (6, 177).  
The need for new treatment options against staphylococcal infection has been 
previously highlighted (14-16).Two novel therapeutic options, ML:8 and Citrox, 
were also investigated to determine their potential use as a CLS. These agents 
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were shown to be very effective in eradication of staphylococcal biofilm formed in 
static and flow conditions in various nutrient environments. ML:8 and Citrox were 
also shown to be equally effective against biofilm formed over one, three and five 
days. Treatment, with both ML:8 and Citrox, resulted in a complete eradication of 
biofilm at the three stages of growth examined. These encouraging results suggest 
the potential for both agents to be used in the treatment of established 
staphylococcal biofilm infections. This is in keeping with recent research published 
on the anti-biofilm activities of ML:8 on periodontal pathogens (380). However, one 
study that examined the effect of a similar formulation to ML:8 called ML:X 10 was 
not in agreement with our findings (382). In this study, Luther et al., (2014) 
reported vancomycin to be equally effective against staphylococcal biofilm as ML:X 
10. The solution ML:X 10, like ML:8, contains caprylic acid. However, the 
concentration of caprylic acid and other excipiends is not defined in the publication, 
making it difficult to draw a direct comparison. It is also important to note that this 
study did not contain appropriate controls and the testing was confined to one 
assay.  
As mentioned, ML:8 proved to be very effective in various nutrient environments in 
our study. Its effect in nutrient limited conditions on plasma coated surfaces was of 
particular interest as reports have shown higher concentrations of antimicrobial 
fatty acids are required to inhibit bacteria growth in the presence of human blood 
proteins (532, 533). The anti-biofilm properties of Citrox or the flavonoids included 
in its formulation have not previously been investigated. 
To further investigate the potential for therapeutic use of ML:8 and Citrox, cytotoxic 
potential was examined. Cytotoxicity was evident at concentrations shown to be 
effective against bacteria (1%). However, when compared to currently used CLSs, 
such as ethanol and sodium citrate solutions, cytotoxicity levels were shown to be 
equivalent. The effect of ML:8 and Citrox on erythrocytes was also examined to 
determine if either agent caused haemolysis of human blood. Haemolysis was 
observed after exposure to high concentrations (≥0.25% v/v). Due to the 
positioning of an IVC, if leakage did occur from the catheter into systemic 
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circulation the solution would be rapidly diluted. As a result of this, we do not see 
the haemolytic properties of novel agents at high concentrations being a cause for 
concern.  
The potential of ML:8 or Citrox  to induce an innate immune response involving 
cytokines was also investigated. Encouragingly, no response was detected from 
whole fresh blood following exposure to either novel agent. A range of 
immunogenic adverse drug events to other therapeutics, such as Neumega- a 
chemotherapeutic agent, have previously been reported with varying severity 
(534). As discussed previously, staphylococci have the potential to induce an 
immune response (47), this was shown in chapter 4 with biofilm cells being used 
as a positive control in the stimulation of cytokine production in human blood. It 
would be interesting to determine the effect of staphylococcal biofilm cells in 
combination with ML:8 and Citrox on the innate immune response. The killing of 
biofilm cells by either agent may result in an increased amount of biofilm cell 
detritus being accidentally flushed into the bloodstream of the host. The increased 
amounts of known agonists of innate immunity to Gram-positive organisms, 
namely LTA, peptidoglycan and PIA, may have detrimental effects on the host, 
similar to those seen in toxic-shock like syndrome (35, 43). Indeed, this is a 
concern for the in situ treatment of an IVC using any antimicrobial agent.  
ML:8 and Citrox were shown to be effective in all in vitro antimicrobial testing 
against staphylococci in planktonic and sessile assays. However, further testing 
was needed to determine the effect of these agents in vivo. It was for this reason 
that a model of IVC infection in a rat was optimised and used to assess the effect 
of these agents. Citrox (1% v/v) was shown to be very effective against biofilm 
formed over five days in this model, using an initial inoculum of 106 CFU/ml. In 
comparison, ML:8 (1% v/v) did not result in a significant reduction in biofilm viability 
against biofilm formed under the same conditions. Previously, intermittent 
compression of the catheter, resulting from routine movement, has been shown to 
result in CLSs at the internal tip of the catheter being diluted up to 50% with host 
blood (535). This may partially explain the minimal reduction in biofilm viability on 
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further testing. ML:8 was shown to eradicate biofilm viability in this model when 
biofilm was formed over one day using a lower inoculum of 104 CFU/ml. Bacterial 
cell density, as well as thicker biofilm growth, may be important contributing factors 
in the resistance of five day, in vivo, biofilms to ML:8 treatment. Previous studies 
have reported that the bacterial burden harvested from explanted, clinical, catheter 
segments is approximately 1 x 106 CFU/ml (536). The bacterial burden and 
maturity of a staphylococcal biofilm-related IVC infection, should be considered 
before using ML:8 as a treatment option.  
Efforts were made to determine the mode of action of ML:8 and Citrox using global 
gene expression analysis. Other have shown that global gene expression profiles 
can be used to provide valuable information on transcriptional response of bacteria 
to potential treatment agents (67). Cellular response data presented suggest a 
similar response of bacteria to both ML:8 and Citrox. Genes associated with 
capsule production were shown to be up-regulated after exposure to both agents. 
The testing was expanded to examine the effects of Cap5E deletion mutants on 
the MIC of ML:8 and Citrox. The results revealed no difference in concentration 
required to inhibit growth of wild type and mutant strains, casting doubt on capsule 
proteins being a potential target for either ML:8 or Citrox. Capsular 
polysaccharides have been shown to be involved in facilitating attachment to 
biomaterials as well as forming a component of a biofilm layer (165, 166). The up-
regulation of cap genes observed in our data set may increase the bacteria’s ability 
to adhere to and subsequently form biofilm on implanted IVCs.  
The gene sequencing analysis suggests that both ML:8 and Citrox may target the 
cell membrane. In further support of this, many studies have suggested fatty acids 
target bacterial membranes, causing depolarisation and increased permeability 
(343, 387). Interestingly however, when compared to cell wall and membrane 
active antibiotics little overlap in expression responses were observed. Bacterial 
response to treatment with other fatty acids, such as oleic and linoleic acid, have 
been shown to result in 42 and 45% overlap respectively in expression when 
compared to ML:8 treatment. This high level of correlation between the treatment 
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groups suggests, perhaps, that ML:8 may be acting in a similar way to these cell 
membrane targeting agents. In keeping with this, monocaprylate, which is the 
monoglyceride of caprylic acid, has been shown to compromise bacterial cell 
membranes (387). Citrox due to its high flavonoid content was compared to orange 
oil, orange oil has previously been shown to induce cell lysis (482). Similarities in 
gene regulation in 42% of the genes differentially regulated were observed 
between the two treatment groups. This is likely to indicate a common mode of 
action between orange oil and Citrox. Future testing using scanning electron 
microscopy (SEM) imaging of biofilm cells treated with ML:8 and Citrox may aid in 
the elucidation of a definite mode of action of both agents. Previously, taurolodine, 
an antimicrobial component of TaurolockTM, was shown to result in cell lysis (537). 
This indicates that the use of a cell wall/membrane targeting antimicrobial may be 
safe for the use as a CLS.  
Transcriptional analysis revealed changes in a number of genes involved in 
staphylococcal pathogenesis. Genes associated with adherence were shown to be 
down-regulated after exposure to both ML:8 and Citrox, this may affect the 
bacterial cells ability to form biofilm. The expression of proteins such as SdrC, Eap 
and FnbA were decreased. The protein Eap in particular plays in important role in 
DRIs as it not only binds serum proteins such as fibrinogen and fibronectin (216, 
218, 219) but also facilitates attachment to polystyrene (216, 220). The down-
regulation of expression of adherence proteins may impair the ability of the 
bacteria to form biofilm after exposure to ML:8 and Citrox. However, other proteins 
previously linked to staphylococcal biofilm formation were also shown to be 
effected such as Coa. This was shown to be up-regulated after exposure to either 
agent. Coa was recently shown in research performed in our laboratory to be 
essential for the formation of biofilm on plasma coated surfaces in nutrient limited 
conditions (126).   
As previously mentioned, global gene expression can be controlled via the agr-
system and the effector molecule RNAIII. Although not significantly effected in our 
data set, RNAIII was observed to be down-regulated after exposure to ML:8 and 
220 
 
Citrox, down regulation of RNAIII has previously been shown to be beneficial for 
the development of protein mediated biofilm (29). The up-regulation of coa, 
coupled with decreased RNAIII expression, may result in increased protein 
mediated biofilm production upon exposure to sub-MIC levels of either agent. 
These findings may be important in the future consideration of using ML:8 and 
Citrox as a CLS, in the prevention of staphylococcal biofilm infections.  
The toxin encoding genes, hlgA and hlgC, were observed to be down-regulated 
after exposure to ML:8 and Citrox. This is likely to be related to the down-
regulation of RNAIII, as previous studies have shown RNAIII is linked to 
haemolysis toxin production (29). In contrast, other toxins were found to be up-
regulated. Expression of the gene hlgA has previously been shown to be required 
for S. aureus biofilm formation (512). The decrease in expression observed in our 
dataset, may therefore impair the ability of S. aureus to form biofilm after exposure 
to sub-MIC ML:8 or Citrox. The increase or decrease in the expression of other 
toxins may not be significant to the pathogenesis or CRIs and their treatment, as 
contents of the catheter should not enter systemic circulation. However, it may be 
of critical importance if either ML:8 or Citrox were to be used in the treatment of 
staphylococcal infection at other sites or in cases of leakage or accidental flushing 
of catheter contents into systemic circulation.  
As mentioned, the development of resistance is a major concern in a clinical 
setting. It was therefore important to ensure resistance to either ML:8 or Citrox did 
not emerge.   No resistance to ML:8 or Citrox was observed in the MSSA strain 
SH1000 or the MRSA strain BH1CC over a 90 day period. Exposure of cells to 
ML:8 and Citrox did result in increased expression of genes associated with 
antibiotic resistance to fosfomycin. However, further testing showed no increase in 
the MIC for strains grown in the presence of ML:8 to fosfomycin. MICs of other 
antibiotics included in this project were also examined after exposure to ML:8 and 
Citrox. All MICs were shown to be the same pre- and post-exposure to treatment 
agents. It is possible that repeated or long term exposure to sub-MIC levels of 
ML:8 or Citrox may lead to small increases in the MIC to antibiotics such as 
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fosfomycin. Previous studies have shown exposure to sapienic acid and other 
agents such as tea tree oil can lead to development of intermediate resistance to 
antibiotics such as vancomycin (483, 497). The use of ML:8 or Citrox in a CLS 
should be monitored to ensure bacterial resistance to other antibiotics does not 
emerge over time.  
6.2 Future directions 
A limitation of CLSs is that they can only be used in the treatment of intraluminal 
infections of IVCs. Infections can also develop on the extraluminal section of the 
implanted catheter (538). In an effort to reduce extraluminal infections, 
antimicrobial agents can be coated or impregnated onto or into the surface of a 
catheter to prevent bacterial colonisation (308). ML:8 and Citrox could potentially 
be incorporated into a gel for the coating of a device in an effort to reduce 
extraluminal infection. The findings reported in this thesis should be extrapolated to 
include other staphylococcal in vivo like models of infection such as, prosthetic 
joints, surgical site infections and wound infections to determine the effectiveness 
of existing antimicrobials as well as agents ML:8 and Citrox in the treatment of 
these infections. While we have focused on staphylococcal infection in this project, 
ML:8 and Citrox may have a wider spectrum of activity as both fatty acids and 
flavonoids have previously been reported to have a broad spectrum of activity. 
Testing should be expanded to determine the effect of both ML:8 and Citrox on a 
wider range of clinically problematic bacteria, such as Streptococcus species, 
Gram-negative bacteria, such as Pseudomonas aeruginosa and Escherichia coli  
and fungi,such as Candida albicans. Establishing the spectrum of activity of these 
two agents may further help in elucidating a mode of action for each agent.  
Further investigation into the differences between the nutrient enriched and 
nutrient limited assays, used in this study, is warranted and could reveal important 
differences in the regulation of staphylococcal biofilm, in particular for S. 
epidermidis. The development of an in vitro model representing the in vivo setting 
that supports S. epidermidis growth is essential for the future examination of 
therapeutics against infections caused by this species. It would be interesting to 
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use the RNA-sequencing technology, described here, to determine the differences 
in bacterial gene expression of biofilm cells of S. aureus and S. epidermidis under 
various different growth conditions.  
Examination of other potential novel therapeutics should be performed in 
conditions resembling the in vivo environment; this may lead to the discovery of 
potentially suitable treatment options for clinical use. Such novel therapeutics could 
include enzymes to target the biofilm matrix or the plasma coating to which it is 
likely to attach. Coagulase, as mentioned, was shown to be essential for biofilm 
formation in the in vivo mimicking conditions discussed in this thesis (126). This 
may represent a future target for the prevention and treatment of staphylococcal 
biofilm infections.  
6.3 Final thoughts 
Although the optimal treatment for patients with a CRI is removal of the IVC, this 
may not always be possible. An underlying diagnosis or the lack of alternative 
vascular access may prevent device removal as a treatment option. In these 
cases, an alternative solution, such as systemic antibiotic treatment coupled with 
an antimicrobial CLS, may be required. Whilst many antimicrobial agents kill 
bacteria in a planktonic state only a limited number of agents are effective in 
treating device-related staphylococcal biofilm infections.  Results from this study, 
using a novel in vivo relevant model of infection, have clear clinical significance as 
they demonstrate that the antibiotics in regular clinical use most likely allow rapid 
clearance of staphylococci from an infected IVC and potentially salvage the 
catheter. These agents include daptomycin, tigecycline and rifampicin; whilst 
ethanol and TaurolockTM are the two most effective antiseptics in eradicating 
staphylococcal biofilm within a CLS. These findings have direct clinical applicability 
and should be used to guide future guidelines and treatment recommendations. 
Use of CLSs in combination with adherence to current guidelines on implanting, 
handling and care of IVCs, as well as appropriate prescribing of antibiotics, may 
greatly reduce IVC infection rates and the need for device removal due to infection. 
223 
 
The need for new therapeutic options in the treatment of staphylococcal IVC 
infection is of major clinical importance. Results presented in this thesis have 
highlighted strong antimicrobial and anti-biofilm properties of two novel solutions, 
for the use as a CLS, namely ML:8 and Citrox. This was shown using a 
combination of in vitro and in vivo assays of staphylococcal biofilm infection. 
Cytotoxicity of both agents was shown to be equivalent to currently available CLSs. 
Further testing into the suitability of these agents for in vivo use revealed both 
agents to be non-immunogenic. The mode of action of both agents is thought to be 
confined to the bacterial cell wall/membrane. These data, coupled with low 
potential of resistance development, suggest ML:8 and Citrox could be viable 
therapeutic options for the treatment of CRIs involving staphylococcal biofilms. 
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